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1.1 STATEMENT OF THE PROBLEM INVESTIGATED IN THIS THESIS 
In England and Wales, deaths involving heroin and/or morphine doubled in the last three 
years and are now the highest on record (ONS, 2016). Despite the relatively rare 
prevalence of opioid use, compared with other illicit substances (CSEW, 2015), there 
were more than 6000 drug-related deaths involving opioids in the last 5 years (ONS, 
2016). Enrollment in treatment is the single most effective road to recovery and to 
minimize harms associated with opiate drug-use during this journey (Darke et al., 2000; 
Davidson et al., 2003; McGregor et al., 1998; Pierce et al., 2016). However, certain 
mortality risks within OUD treatment exist and these need careful exploration and 
interpretation.  
This thesis utilized anonymizes patient health records from one of the largest mental 
health service providers in Europe and explored mortality risk factors, at both patient-
level and service-level, in individuals with OUD enrolled in secondary drug and alcohol 
treatment. The aims of the thesis are: 
1. To explore associations between psychological wellbeing, comorbid diagnosis of 
PD, SMI and AUD, in relation to all-cause and cause-specific mortality in opioid 
dependence. 
2. To determine if addiction-specific, routine brief risk assessments given to OUD 
patients can predict all-cause or cause specific mortality. Also, to determine if these 
risks may be modified by admission to services. 
3. To investigate clustering of deaths, especially fatal overdoses, in the period 
immediately after transfer of patients and their care, and after end of OST in a cohort 
of opioid dependent individuals in specialist addiction treatment. 
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4. To investigate the associations between planned OST cessation, unplanned OST 
cessation and transfer of patient and their care with arranged continuation of OST, in 
relation to all-cause and cause-specific mortality in opioid dependence with 
adjustment for potential confounders. 
 
The findings of this thesis might provide evidence of the burden of opioid use disorder in 
secondary mental health services and the general population. The specific aims in this 





1.2.1 HEROIN, OPIATES AND OPIOIDS 
Heroin, a crude preparation of diamorphine, is a semisynthetic product obtained by 
acetylation of morphine, which occurs as a natural product in opium, the dried latex 
of certain poppy species (e.g. Papaver somniferum) (Darke, 2011; European 
Monitoring Centre for Drugs and Drug Addiction [EMCDDA], 2015); King, 2009). 
Diamorphine is a narcotic analgesic used in the treatment of severe pain. Illicit heroin 
may be smoked, inhaled as a sublimate, or dissolved with a weak acid and injected. 
Whilst opium has been smoked since historical times, diamorphine was first 
synthesised in the late nineteenth century. Diamorphine is 2–3 times more potent than 
morphine (EMCDDA, 2015). 
 
The opioids are a class of drugs that include the natural products from the opium 
poppy and synthetic compounds derived from it. The term describes any of the 
narcotic opioid alkaloids found as natural products in the opium poppy plant, as well 
as many semi-synthetic chemical derivatives (EMCDDA, 2010). In addition to heroin, 
the class includes drugs such as morphine, codeine, methadone, oxycodone and 
fentanyl. Although the term ‘opiate’ is often used as a synonym for opioid, this term 
is properly limited to only the natural alkaloids from in the resin of the opium poppy 
(Darke, 2011; King, 2009). This thesis concentrates on individuals who misuse 
opioids. Although heroin is the primary problematic substance, the cohort studied 
here does not exclude the misuse of other opioids.  
 
One of the primary clinical characteristics of opioids is that they produce analgesia. 
Opioids act as agonists for a group of neuro-receptors that are normally acted upon by 
 18 
endorphins, the body’s endogenous opioids (Berridge, 2009). Apart from analgesia, 
opioids induce drowsiness and sleep, and produce a sense of euphoria and 
detachment. The onset of these effects can be very rapid. Following heroin injection, 
diamorphine rapidly crosses the blood-brain barrier within approximately 20 seconds 
(which is one of the major reasons why injection is often the favoured choice of route 
of administration), and includes feelings of warmth and pleasure followed by a long 
period of sedation (Darke, 2011). The major clinically significant negative effect of 
the opioids is that they are central nervous system (CNS) respiratory depressants 
(Karch, 2009). Respiration rates are suppressed, even amongst the tolerant and, in 
overdose, may decline to just four breaths per minute, if the person still lives. Death is 
usually due to respiratory failure, although cardiac arrests may occur due to 
myocardial oxygen deprivation (Goodman & Gilman, 1996).  
 
1.2.2 OPIOID USE DISORDER 
The cohort analysed in this thesis consists of patients diagnosed with an opioid use 
disorder (OUD) in accordance with the 10th edition of the International Classification 
of Diseases (ICD-10) (World Health Organisation [WHO], 1993). The ICD-10 
classification of mental and behavioural disorders due to use of opioids is categorized 
into three pathological syndromes: intoxication, dependence syndrome and 
withdrawal state. Detailed diagnostic criteria for each of the syndromes are presented 
in Table 1.1. 
 
Of all the drug classes, heroin is second in dependence liability (after tobacco), with 
approximately one in four who use heroin developing dependence upon the drug, and 
with no gender differences in that respect (Anthony et al., 1994). Higher rates of use 
 19 
and transitions to dependence (1 in 2) were found in combat setting (Robins, 1993); 
and with injecting of heroin being associated with the highest level of dependence 















Table 1.1 ICD-10 diagnostic criteria for Mental and Behavioral Disorders due to use of 
opioids (WHO, 1993) 
 
OPIOID INTOXICATION 
1) There must be clear evidence of psychoactive substance at sufficiently high dose levels. 
2) There must be symptoms or signs of intoxication, of sufficient severity to produce 
disturbances in the level of consciousness, cognition, perception, affect, or behaviour that 
are of clinical importance. 
3) These symptoms and signs cannot be accounted for by a medical disorder unrelated to 
substance use disorder. 
4) There must be dysfunctional behaviour as evidenced by the presence of at least 1 among 
the following: apathy, sedation, disinhibition, psychomotor retardation, impaired attention, 
impaired judgement, interference with personal functioning. 
5) At least 1 of the following signs, such as drowsiness, slurred speech, pupillary constriction, 
decreased level of consciousness, must be present. In severe acute opioid intoxication, 
respiratory depression, hypotension, and hypothermia will be present. 
OPIOID DEPENDENCE SYNDROME 
Three or more of the following manifestations should have occurred together for at least 1 
month, or if persists for <1 month, should have occurred together repeatedly within a 12-
month period: 
1) A strong desire or sense of compulsion to take opioids 
2) Impaired capacity to control substance-taking behaviour in terms of its onset, termination, 
or levels of use 
3) A physiological withdrawal state when use is reduced or ceased, or use of same substance 
with intention of relieving or avoiding withdrawal symptoms 
4) Tolerance: marked increase in amount with marked decrease in effect 
5) Preoccupation with opioid use: more time spent to obtain, take, or recover from effects of 
substance 
6) Persistent opioid use despite clear evidence of harmful consequences. 
OPIOID WITHDRAWAL STATE 
1) There must be clear evidence of recent cessation or reduction of opioid use after repeated, 
and usually prolonged and/or high-dose, use of that substance. 
2) Symptoms and signs compatible with known features of withdrawal state. Any 3 of the 
following signs must be present for opioid withdrawal state: craving for opioid drug, 
rhinorrhoea or sneezing, lacrimation, muscle aches or cramps, abdominal cramps, nausea 
or vomiting, diarrhoea, pupillary dilation, piloerection, recurrent chills, tachycardia, 
hypertension, yawning, or restless sleep. 
3) All these symptoms and signs cannot be accounted for by a medical disorder unrelated to 
opioid use disorder. 
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1.2.3 OPIOID SUBSTITUTION THERAPY 
Opioid substitution therapy (OST) with methadone, buprenorphine (commercially 
marketed as Subutex or Suboxone [buprenorphine/naloxone]) is currently the most 
effective and approved treatment to achieve abstinence from heroi, and to avoid or 
minimize harm associated with drug use (Strang et al., 2012), although some risks 
associated with OST have been highlighted in the literature (e.g. Degenhardt et al., 
2014a), as will be explored in further chapters.   
 
These long-acting opioids provide relief from craving and withdrawal symptoms and 
allow the patient to escape the domination of illicit opioids over the rest of their lives. 
The large amounts of time previously spent getting money to buy the drug, being 
intoxicated, or withdrawing is now freed up by the use of a single daily dose of 
supervised, pure and long-acting opioid (Darke, 2011).  
 
Once stability is achieved and sustained the opioid maintenance dose can be slowly 
reduced, and in stable cases, weaned off altogether. Maintenance opioid treatment of 
heroin dependence results in 70% reduction in heroin use and improved treatment 
retention compared with non pharmacological treatments, but with substantial dropout 
from treatment with only about 40%-50% of patients remaining in treatment at six 
months (Mattick et al., 2014; Connock, 2007; The National Institute for Health and 
Clinical Excellence [NICE], 2007). It avoids the multiple complications associated 
with injecting drug use, substantially reduces criminal activity and enables re-
engagement in routine life (Darke, 2011).  
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Public Health England’s (PHE, 2015) report states that the number of people in 
treatment for opiate misuse has been steadily declining in recent years from 170,032 
in 2009/10 to 152,964 in 2014/15. This is particularly the case for younger people 
(under 25) where the number of people presenting for treatment for opiate misuse has 
declined by 60% between 2009/10 and 2014/15. In contrast, since 2009/10, the 
number of opiate users aged 40 and over starting treatment has risen by 21%. This 
ageing cohort of heroin users often have a range of complex physical illnesses as a 
result of long-term drug use, which may make them particularly vulnerable (Office 





1.3 EPIDEMIOLOGY OF OPIOID USE 
1.3.1 HISTORICAL USE OF OPIOIDS 
Despite difficulties in interpreting ancient writings and archaeological data, a picture 
of opium use in antiquity does emerge from them. The Sumerians (Iraq) cultivated 
poppies and isolated opium from their seed capsules at the end of the third 
millennium B.C. It appears that opium spread from Sumeria to the remainder of the 
old world (Brownstein, 1993). Most authors agree that, as early as the eighth century 
A.D., Arab traders brought opium to India (Dwarakanath, 1965) and China (Fort, 
1965) and that between the tenth and thirteenth centuries opium made its way from 
Asia Minor to all parts of Europe. After the invention of the hypodermic syringe and 
hollow needle in the 1850s, morphine began to be used for minor surgical procedures, 
for postoperative and chronic pain, and as an adjunct to general anaesthetics 
(Brownstein, 1993). 
 
Throughout the 19th century opium could be purchased directly from chemists and 
even grocers (Berridge, 2009; Berridge & Mars, 2004; Strang, 1990). Opium imports 
rose from 17,302 pounds in 1827 to 61,269 by 1859 (London, 2005). Britain became a 
major world supplier of narcotics through its colonial possessions and only 
relinquished this role after World War I. In 1868, the Poisons and Pharmacy Act was 
passed, which restricted the right to supply opium to health professionals and required 
precise labeling and recording (Berridge, 2009). Patent medicines were restricted 
towards the end of the century, and in 1908, opium was placed on the Poisons List. 
During the five years after 1868, accidental opiate poisonings fell by 26%, and 
dropped a further 20% following the 1908 Act (London, 2005) 
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In the early decades of the 20th century, opiate use was rare, and in the 1920s, fewer 
than a hundred cases were prosecuted each year under the Dangerous Drugs Act 
(Berridge & Edwards, 1981; London, 2005). Heroin was unusual and half the cases 
were Chinese men using opium. Of morphine users, two-thirds were doctors, nurses, 
or pharmacists, and most offenses were for forged prescriptions. The illicit opiate 
trade was small, and the management of opiate addiction was left largely in the hands 
of the medical profession (Berridge & Edwards, 1981; London, 2005). Concern 
mounted in the 1960s when the profile shifted toward marginalized young men using 
heroin in a way that was more akin to the situation in the United States. The number 
of known heroin addicts grew from around 50 in 1957 to almost 1300 a decade later, 
finally reaching 20,000 in 1996, half of them new to treatment services (Ghodse, 
2002). There has been a steady rise in opiate use, with consumption spreading from 
metropolitan centres into rural communities and notable surges in response to 
international events altering the illicit chain of supply (United Nations on Drugs and 
Crime [UNODC], 2015). 
 
1.3.2 CURRENT PREVALENCE OF OPIOID USE 
Opioid use is a global problem. It was estimated that, worldwide, between 26 and 36 
million people aged between 15 and 64 used opioids in 2010 (UNODC, 2012), which 
translates to between 0.6% and 0.8% of the global population. Rates appeared to be 
highest per capita in Europe (0.6%-0.7%), followed by Americas and Oceania (0.4%), 
Africa (0.2%-0.5%) and Asia (0.3%-0.5%). Nearly half, or between 13 million and 21 
million, of global opioid use constitutes the use of opiates, particularly heroin 
(UNODC, 2012). Recent use estimates in some major heroin markets include the 
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United Kingdom (0.1%), the United States (0.2%) and Australia (0.2%) (Darke, 
2011).  
 
Approximately 10.4 million people aged 15 years and older in 1990 were opioid-
dependent and 15.5 million people in 2010, according to the Global Burden of 
Diseases, Injuries, and Risk Factors Study (GBD) - the largest and most 
comprehensive effort to date to measure epidemiological levels and trends worldwide 
(Degenhardt et al., 2014b).  
 
The largest absolute numbers of opioid-dependent people in 2010 were estimated to 
be in South Asia (4.3 million people), East Asia (2.2 million), North Africa and the 
Middle East (1.37 million) and western Europe (1.32 million) (Degenhardt et al., 
2014b). However, the underlying methodology, as defined in DSM-IV (4th edition of 
the Diagnostic and Statistical Manual of Mental Disorders) (American Psychiatric 
Association [APA], 2000), for these estimates are restricted to dependence and 
exclude abuse or harmful use (as defined in ICD-10), therefore are likely to 
underestimate the real burden of drug use.  
 
In England and Wales, only 0.1% of responders in the recent Crime Survey in 
England and Wales (CSEW, 2015) indicated the use of opioids, which is relatively 
rare when compared to other illicit drugs (presented in Table 1.2). However, as a 
household survey, the CSEW does not cover groups such as the homeless, or those 
living in institutions such as prisons, therefore, are likely to underestimate the burden 
of opioid use within England and Wales. The PHE, a more accurate estimate (but only 
reporting figures for opiates and/or crack cocaine) reports that more than 250,000 
people in England used opiates in 2011/12 (PHE, 2013) 
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Nonetheless, despite differences in prevalence reporting, more than 150,000 people 
who were using opiates were in addiction treatment (between 2014-15), which 
constitutes an overwhelming majority of all clients in contact with addiction treatment 




1.4 WHY MORTALITY AMONG OPIOID-USERS MATTERS 
1.4.1 ETHICAL RESPONSIBILITY 
The prevention of premature death is generally considered uncontroversial and the 
same approach should be applied for drug-related harm. Literature demonstrates 
several clear precursors for increased risk of opioid use and opioid dependence. In 
particular, the development of problematic drug-use has been strongly associated with 
“shattered childhood” (Rosow & Lauritzen, 2001), parental psychopathology, parental 
drug and alcohol problems, early loss of parents, and childhood sexual and physical 
abuse (Rossow & Lauritzen, 2001). The development of opioid-dependence is 
therefore not a random occurrence.  
 
Consistent with this view, levels of psychopathology such as major depression and or 
personality disorders are high amongst opioid-users (Drake & Ross, 1997; Teesson et 
al., 2005) (discussed in more detail in Chapter 2 and 4). Therefore, the majority of 
problematic drug users come from backgrounds that increase their risk of serious 
psychopathology and of drug dependence. 
 
Furthermore, the majority of drug-related fatalities occur amongst dependent drug 
users (Darke et al., 2007). Opioid dependence is a well-recognized psychiatric 
diagnosis and the syndrome includes both physical and psychological symptoms. The 
core feature of opioid dependence is a loss of control over use of the drug (as 
specified earlier) (WHO, 1993; APA, 2000). The person may be physically dependent 
on the drug, experiencing drug tolerance and withdrawal symptoms, and continue to 
use despite repeated efforts at abstinence (Darke, 2011). Therefore, drug-use should 
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not be regarded as a choice when the person had been diagnosed as having lost control 
over their drug use.  
 
It is also unclear how drug-related deaths could be distinguished from other fatalities 
that are universally deemed worthy of clinical intervention - for example, tobacco, 
alcohol-related disease or suicide. Suicide itself, as will be discussed further below 
and in Chapter 4, is a major cause of death amongst opioid users (Darke & Ross, 
2002). 
 
Finally, the typical onset of illicit drug use occurs in the teenage years (Degenhardt et 
al., 2000), prior to the person becoming an adult deemed ethically or legally 
responsible for their own actions. While the person may die as an adult, the 
dependence that leads to his or her death, typically, was acquired as a minor, 
particularly when adverse events in childhood have occurred.   
 
1.4.2 COSTS TO SOCIETY 
Opioid use places a substantial cost burden upon societies. For example, there is a 
strong association between dependent drug use and crime (Flynn et al, 2003). This 
association, however, is between drug use and crimes committed by dependent drug 
users to acquire money to purchase drugs (Darke, 2011; Flynn et al, 2003). 
Importantly, the frequency of acquisitive crime has been demonstrated to co-vary with 
the frequency of illicit drug use (Flynn et al., 2003) and with criminal behaviours 
declining markedly as a result of drug-treatment programs (Hardwood, 1990).  
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In addition to crime, injecting of drugs, especially opioids, is strongly associated with 
disease and disease transmission. The sharing of used injecting equipment is a major 
transmission factor for human immunodeficiency virus (HIV) and hepatitis C virus 
(HCV) (Karch, 2002), as discussed further below. There are also a range of other 
pathologies associated with drug use, including cardiovascular disease, pulmonary 
disease, renal complications and neuropathology (Pierce et al., 2015). As with crime, 
however, the health of illicit drug users improves substantially after entering drug-
treatment programs (Gossop et al., 2002).  
 
While there are substantial costs associated with illicit drug use, the deaths of large 
numbers of drug users also imposes a substantial cost upon society. As will be seen in 
later chapters, the average age of death amongst illicit drug users is around 35 years 
(Gossop et al., 2002; Stebnacka, 2010). Given the relatively young age of such deaths, 
there is considerable lost productivity due to truncated lifespan.  
 
1.4.3 NATURAL HISTORY OF DRUG USE 
Illicit drug use typically commences in the mid-teenage years, peaks in the 20-30-year 
age group, and declines sharply in older age groups (Chen & Kendel, 1995). The 
natural history of illicit drug use is therefore skewed toward the younger years. A 
person may use drugs in their 20s or 30s, but he or she may cease to do so in later 
years. The highest risk of illicit drug use, and of mortality, is therefore focused over a 
relatively short period of time in one’s life. Many dependent users may be seen to 
“mature out” of drug use, although this may take considerable time (Flynn et al., 
2003; Darke et al., 2007). Drug-treatment programs produce substantial 
improvements in the psychological profile of dependent users (Mattick et al., 2009; 
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2014). A dependent user may be a high-risk person who imposes a societal burden, 
they may not however remain a dependent user or continue to impose such burden. 
 
1.4.4 FAMILIES OF DRUG USERS 
Although not directly discussed in this thesis, the impact of deaths upon the families 
of opioid users must also be considered in this section. The loss of loved ones through 
drug use matters greatly to the families of drug users (Strang et al., 2008; Williams et 
al., 2014). In considering whether drug use mortality is a legitimate matter of concern, 
the drug user must not be seen in isolation. The death of a drug user does not only 
affect the user themselves, but also those surrounding them (Strang et al., 2008). The 
most salient issue here clearly concerns the children of drug users. As mentioned 
earlier, early parental loss is associated with increased risk of the development of 
subsequent psychopathology, as well as increased risk of drug dependence and of 





1.5 MORTALITY RATES AND THE BURDEN OF DISEASE 
According to the GBD (Degenhardt et al., 2014b) a total of 9.2 million DALYs 
(disability-adjusted life years) were attributed to opioid dependence in 2010: 0.37% of 
global DALYs. The GBD is the most comprehensive worldwide observational 
epidemiological study to date, which describes mortality and morbidity from 
major diseases, injuries and risk factors to health at global, national and regional levels. 
 
This burden was estimated to have increased markedly over time, with increased 
prevalence of opioid dependence the predominant driver of increased burden, rather than 
changes in the age structure or size of the global population. The GBD concluded that 
opioid dependence is an increasing source of global disease burden, with substantial 
regional variations; and also with striking variations in the contribution made by YLLs 
(years of life lost due to premature mortality) to regional-level opioid burden. In 
particular, North America, Eastern Europe and Southern sub-Saharan Africa had greater 
than 50% of DALYs attributable to YLLs; possibly due to limited access to interventions 
that reduce mortality (e.g. OST, needle exchange, HIV/HCV medication).  
 
In England and Wales, deaths involving heroin and/or morphine (heroin is metabolised 
as morphine and hence, the presence morphine often indicates heroin use) doubled in the 
last three years, from 579 in 2012 to 1,201 in 2015, and are now the highest on record 
(ONS, 2016).  
Despite relatively rare prevalence of opioid use, compared with other illicit substances 
(CSEW, 2015), there were more than 6000 drug-related deaths involving opioids in the 
last 5 years (ONS, 2016) (presented in Table 1.2).  
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Between 2008 and 2012, the ONS noted a decline in heroin/morphine related deaths, 
with a particularly sharp fall between 2009 and 2011 (ONS, 2016). This most recent 
reversal means that the mortality rate in 2015 was the highest since records began in 
1993 and now exceeds the previous peak in 2008, which occurred before the “heroin 
drought” in 2010/11 (Serious Organized Crime Agency [SOCA], 2011, 2012, 2013, 
2014). Heroin and methadone continuously form the largest proportion of opioid-related 
deaths (presented in Figure 1.1) (PHE, 2016). 
Increases in the number of drug related deaths (DRD), particularly those involving 
heroin/morphine, were seen across all ages between 2014 and 2015, with the biggest 
rises occurring in those aged 50 to 69. Both the male and female mortality rate for deaths 
involving heroin/morphine increased in 2015, but the increase was sharper in males 
(31% compared with 9%) (PHE, 2016). Different DRD trends between gender are seen 
over time; for example, the sharp fall between 2009 and 2011 was only seen in males, 
while female rates remained stable during this time. These gender differences may be 
partially explained by the fact that a greater proportion of female deaths involving 
heroin/morphine are suicides (rather than accidental overdoses), which are less likely to 














1.6 CAUSES OF DEATH 
1.6.1 OVERDOSE 
By the age of 50, approximately half of any cohort of opioid users will have died 
(Degenhardt et al., 2011), although there will be geographical variation to this 
estimate depending on, for example, availability of treatment, availability of harm 
reduction intervention and the prevalence of BBV.  Nonetheless, as will be seen in 
later chapters, overdose (OD) is the most common cause of death (Brugal et al., 2005; 
Darke & Hall, 2003; Warner-Smith et al., 2001). Worldwide, an estimated 69,000 
people die from opioid overdose (accidental or deliberate) each year (WHO, 2014). In 
England and Wales, more than 1700 deaths registered in 2014 (53% of all deaths from 
drug poisoning) involved an opiate drug (ONS, 2015).   
 
Existing literature has identified several prominent overdose risk factors. The typical 
overdose fatality occurs in a long-term, dependent, drug-injecting user in their 30s or 
older (Pierce et al., 2015; Stebnacka et al., 2010). Overdoses overwhelmingly occur 
when the person is not enrolled in drug treatment (Darke et al., 2000; Davidson et al., 
2003; Pierce et al., 2016). An important feature to be noted (and one which this thesis 
considers) is that while the “picture” here is of high heroin tolerance due to frequent 
use, there are occasions of reduced tolerance that increase transient overdose risk. 
This aspect is explored in the next chapter and more fully in Chapters 6-7, where 
reinstatement of use after a period of abstinence, such as post-detoxification with 
cessation of OST or after prison release, is associated with substantially increased 
mortality risk (Cornish et al., 2010; Cousins et al., 2016; Farrell & Marsden, 2008; 
Strang et al., 2003).  
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Concomitant use of other CNS depressants, such as alcohol and benzodiazepines, has 
also been identified as one of the most prominent overdose risks, due to the 
potentiation of the respiratory depressant effects of heroin (Darke et al., 2007; Jones et 
al., 2012). This risk also extends to deaths attributed to other opioids such as 
methadone and buprenorphine (Oliver et al., 2007). By far the most common 
substance detected is alcohol, presented in half or more of overdose cases (Darke et 
al., 2010). Concomitant alcohol use and overdose mortality is also explored in more 
detail below and in Chapter 4. 
 
The route of heroin administration is also of importance. In particular, injecting is 
associated with the highest risk for overdose, due to delivery of a bolus to the brain 
(Gossop et al, 1996; Milloy et al., 2008; Pierce et al., 2016; Powis et al., 1999).  
 
Finally, non-fatal overdoses are of clinical significance because a history of overdose 
strongly predicts future overdoses, thus those who overdose are more likely to do so 
again (Darke et al., 1996; McGregor et al., 1998; Powis et al., 1999; Kerr et al., 2007). 
Non-fatal overdose often includes prolonged unconsciousness and is associated with a 
range of serious health risks, such as pulmonary oedema, bronchopneumonia, ‘crush 
syndrome’ (rhabdomyolysis), renal failure, cognitive impairment and traumatic 
injuries sustained during an overdose (Warner-Smith et al., 2001, 2002). It is 
estimated that the proportion of heroin overdoses that result in death is between 2% 
and 4% (Darke et al., 2003). Thus, for every fatal overdose, 25-50 ‘near-misses’ 
might be expected.  
 
Studies consistently report that one- to two-thirds of users have overdosed, usually on 
multiple occasions, with annual rates of 15%-25% (Britton et al, 2010; Wines et al., 
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2007). While non-fatal overdoses are certainly a matter of importance, I was unable to 
explore non-fatal overdoses in these thesis due to the methodological constraints 
described in Chapter 3. 
 
1.6.2 SUICIDE 
It is estimated that heroin dependence is associated with a completed suicide risk 14 
times that of the general population (Harris & Barraclough, 1997; Wilcox et al., 
2004). Studies report that 5–10% of heroin user deaths are due to suicide (Maxwell et 
al., 2005, Stenbacka et al., 2010).  
 
A range of psychopathology has been associated with suicide, with mood disorders 
having a particularly strong relationship, where risk increases 20-fold (Harris & 
Barraclough, 1997, Wilcox et al., 2004). Similarly, a history of family dysfunction, 
social isolation and disadvantage are also associated with higher suicide risk (King & 
Merchant, 2008).  
 
Research has consistently identified a considerable gender difference in suicide risk in 
OUD. Studies indicate that, while females are three times more likely than males to 
attempt suicide, males are three times more likely to complete suicide (Diekstra & 
Gulbinat 1993). Males predominantly employ violent methods for suicide, such as 
shooting and hanging, while females are more likely to employ non-violent methods 
such as drug poisoning (Tsirigotis et al., 2011). This gender difference in suicide 
method may at least partially explain the male predominance in completed suicides.  
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In the case of drug-poisonings, it is necessary to distinguish between suicide and 
accidental overdose. Differentiating deliberate and accidental heroin overdose can be 
problematic, due to ambiguous circumstantial information and unclear intent 
(Cantor et al., 2001).  
 
Several authors have noted an overall association between heroin overdose and 
suicide (Best et al., 2000; Murphy et al., 1972; Neale 2000; Rossow & Lauritzen 
1999) and suicidal intent is argued to occur in at least some of the of overdose cases 
(Best et al. 2000; Neale 2000). However, most studies have concluded that the 
majority of overdoses are accidental (Best et al., 2000; Darke et al., 2000; Darke & 
Ross 2001). The latest figures on drug related deaths in England and Wales also 
report that most opioid misuse deaths are accidental poisonings (PHE, 2016), the 
proportion of drug-misuse deaths which are suicides was 28% in females and 11% in 
males in 2015 (ONS, 2016). However, limitations in coding and methodology are also 
noted (ONS, 2014). Figure 1.2 below indicates that accidental overdose fatalities 
make up a larger proportion of drug related deaths than suicides in England and that 
this has been consistently the case over a number of years (PHE, 2016). 
 
As will be explained in later chapters, where cause-specific mortality is analysed, the 
primary focus of this thesis is on overdose fatalities. Therefore, both deliberate drug 
poisonings (i.e. suicide) and unintentional drug poisonings (i.e. accidental overdose) 
are grouped together, but with violent suicides grouped into unnatural deaths. The 
assessment of suicide risk and subsequent detection of suicidality in OUD patients is 











There are specific disease risks associated with illicit opioid use that occur at much 
lower levels amongst the general population. Hepatic, infectious, respiratory and 
circulatory diseases form a large proportion of deaths in opioid dependent patients (as 
will be explored in Chapter 3) (Darke et al., 2006; Pierce et al., 2015).  
 
People who inject drugs (PWID) are at particular risk of infection with HIV or HCV 
transmitted through shared needles and syringes or through unprotected sexual 
activity (in the case of HIV) (Nelson et al., 2011; Page et al., 2013). Injecting drug use 
is thought to be the primary risk factor responsible for the spread of HIV in Eastern 
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Europe, Central Asia and Latin America (Joint United Nations Programme on 
HIV/AIDS [UNAIDS], 2004). In England, Wales and Northern Ireland, 1.0% of the 
PWID surveyed in 2014 were infected. Among those attending needle and syringe 
programs in Scotland during 2013-14, 0.8% were HIV antibody positive (PHE, 
2015a). In 2013 alone, 530 deaths among people with HIV in England and Wales 
were reported (PHE, 2015). 
 
HCV is a disease of the liver which, if not resolved, can lead to chronic liver disease, 
cirrhosis and cancer. HCV is also a more robust virus than HIV and more easily 
spread (EMCDDA, 2016). The incidence of HCV among PWID in Europe is high 
(range 2.7–66 per 100 person-years, median 13), according to a recent review 
(Wiessing et al. 2014). Hahné et al. (2013) estimated the prevalence of anti-HCV 
(HCV positive test result) in PWID was on average almost 50 times higher than that 
in the general population. Co-infection of HIV and HCV is also common, with 
prevalence as high as 70-95% (Strader, 2005; Wiessing et al. 2014).  
 
PHE estimates that 160,000 people in England are living with HCV. Between 2005 
and 2014, deaths from HCV-related end-stage liver disease and hepatocellular 
carcinoma (liver cancer) in the UK more than doubled, rising from 215 in 2005 to 457 
in 2014 (PHE, 2015). 
 
Pulmonary diseases are also common in this patient group. PWID have a 10-
fold increased risk of community-acquired pneumonia compared with the general 
population (Hind, 1990). The incidence of tuberculosis in those who misuse heroin 
increases by 6-fold compared to the general population, and 13-fold if the heroin user 




CHAPTER 2 MORTALITY RISK FACTORS IN OPIOID USERS: LITERATURE 






2.1 CHAPTER OVERVIEW 
This chapter discusses key mortality risk factors in people who misuse opioids. These risks 
are categorized into patient-level risk factors and service-level risk factors. The former 
includes risks associated with socio-demographic factors, concomitant drug use and 
psychiatric well-being. The latter focuses on assessment of drug-related risks in secondary 
drug and alcohol services, risks associated with cessation of OST and those associated with 
disruptions in patient care (such as that during a transfer of patient and their care to an 
alternative service provider). Research limitations and gaps in existing literature are 





2.2 MORTALITY RISK FACTORS: PATIENT-LEVEL 
2.2.1 SOCIO-DEMOGRAPHIC FACTORS 
Table 2.1., below, presents known demographic and psychosocial risk factors 
associated with increased mortality amongst opioid users, which will be described 
here and in the following subsections.  
 
Although recent evidence (Pierce et al., 2015) shows a narrowing gender-specific risk 
with age, being male is still considered a risk factor for mortality, especially fatal 
overdose, amongst heroin users. The majority of deaths worldwide attributable to 
heroin use occur amongst males (Degenhardt et al., 2011). Males constitute around 
three-quarters of deaths in both cohort and coronial studies (Bargagli et al., 2001; 
Bartu et al., 2004; Cornish et al., 2010; Darke, 2011; Davoli et al., 1997; Davoli et al., 
2007; Ghodse et al., 1998; Gossop et al., 2002; Pierce et al., 2015; Oppenheimer et 
al., 1994), and an overwhelming number of fatal overdoses, with some studies 
showing rates up to 80% (Darke et al., 2000; Davidson et al., 2003; Fugelstad et al., 
2003; Hickman et al., 2003; Preti et al., 2002).  
 
Given that most heroin users typically begin their heroin use in their late teens, age at 
first drug-use is also an important factor to consider because longer duration of 
heroin-using has been related to higher risk of mortality (Brugal et al., 2005). While 
death among young heroin users does occur, it is the older and more experienced user 
who is at most risk of death, as older age (older age relative to age at first use - i.e. 30 
years old and over) is repeatedly reported as an independent predictor of mortality 
(Bargagli et al., 2001; Bartu et al., 2004; Cornish et al., 2010; Ghodse et al., 1998; 
Gossop et al., 2002; Pierce et al., 2015; Stebnacka et al., 2010).  
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The social profile of a typical heroin user is also one of poverty, which is known to 
increase mortality considerably (Coffin et al., 2007). Studies of street heroin users, 
those entering treatment and those in treatment almost universally report that most 
heroin users are unemployed, with rates ranging from two-thirds to 90% (Bell et al., 
2007; Haasen et al., 2007; Hser et al., 1999; Maloney et al., 2009; Ross et al., 2005). 
Relating to this, the majority of heroin users have not completed high school and 
university qualifications are rare (Coffin et al., 2007; Darke et al., 2010b). Lower 
socio-economic status, including homelessness and housing instability, is common 
among mature users (Coffin et al., 2007) and is known to be associated with higher 
levels of psychopathology, poorer health and is a risk factor for overdose and 






Table 2.1 Key patient-level factors associated with increased overdose and mortality in 
opioid users. 
Variable Risk factor Key studies 
Gender Males 
Bargagli et al., 2001; Bartu et al., 2004; 
Davoli et al., 1997; Davoli et al., 2007; 
Ghodse et al., 1998; Gossop et al., 2002; 
Oppenheimer et al., 1994; Pierce et al., 2015 
Age 
Older opioid users 
(30y/o+) 
Bargagli et al., 2001; Bartu et al., 2004; 
Cornish et al., 2010; Ghodse et al., 1998; 
Gossop et al., 2002; Pierce et al., 2015; 




Amundsen, 2015; Darke & Ross, 2001; 
Davoli et al., 1993; Hser et al., 2001; Lee et 
al., 2013. 
Treatment status Not enrolled 
Darke et al., 2000; Davidson et al., 2003; 
McGregor et al., 1998; Pierce et al., 2016 
Tolerance Reduced  
Cornish et al., 2010;  Cousins et al., 2015; 
Davoli et al., 2007; Merrall et al., 2010;  
Ravandal & Amundsen, 2010; Singleton et 
al., 2003; Strang et al., 2003;  Tagliaro et al., 
1998 
Polydrug use 
Alcohol and other 
CNS depressants 
Darke et al., 2010; Davidson et al., 2003; 
Degenhardt & Hall, 2012; Fugelstad et al., 
2003; Hickman et al., 2003;  Kerr et al., 
2007; Pierce et al., 2016; Preti et al., 2002 
Psychiatric 
wellbeing 
Poor. High levels of 
psychopathology 
Arendt et al., 2011; Bargagli et al., 2006; 
Darke & Ross 2002; Ghodse et al., 1985; 
Gossop et al., 2002; Davoli et al., 1993; 
Shah et al., 2008 
Route of opioid 
administration 
Injecting 
Brugal et al., 2002; Carpenter et al., 1998; 
Darke et al., 2005b; Milloy et al., 2008;  
Pierce et al., 2016; Swift et al., 1999; Yin et 
al., 2007;   
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2.2.2 CONCOMITANT DRUG USE 
Possibly the most important finding to emerge from heroin overdose research is the 
role of polydrug use (Darke, 2011). The overwhelming majority of overdoses, both 
fatal and non-fatal (Darke et al., 2010; Davidson et al., 2003; Degenhardt & Hall, 
2012; Fugelstad et al., 2003; Hickman et al., 2003; Pierce et al., 2016; Preti et al., 
2002) involve the concomitant consumption of heroin with other drugs. The extent of 
polydrug use among “heroin” overdoses suggests that “polydrug toxicity” is a better 
description of the toxicology of overdose (Darke & Zador, 1996). The major drugs 
associated with an increased risk of fatal and nonfatal heroin overdose are alcohol and 
benzodiazepines (Warner-Smith et al., 2001). 
 
Alcohol is, by far, the most common concomitant drug and is present in a half or 
more of fatal overdose cases (Darke & Zador, 1996; PHE, 2016; Sporer, 1999; 
Warner-Smith et al., 2001). Figure 2.1 displays a general falling trend in the 
proportion of heroin deaths where only heroin was mentioned (30% in 2012), whereas 
the proportion where alcohol was mentioned alongside heroin has increased and now 
exceeds the figure for heroin alone (being 43% in 2012) (PHE, 2016). 
 
Studies report rates of current drinking by heroin users as ranging between 25-75% 
and with about a quarter or more drinking to excess daily (Darke et al., 2006, Quan et 
al., 2007). Consistent with this view, high levels of alcohol dependence among OUD 
patients is present (as will be explored in Chapter 4). Studies report the presence of 
AUD ranging between 25% to 50% amongst OUD patients (Cacciola et al., 2001; 








An extensive literature focus on the link between overdose deaths and the 
concomitant use of alcohol and heroin (Darke et al., 2010; Davidson et al., 2003; 
Fugelstad et al., 2003; Hickman et al., 2003; Preti et al., 2002). While the co-use of 
alcohol and heroin poses a serious risk of fatal overdose, relatively limited attention 
has been given to investigations beyond overdose deaths (Johnson et al., 2015).  
 
Independently of opioid use, heavy alcohol use and dependence is associated with a 
higher risk of mortality (Harris & Barrclough, 1998), including liver disease, 
cardiovascular disease, cancers, suicide and traumatic accidents (Murray et al., 1997). 
Liver disease is particularly problematic in the heroin using population due to high 
rates of HCV. Therefore, any additional use of alcohol in conjunction with hepatic 
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disease might speed up the progression of liver disease. The risk of developing 
cirrhosis in patients who are HCV-positive and abuse alcohol is 147 times greater 
than HCV-positive patients who abstain (Poynard et al., 1997).  
 
Although previous studies have denoted that fatal overdose accounts for the majority 
of deaths in the illicit drug using population (Darke & Hall, 2003; Brugal et al., 2005), 
other acute and chronic diseases also contribute to mortality. This is especially true 
for PWID, where the majority of non-overdose related deaths are attributable to 
preventable risk factors including infectious disease and suicide (Johnson et al., 2015; 
Miller et al., 2007). This limitation was raised in a recent publication (Johnson et al., 
2015) but specific non-overdose causes were not fully explored (a limitation which is 
addressed in Chapter 4). Furthermore, there also seems to be contradictory evidence 
with regards to overdose - that although a major cause, overdose accounted for a 
minority of premature mortality in a recent, large, English cohort (Pierce et al, 2015). 
There may also be epoch effects /geographical variability (vs. non-UK) due to the 
ageing – thus increased vulnerability to disease/overdose due to accelerated ageing - 
of UK opioid user cohorts that initiated use in the 1980s/90s.  
 
2.2.3 PSYCHOLOGICAL WELL-BEING   
OUD is also strongly associated with other psychiatric disorders, especially mood and 
personality disorders, in both clinical (Brooner et al., 1997; Weaver et al., 2003) and 
general population samples (Rodriguez-Llera et al., 2006). Lifetime psychiatric 
comorbidity ranges from 44% to 93% amongst the heroin using population (Brooner 
et al., 1997; Cacciola et al., 2001; Khantzian and Treece, 1985; King et al., 2000; 
Krausz et al., 1999; Mason et al., 1998).  
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Individuals with OUD are at risk of developing mild to moderate depression that 
meets symptomatic and duration criteria for persistent depressive disorder 
(dysthymia) or, in some cases, for major depressive disorder (Compton et al. 2005). 
These symptoms may represent an opioid-induced depressive disorder or an 
exacerbation of a pre-existing primary depressive disorder. Periods of depression are 
especially common during chronic intoxication or in association with physical or 
psychosocial stressors that are related to the opioid use disorder (APA, 2013).  
 
Antisocial personality disorder is a rare diagnosis in the general community (4%) 
(Robins and Regier, 1991), but has been reported to occur at rates of up to 65% in 
heroin-using samples (Bargagli et al., 2006; Compton et al., 2005; Darke et al., 1994). 
In addition, people with a diagnosis of PD have a four-fold higher mortality, with 
substantially reduced life expectancy (Fok et al., 2012). Similarly, substantially higher 
mortality rates are found in people with SMI and depressive disorders when compared 
to the general population (Chang et al., 2010).  
 
Psychiatric comorbidity is associated with poor treatment prognosis, greater 
psychosocial impairment, increased risk of relapse and higher rates of HIV risk 
behaviour (Arendt et al., 2007; Brooner et al., 1997; Darke and Ross, 1997; Disney et 
al., 2006; Landheim et al., 2006; Rounsaville et al., 1982, 1998). In spite of this, the 
impact of psychiatric comorbidity on mortality risk in substance use disorders has 
received only moderate attention, with existing investigations reporting mixed results 
(Arendt et al., 2011; Gossop et al., 2002; Mattisson et al., 2011)  
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For example, a nationwide Norwegian study found no associations between 
psychiatric comorbidity (schizophrenia-spectrum disorder, affective disorder, 
personality disorder) and all-cause mortality in heroin/opioid users (Arendt et al., 
2011). Gossop and colleagues (2002) on the other hand, presented findings of the 
association between psychological problems and mortality, but the results were 
somewhat unexpected because higher levels of anxiety were predictive of increased 
mortality but no statistically significant association was found between depression and 
mortality. This study, as well as others (Bartu et al., 2004; Johnson et al., 2005; 
Ravndal & Vaglum, 1998), also only assess one type of symptom (e.g. anxiety score, 
thoughts of suicide) rather than psychiatric diagnosis; and are limited to investigations 
of only all-cause or drug-related deaths and often does not specifically investigate 
natural causes of death (as discussed earlier). Results presented in Chapter 4 explore 





2.3 MORTALITY RISK FACTORS: SERVICE-LEVEL 
2.3.1 ASSESSMENT OF RISK 
Assessing and managing risks is a paramount element of care planning and treatment 
provision for people with drug dependence, particularly in opioid dependence where 
risk of mortality is especially high (DoH, 2007). Structured risk assessments are 
frequently used but the NTA advises that risk assessments should be substance misuse 
specific, prioritizing risks directly related to opioid dependence (NTA, 2006a; 2006b)  
 
However, the effectiveness of risk assessment tools in predicting mortality in mental 
healthcare is still unclear. Wand and colleagues reported the inability to conduct a 
systematic review due to paucity of studies evaluating the effectiveness of risk 
assessments and found little evidence to conclude whether risk assessments are 
effective in relation to self-harm or suicide reduction (Wand, 2012).  Other studies 
attempting to identify high-risk individuals have been largely unsuccessful primarily 
due to its low prevalence, even within high-risk groups (Harris & Hawton, 2005); or 
were limited to all-cause mortality and generalized mental-health diagnosis (Wu et al., 
2012). 
 
Within South London and Maudsley (SLaM) NHS Foundation Trust, substance 
misuse and dependence relevant risks are recorded using the Brief Risk Scale 
Assessment for Addictions (BRSA-A) (see Chapter 5) – a measure developed by 
SLaM addiction clinicians to encourage identification and formal recording of risk 
areas specific to substance misuse patients; and used in their care planning (SLaM, 
2011). However, no formal evaluation of this risk tool was conducted and Chapter 5 
addresses this gap.  
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2.3.2 “SUCCESSFUL” END OF TREATMENT  
OST is the most widely used treatment approach for opioid dependence and it is 
associated with substantial reduction of heroin use and associated risks (Brugal et al., 
2005). Overdoses overwhelmingly occur when the person is not enrolled in drug 
treatment (Darke et al., 2000; Darke et al., 2005; Davidson et al., 2003). An important 
feature to be noted (and one which this thesis considers) is that the picture here is of 
high heroin tolerance due to frequent use. However, there are occasions of reduced 
tolerance that increase transient overdose risk (Cornish et al., 2010; Cousins et al., 
2016; Davoli et al., 2007; Merrall et al., 2010; Ravndal & Amundsen, 2010; Singleton 
et al., 2003; Strang et al., 2003; Tagliaro et al., 1998). 
 
There appears to be a transient elevated risk of death in the very early stages of 
treatment (first 28 days) (Degenhardt et al., 2009) and following the end of OST 
treatment (Cornish et al., 2010; Davoli et al., 2007; Cousins et al., 2016).  
 
Table 2.2. summarises results and limitations of studies which have specifically 
investigated mortality after discharge from services in opioid users. The search 
strategy for this peer-reviewed study search was conducted in PubMed/MEDLINE 
and PsychINFO, using Boolean operators for opioid / heroin / opiates / drug-use / 
substance (ab/mis)use and death / mortality and treatment / discharge / detoxification 
(wildcards were used where appropriate). The search was restricted to originally 
published research between 1980 – 2016. Hand search through references of relevant 
studies was also conducted, which is how two meta-analysis (Degenhardt et al., 2010; 
Mathers et al., 2013, included in Table 2.2) were found.   
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To summarize, Strang and colleagues (2003) conducted a small study to test whether 
loss of tolerance increased the risk of overdose and found that patients who 
“successfully” completed inpatient detoxification (“lost tolerance” group) were more 
likely than other patients to have died within a year. None of the patients who failed to 
complete detoxification (i.e. dropped out) died.  
 
These findings were subsequently confirmed by larger studies (Cornish et al., 2010; 
Cousins et al., 2015; Davoli et al., 2007; Merrall et al., 2013). A large Italian study 
(Davoli et al.,2007) demonstrated higher excess mortality by overdose in the first 30 
days after treatment completion or cessation: more than three times higher than 
subsequent period 31 or more days after treatment. Cornish (2010) found that the risk 
of death increased eightfold to ninefold in the month immediately after the end of 
OST (presented in Figure 2.2 below). They also found no strong evidence that these 
effects varied according to the type of treatment (methadone or buprenorphine) or 





Figure 2.2 Adjusted risk of death, compared with not being on treatment, during and after 




However, as presented in Table 2.2 below, several limitations in literature 
investigating mortality rates after cessation of treatment were noted. First, studies are 
limited to very small or inpatient or methadone or primary healthcare only samples 
(Cornish et al., 2010; Cousins et al., 2016; Strang et al., 2003; Rvandal & Amundsen, 
2010; Merrall et al., 2013), therefore limiting generalizability of findings to specific 
OUD subgroups. Problems with residual confounding is also likely as associations 
between treatment exit and mortality often included crude measures (Clausen et al., 
2008; Dagenhardt et al., 2009; Fugelstad, 1995; Mathers et al., 2013; Strang et al., 
2003) or limited adjustment for potential confounders (Bjornaas et al., 2009; Davoli et 
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al., 2007; Merrall et al., 2013). Davoli et al., (2007) for example did not adjust for any 
socio-demographic factors other than age and gender.  
 
Second, while a study carried out by Cornish et al., (2010) is the most comprehensive 
one to date, it is inclusive of only primary health care OUD patients, thereby not 
including a large proportion of patients receiving care through secondary services, 
who are likely to have more severe levels of dependence. Also, specific causes of 
death were not explored. This study, however, was the only study to have compared 
planned and unplanned cessations of OST treatment. Although no difference was 
found between the two exit types, the planned discharge was based on tapering down 
of OST medication dose rather than a direct indication of discharge. 
 
Inconsistencies around misclassification of patients into on or off treatment episodes 
were also present. Some studies have considered that a gap of less than 28 days 
between the end of one on treatment episode and the start of the next one is not long 
enough to assume that a patient would genuinely stop and restart treatment within a 4-
week period (Cornish et al., 2010). Other studies, however, have categorized patients 
into an off treatment group after just the 3rd consecutive day of missed OST dose 
(Cousins et al., 2015; 2011), or after the 7th missed dose (Degenhardt et al., 2009). 
 
Moreover, a recently published commentary by Hickman and colleagues (2016) 
stressed that further evidence on risk of mortality on and off OST is needed. The 
commentary summarises that more studies of this kind are necessary so that ‘stratified 
medicine’ for treatment of OUD can be provided.  Pooled experience and evidence 
from different health-care systems is necessary in order to tailor specific treatments 
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and ensure that ‘the right patient gets the right treatment at the right time’. Chapters 6 
and 7 explore mortality post cessation of OST in more detail.   
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Table 2.2 Studies investigating mortality after discharge from services in opioid users. 







cause deaths among 
opioid users. 
Opioid addiction was associated with a 
twofold increase of all-cause mortality 
during a 20-year follow-up after 
discharge from general hospital 
following self-poisoning (compared to 
the general population on Norway). 
OUD did not predict further suicide. 
Very limited adjustment for potential 
confounders; classification of opioid 
addiction based on patient interviews at 
the time of admission with no further 
follow-up; no information regarding 




UK N=5577 OST patients; 
n=178 all-cause deaths 
All-cause mortality in the first month 
after cessation of OST treatment was 
more than 8 times higher, compared 
with 28+ days of OST maintenance.  
Primary healthcare cohort; no specific 
causes of deaths reported; patients 
transferred out of services were 
considered lost to follow-up; limited 
adjustment for potential confounding; 
planned cessation of treatment based on 
tapering down of dose rather than a direct 
indication of discharge. 
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Author Location Study sample Results Limitations of relevance 
Clausen et 
al., 2008  
Norway N=3,789 OUD 
patients; n=77 deaths 
(n=61 OD) 
Patients post-treatment had reduced all-
cause and OD mortality rate compared 
to that pre-treatment (rate ratio 
[RR]=1.4). Mortality in treatment was 
reduced, compared to that pre-
treatment, in both all-cause and OD 
mortality (RR=0.50; RR=0.20) 
Crude estimations; no information of the 
type of maintenance treatment, drug use 
history, or whether exit from treatment 
was planned or not. No information with 
regards to disruptions in treatment. 
Inclusion to OST treatment in Norway 
varies to that in the UK in terms of 
severity of dependence required to enter, 




Ireland N=6,983 patients 
prescribed methadone; 
n=213 deaths; n=78 
DRD (drug related 
deaths) 
Overall, all-cause mortality off-
treatment was more than 3 fold higher 
than that on treatment. All-cause 
mortality off-treatment was over 6 times 
higher in the first 2 weeks and 9 times 
higher in weeks 2-4, compared with 
time 5+ weeks on treatment. However, 
adjusted DR mortality overall and in 
Methadone-prescribed patients only; 
primary care cohort; limited adjustment in 
the DRD models; transfer of patients and 
other disruptions in treatment not 
reported; mixed findings with regards to 
DRD; cessation of methadone treatment 
established after 3rd consecutive day of 
missed dose; planned vs unplanned 
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Author Location Study sample Results Limitations of relevance 
period specific analysis was not 
significant.  
cessations of treatment not investigated.  
Cousins et 
al., 2011 
Ireland N=2,048 patients 
prescribed methadone; 
n=64 DRD 
Risk of DRD was minimally lower after 
the first 30 days following cessation of 
methadone treatment, relative to the 
first 30 days off treatment. 
 
Methadone prescribed primary care 
cohort; planned and unplanned treatment 
cessations not investigated. Cessation of 
treatment established after 3rd consecutive 
missed methadone. Transfers and other 
disruptions in treatment not reported. 
Mixed, possibly underpowered results 
owing to limited number of deaths. 
Dagenhardt 
et al., 2009 
Australia N=42,676 in OST 
treatment; n=3,803 
deaths; n=87 DRD 
Excess mortality in first 2 weeks after 
cessation of treatment compared to the 
general population. Also high risk of 
mortality in first two weeks after starting 
treatment was also found.  
Crude estimations; planned and 
unplanned exits from treatment not 
explored. New treatment episode defined 
at 7+ days after the end of the previous 
episode.  
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Author Location Study sample Results Limitations of relevance 
Degenhardt 
et al., 2010 
N/A N=2832 all-cause 
deaths across 6 
studies; n=1427 OD 
deaths across 6 studies 
CMR were 2.38 times higher for time 
spent out of treatment compared to in-
treatment periods. OD was 3.5 times 
higher compared to time in treatment – 
Meta-analysis of 6 studies.  
Crude estimations. Transfer periods not 
taken into account. 
Davoli et al., 
2007 
Italy N=10,454 heroin users 
in treatment; n=41 
OD.  
The risk of fatal OD for patients out of 
treatment was 11 times higher than that 
in treatment, after adjustment. Adjusted 
OD hazard ratio (HR) within 30 days of 
cessation of treatment was 26.6. 
Low number of OD deaths in groups. 
Cohort was not restricted OST and 
included psychosocial and therapeutic 
community interventions where overall 
out of treatment risks appeared to be 
highest. Limited socio-demographic 
adjustment. Transfers and disruptions of 
care not reported. The follow-up time for 
patients out of treatment was substantially 
lower than that on treatment and 
examination of differences in risk 
between treatment modalities was limited.  
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Author Location Study sample Results Limitations of relevance 
Fugelstad, 
1995 
Sweden N=135 HIV+ PWID 
in methadone 
programme; n=69 
deaths (n=52 deaths 
due to violence or 
poisoning). 
RR ratio for mortality attributed to 
violence or poisoning for patients 
discharged from methadone treatment 
was 2.9 times higher compared to those 
never admitted, within a 4-year follow-
up 
Crude estimations. Cohort inclusive of 
HIV+ PWID in residential treatment 
only. Specific risk periods not explored; 
Planned treatment cessations and drop-
outs not reported.  
Fugelstad, 
1998 
Sweden N=101 OUDs in 
residential treatment; 
n=40 deaths  
N=24 / 29 people died from non HIV 
related causes in the 3-year follow-up 
after cessation of treatment.  
Inclusive of patients in OST and non-




International Meta-analysis of 6 
cohort studies in 
PWID 
Meta-analysis suggested crude all-cause 
mortality was 2.5 times higher during 
off-treatment periods than in treatment 
periods. 
Crude estimations of 6 studies, described 
within this table separately. Cohort 
inclusive of PWID only.  
Merrall et 
al., 2013 
Scotland N=69,457 drug users; 
n=45,378 opioid users; 
n=1383 DRD 
DRD rate within 28 days after inpatient 
discharge (any kind of hospitalisation) 
was 21 times higher, for drug users 
registered with addiction services 
Comparisons of periods on and off 
treatment are inclusive of drug users in 
cohort (not separated by substance use 
problem); includes instances where 
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Author Location Study sample Results Limitations of relevance 
Referent group were drug users never 
admitted for hospitalisation.  
unsuccessful resuscitation attempts were 
made on site, therefore introducing 
potential misclassification of a “hospital 





Norway N=276 inpatient drug 
users; n=36 deaths 
(n=24 OD) 
Unadjusted elevated risk of OD within 
4 weeks of leaving medication-free 
inpatient treatment was 29.9.  
Inpatients drug users, unknown number of 
opioid users. Limited adjustment for 
potential confounders. End of treatment 
included voluntary drop-outs and planned 
completion with the view to continue 
psychosocial rehabilitation elsewhere 
(which constitutes a transfer to another 
therapy), which were not investigated 
seperately.  
Strang et al., 
2003 
UK N=137 inpatient OUD 
patients; n=5 deaths  
Total of 5 patients died within 12 
months post-discharge from inpatient 
opiate detoxification programme. Three 
Descriptive analysis. Small sample 
inpatient OUD patients. Low number of 
deaths. 
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Author Location Study sample Results Limitations of relevance 
died of OD within first 4 months. All 3 
OD deaths occurred in patients who 
“successfully” completed 
detoxification.  
White et al., 
2015 
Scotland N=98,000 drug users; 
n=1409 DRD 
DRD rate within 28 days after discharge 
from general hospital was 15 times 
higher. Referent group were drug users 
never admitted into services. 
Inclusive of inpatient general hospital 
admissions; insufficient power to fully 
investigate the effect of longer hospital 
stays (where a loss of tolerance would 
occur). Comparisons of post-discharge to 
those who were never admitted inclusive 
of all drug-users without providing 




2.3.3 DISRUPTIONS IN PATIENT CARE 
Interruptions of continuity of care is a current area of concern. The Advisory Council 
on the Misuse of Drugs (ACMD, 2015) has recently highlighted that frequent re-
procurement of local drug treatment services (every 3 to 5 years) and cuts in 
resources, which often result in group-transfer of patients to alternative service 
providers, could have a negative impact on treatment outcomes. At present, however, 
very little is known with regard to de-stabilisation that may occur with changes to 
service delivery. Evidence from a survey of commissioners and surveys of providers 
(DrugScope, 2015) indicates that frequency of re-procurement appears to have a de-
stabilizing and negative impact on local service user recovery outcomes. 
 
No studies have investigated the possible impact of disruptions in OUD patient care, 
treatment outcomes and mortality. Although the studies presented in Table 2.2 have 
examined risks associated with planned and unplanned cessations of OST treatments, 
none has taken into account disruptions in patient care (other than patient drop out), 
such as a transfer of patient and their care into an alternative service provider during 
their OST (a limitation which is addressed in Chapters 6 and 7).  
 
The study carried out by Cornish and colleagues (2010) does report that 
approximately 10% of patients per annum were transferred out of services in their 
cohort, but these patients were considered lost to follow-up and not investigated 
further. A larger proportion of transferred patients might be expected in secondary 
care, as these would include a “step-down” transfer from secondary to primary 
healthcare, as well as those transferred after re-organizational changes. Ravndal & 
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Amundsen (2010) defined “discharge” from treatment as completion of inpatient 
treatment and a transfer to psychosocial rehabilitation. The study reported unadjusted 
excess overdose mortality rate ratio of 15.7 but all deaths occurred in patients who 
had dropped out of treatment and inpatient treatment did not involve prescription of 
any OST.  
 
Similar limitations are seen in post-prison release studies. It is recognized both in the 
United Kingdom (Bird & Hutchinson, 2003; Farrell & Marsden, 2008; Seaman et al., 
1998) and internationally (Merrall et al., 2010) that recently released prisoners, 
notably those with a history of having injected heroin, are at very high risk of DRD.  
 
This increased risk is concentrated in the first 2 weeks after release from prison. For 
example, Seaman et al. (1998) reported that male HIV‐infected drug injectors had a 
RR of DRD of 8 during the first 2 weeks after release versus other comparable times 
at liberty. Bird & Hutchinson (2003) found that males had a DRD risk seven times 
higher in the first 2 weeks compared to the subsequent 10 weeks. Further, 60% of 
DRD within 12 weeks of release had occurred within the first 2 weeks.  
 
These findings have since been confirmed in record‐linkage studies in England and 
Wales (Farrell & Marsden, 2008), Australia (Kariminia et al., 2007) and the United 
States (Merrall et al., 2010). A larger scale study in England and Wales confirmed the 
extraordinary concentration of excess mortality post-release as occurring particularly 











Provision of OST in prisons, besides being good clinical practice, has contributed to a 
reduction of in‐prison deaths (Bird, 2008; Larney et al., 2014) and of injecting while in 
prison (including blood‐borne virus transmissions) (Stallwitz & Stöver, 2007; Taylor et 
al., 2013). Another possible benefit of prison‐based OST might be to prevent the loss of 
opiate tolerance, thereby reduce the risk of DRD after release – that is, during the 
transfer period between prison and post-release drug and alcohol service provision.  
 
Unfortunately, literature on the transfer of patient care and provision of OST 
medication pre- and post-release through transitional care programs remains 
inconclusive (Merrall et al., 2010; Farrell & Marsden, 2008). Only four studies (Bird et 
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al., 2015; Degenhardt et al., 2014; Kariminia et al., 2007; Merrall et al., 2010) have 
monitored the impact of prison‐based OST on DRD risk soon after prison release.  
 
In Australia, Degenhardt and colleagues (2014a) reported that the proportion of 12‐
week post-treatment DRD that occurred in the first 2 weeks was approximately 50% in 
2000–10, unchanged from 1988 to 2002 (Kariminia et al., 2007; Merrall et al., 2010), 
although prison‐based OST had been received in 58% of opiate‐dependent clients’ 
prison episodes.  
 
Following the introduction of a prison‐based OST policy in Scotland, the rate of drug‐
related deaths in the 12 weeks following release fell by two‐fifths. However, the 
proportion of deaths that occurred in the first 14 days did not change appreciably, 
suggesting that in‐prison OST does not reduce early deaths after release (Bird et al., 
2015). 
 
A large-scale, observational study of 20,000 heroin-addicted prisoners assigned to 
opioid maintenance treatment (or to abstinence) is currently being conducted in 
England and Wales. Findings from this investigation will shed light on the benefit 
obtained and on ways to improve prison health care and, crucially, on continuity of care 
on release from prison and return to the community (Strang, 2015). Similar 
investigations are also necessary to investigate transfers of patients between drug and 








2.4 SIGNPOSTS TO THE SCOPE OF COVERAGE IN SUBSEQUENT CHAPTERS 
Chapter 4 
Given the high prevalence of comorbid alcohol, mood problems, PD and SMI among opioid 
users and particularly high hazard ratios for mortality risk in individuals with these diagnoses 
(as explored earlier in this chapter), it is plausible that these psychiatric problems may 
contribute to the elevated mortality risk observed in this patient group, with regard to both 
natural and unnatural causes of death. Therefore, Chapter 4 investigates the impact of 
comorbid psychiatric problems in opioid users and looks beyond overdose mortality. 
 
Chapter 5 
Effective assessment of risk in OUD patients is paramount (DoH, 2007; NTA 2006a, 2006b). 
Risk assessments tools are widely used, but their ability to predict outcomes in OUD 
treatment remains unclear. The aim of Chapter 5 is to investigate if addiction-specific brief 
risk screening is effective in identifying high mortality risk groups and if subsequent clinical 
actions following risk assessment impacts on all-cause and overdose mortality levels. 
 
Chapter 6 
Overdose high-risk periods were identified immediately after release from prison, at the 
beginning of OST treatment and immediately post-detoxification with cessation of OST 
treatment. However, as noted in the literature review, existing research is limited and does 
not take into account disruptions in patient care (beyond drop-outs), such as transfers 
between services. Chapter 6 conducts an investigation of excess overdose mortality 
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immediately after cessation of opioid substitute therapy and following transfer of patients and 
their care, in opioid dependent individuals in specialist addiction treatment. 
 
Chapter 7 
Chapter 6 provided groundwork for much needed further research, requiring deeper 
exploration of findings. However, the preceding chapter was limited to crude estimations of 
clustering of deaths surrounding treatment cessations and transfers. In Chapter 7, I use an 
extended dataset and adjust for a broad range of confounders to explore mortality risks after a 























The data used to conduct this PhD project were derived using the SLaM Biomedical 
Research Centre Clinical Record Interactive Search (CRIS) tool, developed for use within the 
NIHR Mental Health Biomedical Research Centre and Dementia Unit. The CRIS system, 
including mortality tracing at a national level, enables researchers to search and retrieve 
electronic patient health records in a de-identified format, with more than 280,000 cases 
currently represented on the system. In depth understanding of CRIS was essential to fully 
explore and appreciate the scope of my data. Therefore, this chapter describes the study 
setting and the operational models of the CRIS system. Key variables such as diagnoses, the 
scope of electronic patient records and all-cause and cause-specific mortality derived from 
linked data are also explained. In addition, automated extraction and coding of data from free 
text using Natural Language Processing (NLP) is described. Finally, a detailed account of 






3.2.1 SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST 
SLaM is one of the largest specialist mental healthcare services in Europe, which provides 
comprehensive mental healthcare and addiction services to a catchment population of 
approximately 1.2 million residents across seven multicultural, ethnically diverse, highly 
dense boroughs of London. SLaM provides the widest range of NHS mental health services 
in the UK, with services including the Maudsley Hospital and Bethlem Royal Hospital. 
SLaM works closely with the Institute of Psychiatry, Psychology and Neuroscience where 
this PhD was carried out; and are part of King’s Health Partners Academic Health Sciences 
Centre. Within the framework of the NHS in the United Kingdom, mental health trusts have 
close to 100% monopoly for service provision to their geographic catchments. 
 
3.2.2 ADDICTIONS SERVICES 
Addictions services in SLaM are one of the largest providers of NHS addictions services in 
the UK, providing drug, alcohol and smoking cessation services. Addiction services are 
provided in the community through GP surgeries, outpatient services, specialist support 
clinics and inpatient services for people who require more in depth treatment and care. SLaM 
Addictions also provide specialist services for adults from around the country who need 
specialist care and treatment. The National Addiction Centre, part of King’s College London, 
is within their portfolio of services and represents a network of clinicians, researchers and 
clinical teachers with a shared commitment in addiction research, prevention and treatment 
work, providing an excellent platform for clinical research.  
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3.3 CLINICAL RECORDS INTERACTIVE SEARCH 
3.3.1 THE ELECTRONIC PATIENT JOURNEY SYSTEM 
The SLAM electronic Patient Journey System (ePJS) is a bespoke, single, integrated 
electronic clinical records system used across all Trust services. It was designed primarily to 
support the recording and sharing of clinical information, whilst producing relevant 
management and national reports as a natural by-product. EPJS was implemented in most 
SLaM services in 2006 and in Addictions services in April 2008, replacing a number of 
independent clinical and administrative information systems used in the Trust at the time. All 
patient-based information for patients seen from 1999 onwards was migrated into ePJS from 
electronic legacy systems.  
 
EPJS is a comprehensive record of all clinical information recorded throughout patients’ 
journeys through Trust services, including demographic and contact information, dates and 
other details of referrals and transfers, detailed clinical assessments, care plans and 
medication, clinical activity and reviews. Imaging and laboratory data are not, to date, 
recorded there. The record is used and maintained by multi-disciplinary professionals and 
consists of both structured data (such as dates, integers and pick-lists) and unstructured free-
text (including written assessments, progress notes, event notes and correspondence). EPJS 
includes specific assessments such as structured physical health assessments, cognitive 
function and outcome measures (such as the Health of the Nation Outcome Scale [HONOS], 
Treatment Outcome Profile [TOP] (see appendix vi.) and National Drug Treatment 




3.3.2 THE CRIS SYSTEM 
Rapid technological advantages and other developments over the last decade have led to new 
possibilities for case register development. In 2008, using electronic health records (EHRs) 
derived from ePJS, the CRIS system was developed for use within the NIHR Mental Health 
Biomedical Research Centre and Dementia Unit; and approved as a dataset for secondary 
analysis by Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). 
 
CRIS enables researchers, such as myself, to search and retrieve ePJS-based EHRs in a de-
identified form. All data for this Ph.D. project were extracted using the CRIS tool. As a CRIS 
user, I was able to search for any combinations of structured and unstructured fields from 
ePJS health records (providing that these fields were within the scope of the research project, 
which had been approved by an oversight committee, described below), except that CRIS 
‘produced’ these health records in a de-anonymised form. The development of CRIS required 
a strict security model with attention to legal and ethical considerations regarding the use of 
confidential health data, described in detail by Stewart and colleagues (Perera et al., 2015; 
Stewart et al., 2009).  
 
Briefly, all CRIS users must firstly obtain a Letter of Access from the Research and 
Development Team, as well as project-specific approval from the CRIS oversight committee 
for each investigation. The oversight committee was formed not only to review all 
applications to use CRIS, but also to provide practical advice to researchers on how best to 
navigate and manipulate the complex and extensive data from more than 280,000 cases 
represented on the system. The SLaM BRC Clinical Record continues to grow as a database, 
with approximately 20,000 new cases added each year, in addition to extension of follow-up 
for existing cases. 
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3.3.3 FRONT-END CRIS 
CRIS has two distinct search features. First, described here, is the ‘front-end CRIS’, which 
searches and retrieves information from the structured electronic health record fields - these 
may include information such as dates, numerical fields or drop-down menus; and from 
unstructured fields – these are user-defined text strings from ePJS records. For example, 
information submitted to the NDTMS, which collects, collates and analyses information from 
all drug treatment agencies, is recorded in the structured fields in ePJS and subsequently in 
CRIS. Structured forms, such as the BRSA-A (described further in Chapter 4), are also 
present in a structured and binary format and can be viewed or extracted using the front-end 
CRIS. The CRIS tool ‘hits’ relevant records based on search terms, such as ‘opioid use 
disorder’ diagnosis and/or a text string (e.g. “needle-exchange”). The results are then returned 
in spreadsheet format and are exportable as a CSV file for analysis.  
 
An example, adapted from Stewart and colleagues (2009), of the front-end CRIS results table 
is represented in Figure 3.1 (due to data protection and confidentiality agreements, I could 
not present an example of front-end CRIS search table relevant to this PhD). Any 
combinations that match entries in structured name, date of birth and address fields in ePJS 
are replaced with ‘ZZZZZ’ in the searchable index. In addition, an anonymised Biomedical 
Research Centre (BRC) identifier is constructed from the patient’s NHS number, which is 
then excluded from the searchable index. The algorithm for creating BRC identifiers from 
NHS number is hidden and cannot be accessed by myself and other front line researchers. 
 
The front-end CRIS was particularly useful in exploring data on a descriptive level, for data 
presented in this thesis. It enabled basic cohort checks, such as the total OUD sample in a 
given observation period; completeness of data for particular scales, such as the BRSA-A or 
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HoNOS in the OUD cohort; and localizing and exploring the availability and quality of 
available variables specific to addiction services for subsequent analysis.  
 
The front-end CRIS was also frequently used in collecting missing information, which could 
not be extracted using more complex tools or data linkages described further below, or 
instances where manual free-text coding was the only possibility to extract necessary 
information. For example, as described in Chapter 4 where a manual text search was carried 
out to establish causes of death for those individuals where this information was not available 
through a linkage to ONS data, or in instances where patients’ reasons for ending their 
treatment in SLaM needed defining, as described in detail in Chapter 6. 
 
The front-end CRIS however, is a much a simplified format of CRIS.  Problems arise when 
searches requires complex extraction planning and handling of large data - for example, when 
using large samples, where reading through individual notes is not feasible, or when extracted 
data from the free-text fields must take into account the linguistic context rather than a simple 
key word search. Front end CRIS can search and retrieve data but is limited by using basic 
Boolean operators (and/or/not), therefore it cannot perform relational searches. Externally 
linked data, such as cause-specific mortality, is not available for retrieval via the front-end 
CRIS either. The back-end CRIS, also known as CRIS SQL, was therefore developed for 




Figure 3.1 Screen-shot of front-end CRIS results table (Stewart et al., 2009). 
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3.3.4 CRIS SQL 
Structured Query Language (SQL) was the key ‘language’ for interacting with the CRIS 
database and for extraction of data used in this thesis. SQL can handle complex queries, 
which may include multiple sources of information and relational searches. Data extraction 
(see appendix v. for an example of data extraction used in Chapter 5) using SQL can 
search and retrieve information from source structured electronic health records, from 
internally and externally linked data and access data which has been coded using NLP 
software taking into account the linguistic context in free-text fields (described below). 
Data presented in Chapter 4, for example, required CRIS SQL to include: a) NLP to extract 
OUD diagnoses from free-text fields (in addition to information derived from their 
designated structured fields); b) externally linked cause-specific mortality data to identify 
those who had fatal overdose; c) relational search where deprivation score, for example, 
was recorded closest to the recorded variable of interest; or prescription of medication 
within given period after a variable of interest was recorded for each patient.  
 
Effective utilisation of CRIS, its applications, location and quality of available variables, 
its limitations, linked data and data extractions required development of a close working 
relationship with the bioinformatics team who provided advice and assistance in planning, 
handling and extraction of datasets for analyses in this thesis. Development of good 
relationships with clinicians, especially within addictions, was also required, who were 
able to direct me towards efficient identification and localisation of variables of interest 
within ePJS and CRIS. Both CRIS front-end and SQL training were also undertaken to 
understand and plan data extraction and to better communicate with the CRIS team.  The 
full operational model visualising both front-end and SQL CRIS is presented in Figure 3.2, 










Figure 3.2 CRIS Operational Model 
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3.3.5 NATURAL LANGUAGE PROCESSING 
Anecdotally, it is said that up to 70% of the information content of patient records is in free 
text form and accessing this information is a priority for health research1. NLP techniques 
have an important role to play, particularly for mental health patient records where text fields 
are often substantial and contain some of the most important clinical information (Ford et al., 
2016; Névéol et al., 2016; Perera et al., 2015). Traditionally, extracting free-text information 
has required manual coding, where the researcher reads the free-text and codes it by hand 
according to a defined set of coding rules (Perera et al., 2015; Stewart et al., 2009). In this 
study, the traditional method was used in extracting some variables in small subsets of the 
data, described in more detail in Chapters 4 and 6. However, it is near impossible to manually 
code free text fields on a large scale due to time and labour constraints.  
 
NLP data extractions can be carried out in a timely, efficient and reliable manner. General 
Architecture for Text Engineering (GATE) - open source software developed since 1995 at 
the University of Sheffield, is a leading suite of tools that facilitate the use and development 
of NLP applications and features and was chosen as the core NLP infrastructure for CRIS. 
NLP applications to date have brought in new and hitherto inaccessible data on cognitive 
function, education, social care receipt, smoking, diagnostic statements and pharmacotherapy 




1 Retrieved from http://openminted.eu/1129-2/ 
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The first NLP application to be developed was for the MMSE (The Mini Mental State 
Examination), a commonly used 0–30-point assessment of global cognitive function. The 
objective of the application was to ascertain both the numerator and denominator scores 
(because denominator scores of less than 30 are used where some items cannot be attempted 
because of e.g. sensory impairment), as well as the date implied for the assessment (because 
clinical text fields commonly refer to previous as well as current scores). The application was 
tested on 100 patients with high precision and recall scores (97% and 98% respectively) (Su 
et al., 2014). 
 
A number of other NLP applications have since been developed, including an application for 
educational attainment which sought to ascertain the numeric value associated with text 
commenting on school leaving age, whether the age itself or the year (precision 95%; recall 
59%) and an application for ‘living alone’ which sought to identify that phrase or equivalents 
applied to the patient (precision 93%; recall 99%) (Perera et al., 2015). 
 
In developing the smoking application, authors extracted information from open-text fields, 
classifying patients as either ‘currently smoking’, ‘past smoker’ or ‘has never smoked’, with 
smoking of substances other than tobacco (e.g. marijuana/cannabis and cocaine) specifically 
excluded (Wu et al., 2013). The methodology used an iterative process of manual ‘gold 
standard’ annotation of free-text documents, followed by comparison with the results 
generated by the application at each development stage, with analysis of this comparison 
feeding further development of the rules. The smoking application was tested on 100 patients 
with 93% precision and 58% recall scores. The smoking status using this NLP application 
was extracted for data described Chapter 4, however, the variable was excluded from analysis 
for reasons described within the same chapter.  
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The application for ‘diagnosis’ sought to extract any text strings associated with a diagnosis 
statement in order to supplement the existing structured (ICD-10) fields. Its performance was 
evaluated formally in a random sample of 75 documents for ‘vascular dementia’ (Sultana et 
al., 2014), but it is recommended for individual further evaluation in other conditions. The 
‘diagnosis’ application was used frequently in this project and my own precision validation 
for the OUD cohort is described in the ‘Core Variables’ section below.  
 
NLP applications for pharmacotherapy have also been developed, using a gazetteer of generic 
and commercial names for all medications in UK use in order to ascertain instances where the 
patient was reported as receiving these, with supplementary rules for ascertaining recorded 
dose, frequency/timing and starting/stopping statements. Its precision was first tested for 
clozapine receipt against a manual search of 279 documents and recall was ascertained on a 
random set of 200 documents containing the word clozapine and scrutinised to ascertain an 
actual prescription (Hayes et al., 2015). NLP applications have recently been extended to 
cover a range of affective and psychotic symptoms, allowing much more detailed phenol-
typing of large samples than a diagnosis alone provides (Patel et al., 2015a; Patel et al., 
2015b) and a range of adverse drug events have also recently been successfully captured 
(Iqbal et al., 2015). Additionally, for all evaluations, an F-statistic was calculated, 
representing the harmonic mean of precision and recall and defined as: 
F=2×(precision×recall/(precision+recall)). More detailed description and performance data 
for NLP applications are beyond the scope of this thesis but are summarised in Perera et al., 
(2015).   
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3.4 CORE VARIABLES 
Although data-specific variables will be described in their designated chapters, it is useful to 
specify the key variables here, for clarity and completion of the data-source information. 
 
3.4.1 DIAGNOSES 
Diagnoses in SLaM (and subsequently in CRIS) are a mandatory field and are recorded in 
accordance to the ICD-10 (WHO, 1993). Opioid use disorder patients in SLaM are therefore 
retrieved in data extractions if they have been diagnosed with a primary or secondary IC-10 – 
F11 opioid use disorder.  Additionally, OUD diagnoses were searched using the ‘diagnosis’ 
NLP application discussed earlier in this chapter, to supplement data unavailable in structured 
field search/extraction (usually secondary diagnoses) in Chapters 4-7. Furthermore, in 
Chapter 4, the NLP diagnoses application was also used to extract psychiatric comorbidity 
diagnoses for severe mental illness, personality disorders and alcohol use disorder.  
 
The NLP application for ‘diagnosis’ sought to extract any text strings associated with a 
diagnosis statement in order to supplement the existing structured (ICD-10) fields. As 
explained earlier, above, its performance was evaluated formally in a random sample of 75 
documents for ‘vascular dementia’ (Sultana et al., 2014) with precision and recall of 99% and 
98% respectively, but is recommended for individual further evaluation in other conditions. 
Therefore, additional precision testing was carried out for this cohort in 50 randomly selected 
patients whose diagnosis were extracted via GATE. The precision for the ‘diagnosis’ NLP 
application for this cohort was 98%. 
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3.4.2 ALL-CAUSE MORTALITY 
NHS number is a unique identifier for UK NHS records. All death certifications are linked to 
this identifier at national level and health service providers are required by law to keep 
records up to date with respect to this. Every death in the UK, after the issuing of a formal 
death certificate, must be reported to the Office for National Statistics General Records 
Office (ONS–GRO) and conveyed to the NHS Care Records Service, which holds these 
death notifications and makes them available to all NHS organisations. In accordance, on a 
monthly basis, SLaM downloads a list of deceased patients from the NHS Care Records 
Service and updates their dates of death onto patients’ records. This process applies to both 
active and non-active (i.e. discharged or deceased) patients present on the ePJS system.  
 
3.4.3 CAUSE-SPECIFIC MORTALITY 
The CRIS database is also linked with external data sources, such as the Hospital Episode 
Statistics (HES) and the National Pupil Database and Primary Care database (Lambeth 
DataNet). Such record linkages are performed via a personal identifiers matching process, are 
de-identified at linkage, and are available to BRC researchers in an anonymised form.  In this 
study, I was able to establish causes of death via data linkage with the ONS, which collects 
information on cause of death from civil registration records. For registered deaths, the 
underlying cause of death is derived from the sequence of conditions leading directly to the 
death and is recorded on the death certificate. The death registration also records a list of 
other conditions or diseases that the patient had at the time of death, which may or may not 
have directly contributed to the death.  
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Deaths are subsequently coded in line with the ICD and, at request (with appropriate 
approvals), provided to the BRC for anonymised CRIS linkage. All researchers, including 
myself, are required to obtain ONS Approved Researcher approval before handling ONS 
linked data. The ICD-10 diagnostic codes, as extracted within the subsequent chapters, as 
pertaining to specific causes refer only to those codes that are present in that specific dataset, 
and hence, might not include a ‘complete list’ of the cause specific ICD-10 F-codes. 
 
However, cause of death data is a static data linkage, with irregular updates (unlike all-cause 
mortality data). Each update request requires a number of administrative tasks from both the 
SLaM linkage team and the ONS team, resulting in severe delays. Furthermore, ONS reports 
an approximate 6-month to one year delay in establishing causes of death (ONS, 2011). 
These delays require analytical period adjustments at extraction-level to avoid constructing 
data sets with excessive amounts of missing data corresponding to the most recent deaths.  
 
As described earlier, in some cases, for example where a death date is present but no 
underlying ICD-10 cause of death code was provided, I would go back to the event notes 
using front-end CRIS, then search and retrieve information on cause of death if available. 
This technique was carried out for data described in Chapter 4, but not in data presented in 
subsequent chapters. Whilst I was able to match the BRC IDs in front-end CRIS for those 
missing cause of death in Chapter 4, the ONS security model changed, requiring 
annonymization of the BRC IDs for datasets including ONS cause specific mortality. 
Subsequently, this prevented me from searching through front-end CRIS for missing causes 
of deaths in Chapters 5-7 and hence I needed to solely rely on causes of deaths provided by 
the ONS. The last date of death available in the ONS death data is 12 April 2015; therefore, 
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deaths occurring after this date will not have an underlying cause of death code assigned to 




3.5 DATA SOURCE LIMITATIONS 
The CRIS tool provides researchers with access to a long running system of fully electronic 
clinical records, allowing in-depth secondary analysis of numerical, string and free-text data, 
whilst preserving anonymity through technical and procedural safeguards. However, there are 
some limitations to CRIS data source that must be acknowledged before moving on to study-
specific limitations discussed in their designated chapters.  
 
First, the completeness of data in CRIS relies on information entered by the NHS staff. Often, 
designated structured fields are not utilized by clinicians, rather information is typed in free-
text fields, resulting in difficulties in capturing this information using the CRIS front-end. 
Essentially, CRIS relies on clinicians completing electronic forms and fields fully and in 
addition to free-text, which is not often the case.  Although a range of NLP applications are in 
place to extract information from free-text, these are variable-specific and limited to those 
features in the text considered high priority for the research undertaken to date. The 
development of new applications is extremely complex and labour intensive, for example, as 
that described by Kadra and colleagues (2015). 
 
Second, SLaM provides a variety of mental health services and ePJS is an extensive database. 
The internal procedures for completion of electronic data often vary between Clinical 
Academic Groups (CAGs) within SLaM, with different views on the relevance of recorded 
information across the diagnostic groups. A good example of this is the completion of the 
HoNOS. HoNOS is a standard measure of patient wellbeing, widely used in UK mental 
health services, completed by clinicians after routine assessments (Wing et al., 1998). Across 
a number of diagnostic groups the completion of HoNOS scale is relatively high - 83% of all 
SLaM patients with schizoaffective disorder (ICD-10 F25) and 63% of SLaM patients with 
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(ICD-10 F33) major depressive disorder have HoNOS completed. In my OUD cohort 
however, the HoNOS completion rate was only 14%.  This is because alternative and 
addiction-specific measures exist, therefore this information is captured elsewhere. On the 
other hand, information sources, such as the NDTMS or the Brief Risk Assessment Scale 
(which are specific to addictions), are completed at high rates by the addictions staff (91% 
and 84% respectively), completion of which would have little relevance in other CAGs.  
 
Aside from CAG differences in the type of information recorded, problems arise with 
multiple structured fields for recording the same or similar information. A good example of 
this is information relating to prescribing, where relevant information was found in five 
different locations in ePJS. These include various structured fields and through 
‘pharmacotherapy’ NLP free-text searches.  This issue was particularly problematic in 
establishing end of treatment dates in the current cohort, and is further described in Chapter 
6. Therefore, a great deal of time was spent in familiarising myself with the ePJS and CRIS, 
developing close working relationships with the bioinformatics team, and clinicians who use 
ePJS daily and were able to direct me towards variables and information I needed so that no 
information was missed or misinterpreted.  
 
Data linkages, while increasing the richness of available data, can also present their own set 
of challenges. For example, as described earlier, the static ONS-CRIS cause of death data 
linkage results in update delays, requires adjustments in observation windows, and contains 
missing data. Performing new data linkages is also a long and complex process, from 
technical as well as ethical perspectives. For example, during this PhD I tried to perform data 
linkage between CRIS and London Ambulance Services (LAS) so that data on fatal as well as 
non-fatal opioid overdose call-outs could be captured for analysis. This, however, has proven 
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unsuccessful due to the type and volume of approvals required, time constraints, and the type 
of electronic and quality of data available from the LAS. 
 
Finally, treatment provision in SLaM Addiction services is extensive and complex. SLaM 
addictions treatment provisions include inpatient services, specialist prescribing services, 
complex case services, community drug and alcohol treatment (CDAT) services, and 
supervised injecting services. In addition, SLaM addictions services work in close partnership 
with the GP (general practice) shared care services, the dual-diagnosis team, and a number of 
third party/charity sector service providers. Patients, especially opioid dependent patients, 
enter, drop out, re-enter and transfer between services or prison frequently, therefore 
capturing one’s complete journey through services is problematic. This is primarily because 
these additional services are not electronically connected with ePJS or CRIS and valuable 
data is often lost to follow-up with each drop out or transfer. Treatment information beyond 
transfer involves sporadic mentions in event notes or correspondence and requires manual 
retrieval. Where a patient is involved in the shared care team, he or she may be regularly seen 
by the SLaM CDAT for psychological assessment or relapse prevention modalities, but their 
prescription may be provided through his or her GP. In this situation, prescription details may 
be incomplete and only sporadically mentioned in the notes, rather than their designated ePJS 
fields. However this situation can be addressed to some extent though searching and reading 
patient documents using the CRIS front end since correspondence to and from GP is recorded 
on the system.  
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Introduction: Opioid misusers have recognized high mortality but the influence of 
psychiatric comorbidity in excess cause-specific mortality is unclear, with existing literature 
reporting mixed or limited results.  
 
Aim: The aim of the analysis presented in this chapter was to investigate the associations 
between subjective ratings of psychological health - a proxy measure of depression and 
anxiety, comorbid diagnosis of PD, SMI and AUD, in relation to all-cause and cause-specific 
mortality in OUD patients. 
 
Methods: OUD patients were identified in the SLaM case register within the observation 
period between 1st April 2008 and 31st December 2012. Deaths were identified through 
database linkage to the national mortality dataset. Standard mortality ratios (SMR) were 
calculated to compare mortality risk with the general population. Cox and competing risk 
regression models were used to investigate the effect of psychiatric comorbidity and 
psychological health on all-cause and cause-specific mortality (respectively). 
 
Results: Of 4,837 OUD patients, 176 had died. Mortality rates were substantially higher than 
in the general population (SMR 4.23; 95% CI 3.63-4.90). Among those with OUD, comorbid 
personality disorder and comorbid alcohol use disorder was associated with increased all-
cause mortality in all models, including the fully adjusted model, controlling for socio-
demographic factors, severity of drug use factors, risk behaviours and physical health (HR 
2.15, 95% CI 1.17–3.95; HR 2.28, 95% CI 1.54–3.36).  
AUD was associated with increased risk of fatal overdose (SHR 2.53, 95% CI 1.14 – 5.61) 
and liver-related deaths (SHR 7.28, 95% CI 2.65–19.97). Individuals with OUD and 
91 
comorbid PD had almost four times greater risk of liver-related deaths compared to those 
without comorbid PD (SHR 3.82, 95% CI 2.65–10.46). Comorbid severe mental illness and 
poor psychological health were not associated with increased mortality in these analyses, and 
the potential reasons for non-significant results are discussed.  
 
Conclusions: This study finds elevated risks of mortality for OUD patients with comorbid 
personality disorder and alcohol misuse, thereby highlights the importance of assessment for 
PD and AUD in patients with OUD in order to identify individuals at substantially elevated 





4.2.1 EXISTING LITERATURE 
Opioid dependent individuals are at substantially higher risk of mortality compared to the 
general population, to those with other drug-use problems (Harris & Barraclough, 1998; 
Hayes et al., 2011), and to people with SMI (i.e. psychotic disorders and bipolar affective 
disorder) (Chang et al., 2010; Dickey, 2004; Harris & Barraclough, 1998). Previous research 
found that individuals with substance use disorders, especially opioid dependence, have more 
than four times the expected risk of mortality, with life expectancies reduced by more than 
nine years compared to national norms. This difference was most pronounced in females 
whose life expectancy was reduced by more than 17 years (Hayes et al., 2011).  
 
Although there is evidence of the link between opioids and elevated mortality risk, factors 
which may predispose some opiate users to higher or lower mortality risk compared to their 
peers with the same disorder are not properly understood.  
 
Substance use disorders are strongly associated with other psychiatric disorders in both 
clinical (Brooner et al., 1997; Weaver et al., 2003) and population samples (Rodrigues-Llera 
et al., 2006). Lifetime comorbidity with other psychiatric disorders range from 44% and 93% 
(Brooner et al., 1997; Cacciola et al., 2001; Khantzian & Treece, 1985; King et al., 2000; 
Krausz et al., 1999; Mason et al., 1998).  
 
Psychiatric comorbidity is associated with poor treatment prognosis, greater psychosocial 
impairment, increased risk of relapse and higher rates of HIV risk behaviour (Arendt et al., 
2007; Brooner et al., 1997; Darke & Ross, 1997; Disney et al., 2006; Landheim et al., 2006; 
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Rounsaville et al., 1986; Rounsaville et al., 1982). Comorbid alcohol problems are also 
highly prevalent in this patient population (25%) (Gossop et al., 2002) and are reportedly 
associated with an increased risk of fatal overdose (Darke & Ross, 1997). Mood and anxiety 
problems (41%), personality disorders (PD) (40%) and psychotic disorders (12%) are found 
to be the common comorbid diagnosis not only in opioid users (Rodriguez-Llera et al., 2006) 
but also in other drug users (Weaver et al., 2003). Antisocial PD is a rare diagnosis in the 
general community (4%) (Robins, 1991), but occurs at rates of up to 65% in heroin-using 
samples (Bargagli et al., 2007; Darke et al., 1994). 
 
In addition, people with a diagnosis of PD have a four-fold higher mortality, with 
substantially reduced life expectancy (Fok et al., 2012). Similarly, substantially higher 
mortality rates are found in people with SMI and depressive disorders when compared to the 
general population (Chang et al., 2010). In spite of this, the impact of psychiatric comorbidity 
on mortality risk in substance use disorders has received only moderate attention, with 
existing investigations reporting mixed results (as discussed in more detail in Chapter 2) 
(Arendt et al., 2011; Gossop et al., 2012; Mattison et al., 2011), which rarely investigate 
beyond overdose deaths (Johnson et al., 2015).  
 
4.2.2 AIMS AND HYPOTHESIS 
Given the high prevalence of comorbid alcohol, mood problems, PD and SMI among opioid 
users, and particularly high hazard ratios for mortality risk in individuals with these 
diagnosis, it is plausible that these psychiatric problems may contribute to the elevated 
mortality risk observed in this patient group, with regard to both natural and unnatural causes 
of death.   
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Investigating the impact of comorbid psychiatric problems in opioid users and looking 
beyond unnatural causes of mortality may help improve our understanding of the pathways to 
premature mortality among opioid users as well as identifying subgroups at substantially 
elevated mortality risk.  
 
I used the large and well-established SLaM case register (Stewart et al., 2009) (described in 
Chapter 3) to explore these relationships more fully. From analyses of the data described in 
this chapter, I investigated the associations between subjective ratings of psychological 
health, such as feelings of depression and anxiety, comorbid diagnosis of PD, SMI and AUD, 
in relation to all-cause as well as cause-specific mortality, in a large cohort of opioid-





4.3 METHOD  
4.3.1 STUDY SETTING 
This investigation was set within SLaM - one of the largest specialist mental healthcare 
services in Europe, which provides, within the framework of the NHS, comprehensive mental 
healthcare and addiction services to a catchment population of approximately 1.2 million 
residents. Data for this investigation was obtained using the CRIS system – a SLaM based 
de-identified database, developed by the NIHR BRC and Dementia Unit, which allows 
researchers to search and retrieve thousands of patient records in a de-identified form. A 
detailed description of the study setting, including SLaM and addictions services, and a 
detailed account of the CRIS system is explained earlier (Chapter 3). Investigation specific 
variables were initially explored using the front-end CRIS, and a detailed data extraction plan 
was created in accordance with the requirements and advice from the bioinformatics team, 
who extracted the full data set for these analyses. 
 
4.3.2 INCLUSION CRITERIA 
Diagnoses in CRIS are coded according to the ICD-10 (WHO, 1993) (see Chapter 3 for 
extended details). Diagnoses were derived from their designated SLAM EHR structured 
fields and from free-text fields using NLP.  The NLP application for ‘diagnosis’ (explained 
and validated in Chapter 3) sought to extract any text strings associated with a diagnosis 
statement in order to supplement the existing structured fields.  
 
In this analysis, the sample comprised a cohort of 4,837 SLaM patients who were diagnosed 
with an ICD-F11 OUD within the period between 1st April 2008 to 31st December 2012 and 
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who had been assessed by a clinician using the NDTMS and the TOP (Marsden et al., 2008) 
(see appendix vi.) at least once during the observation period.  
 
All drug treatment agencies are required to provide a basic level of information to the 
NDTMS on their activities each month. The TOP is a reliable and valid 20-item instrument 
for monitoring substance misuse treatment outcomes and is designed to capture pertinent 
features such as substance use, health risk behaviour, offending, health and social 
functioning; and both NDTMS and TOP are now firmly embedded in the routine in-treatment 
monitoring of outcomes across the UK. In the SLaM case register, OUD was the second most 
frequently diagnosed substance use disorder after AUD (Hayes et al., 2011); and 
approximately 96% of SLaM patients with an OUD (within the observation period) appeared 
on the NDTMS completed, and 89% had the TOP completed on at least one occasion. 
 
4.3.3 MAIN OUTCOME MEASURES 
The main outcome in this study was all-cause and cause-specific mortality, within the period 
1st April 2008 to 31st December 2012 (inclusive), in individuals with primary or secondary 
OUD. Routine mortality identification is performed on a monthly basis by SLaM through a 
linkage to the national mortality base using the unique NHS number assigned to all UK 
citizens. This mortality tracing allowed me to establish who had died during the observation 
period and includes active as well as non-active SLaM cases.  
 
In addition, a linkage to data specifically derived from death certificates allowed me to 
establish the recorded underlying cause of each death. The full procedure for identifying and 
confirming SLaM patient deaths and cause-specific mortality data linkage has been described 
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in Chapter 3. In this investigation, based on death data extracted within the current cohort, 
ICD-10 codes A00-B99 were classified as infectious diseases; codes C220, K703-K769 were 
classified as alcoholic and other hepatic diseases; codes C349, J13-J449 were grouped as 
pneumonia and other pulmonary diseases; codes V01-Y98 were classified as unnatural 
causes, with codes X420-X450, Y120, Y125 sub-classified as overdose deaths. The 
remainder of ICD-10 cause of death codes within this cohort related to other natural causes of 
mortality and were classified as such. These groupings were based on the most common 
causes of mortality in this patient group to increase power for multivariable analysis. 
 
 
4.3.4 EXPLANATORY VARIABLES 
Exposures of interest 
 
The main characteristics of interest in this study were psychological health and psychiatric 
comorbidity, measured by investigation of four aspects of mental health, including patients’ 
subjective psychological health ratings (a proxy measure for depression and anxiety), and 
comorbid diagnosis of a SMI, PD and AUD.  
 
Psychological health rating data was extracted from the TOP, which is a reliable and valid 
20-item instrument for monitoring substance misuse treatment outcomes and is designed to 
capture pertinent features such as substance use, health risk behaviour, offending, health and 
social functioning (Marsden et al., 2008). Psychological health rating is the patient’s 
subjective rating of psychological health status, such as feelings of anxiety, depressive 




Cohort members were classified as having a comorbid diagnosis of SMI if they had received 
at least one of the following diagnoses during the observation period: schizophrenia (ICD-
F20), schizoaffective disorders (ICD-F25), and bipolar affective disorder (ICD-F31). These 
were collapsed together to increase power.   
 
Similarly, the cohort was classified as having a comorbid diagnosis of PD if they had 
received either a specific personality disorder (ICD-F60) or mixed and other personality 
disorder diagnosis (ICD-F61), and a comorbid diagnosis of AUD if they had received an 
ICD-F11 alcohol use disorder diagnosis.  
 
Consequently, those with more than one comorbid diagnosis could appear in more than one 
category.  As in inclusion criteria, psychiatric comorbidity diagnoses were derived from their 
designated SLAM EHR structured fields and from free-text fields using NLP to supplement 





In addition to the main exposures of interest, an extensive list of other covariates derived 
from TOP and NDTMS were considered as potential confounders. Date of birth, ethnicity 
and gender are routinely recorded on SLaM electronic patient records in their designated 
fields. Age was calculated from the date on which individuals received their ICD-F11 OUD 
diagnosis within the observation period.  Ethnic classifications were condensed into “White 
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British”, “Other White background”, “African, Caribbean and other black background”, and 
“Mixed, unknown and other”.  
 
The level of deprivation for the neighbourhoods was established by linking the patient’s 
residential postcode to the UK Census data projected for 2007, as reported by Hayes and 
colleagues (2012). More specifically, the index of multiple deprivation was used to give a 
summary of the overall socioeconomic status at the level of lower super output area (LSOA). 
Each LSOA contains a minimum of 1000 residents and 400 households, but with an average 
of 1500 residents. The index of multiple deprivation is derived from multiple domains of 
deprivation including: employment, income, education, health, barriers to housing and 
services, crime and the living environment. Each domain is given a specific weighting, in 
accordance with Noble and colleagues (Noble et al., 2007), to reflect its overall importance in 
the calculation of this index. Moreover, each domain is made up of a number of specific 
indicators that reflect different aspects of the deprivation they are intended to measure. 
Increasing scores in the index of multiple deprivation are indicative of more severe 
deprivation level. In this analysis the address that was recorded closest in time to April 1, 
2008 for each patient was used to calculate deprivation scores, which were then divided into 
tertiles. 
 
Severity of drug use was extracted from NDTMS and TOP and included ‘age at first primary 
problem drug use’, frequency of opiate use in the past 28 days and a total number of different 
drugs used, collapsed from both sources. Injecting behaviour was collapsed into a binary 
variable using information from both the NDTMS (administration route data e.g. oral, 
intravenous, inhalation) and from TOP (frequency of injecting administration in the past 28 
days). Physical health, extracted from TOP, was the patient’s subjective measure of physical 
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health, such as symptoms and being bothered by illness, recorded using a single 21-point 
scale (0, ‘poor’ to 20, ‘good’). Likelihood ratio tests indicated that it was acceptable to 
include psychological health rating, age at first diagnosis, level of deprivation, frequency of 
opiate use and the total number of different drugs used as continuous variables in the 
statistical analyses.  
 
Using NLP applications, I also extracted ‘smoking status’ and ‘living alone’ data for this 
cohort, for inclusion as potential confounders. However, these variables were not included in 
the analyses due to large numbers of missing values. The NLP application, searching free text 
annotations to establish patient’s ‘smoking status’ (current, past or never), only returned data 
for 4.32% of patients (n=209 / 4837). This poor recording of patients smoking status within 
addiction was not surprising, as previous research identified that staff rated smoking 
treatment significantly less important than treatment of other substances and only 29% of 
staff thought it should be addressed early in a client’s primary addiction treatment (Cookson 
et al., 2014). 
 
The NLP application to establish whether the patient was living alone at the time of their 
OUD diagnosis was slightly better compared to smoking status, returning data for 66% 
(n=3193 / 4837), leaving 34% of missing data.  
 
4.3.5 STATISTICAL ANALYSIS 
I calculated SMR using indirect standardization in STATA 12 for the period between 1 April 
2008 to 31 December 2012. The numerator was the number of deaths observed in SLAM 
records within the observation period and the denominator was the number of deaths one 
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would expect to occur over the observation period based on age and gender specific death 
rates for the England and Wales population in 2008 (ONS, 2009). SMRs were age-
standardised using 5-year age bands and stratified by gender, and are presented in Table 4.2. 
Cox regression (Cox, 1972) for survival analysis was used to model the associations of 
psychological health and psychiatric comorbidity with all-cause mortality. Competing risk 
regression was performed to model cause-specific mortality in the current cohort.  
 
Each individual patient’s ‘at risk’ period commenced from the date of their first OUD 
diagnosis within the observation period between 1 April 2008 to 31 December 2012 and 
ended on the day of their death or the end of observation period for individuals who survived.  
 
Associations between psychological status/comorbidity (psychological health rating, 
comorbid SMI, comorbid PD, comorbid AUD) and all-cause mortality were estimated after 
adjusting for the following blocks of variables: (i) age at diagnosis and gender, (ii) socio-
demographic factors (age at diagnosis, gender, ethnicity, deprivation level, relationship 
status), (iii) age at diagnosis, gender and severity of drug use (age at first use, frequency of 
opiate use in past 4 weeks, total number of drugs used); (iv) age at diagnosis, gender and risk 
behaviours (intravenous drug administration); (v) age at diagnosis, gender and physical 
health; (vii) adjusted for all of the above, including the principal exposures of interest (fully 
adjusted model).  
 
Furthermore, associations with overdose deaths, hepatic disease deaths (two largest sub-
cohorts), and all other causes of deaths; and psychological well-being were calculated using 
competing risk regression models. Interactions between mortality and age and gender were 
also tested. All variables used in this analysis are listed in Table 4.1. 
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4.4 RESULTS 
4.4.1 COHORT CHARACTERISTICS 
The characteristics of the sample are reported in Table 4.1. The total number of individuals 
extracted from CRIS who met the inclusion criteria was 4,837 (71% male; 68% “White 
British”), with 176 deaths registered within this cohort. Patients contributed a total of 14,782 
person years at risk. Age at diagnosis within the observation period ranged from 14 to 86 
years with a mean age of 37.5 years (although this may not have been patients’ first approach 
to addiction services over their lifetime). Individuals diagnosed aged 70 and over (n=15) 
were primarily diagnosed for medical reasons and/or were in OUD treatment prior to April 























Total 4837 176 (4) 
PSYCHIATRIC WELL-BEING     
Psychological Health Rating (0-20, in 
tertiles) 
    
Poor (0-8) 1318 (27) 57 (32) 
Moderate (9-12) 1477 (31) 49 (28) 
Good (13-20) 1452 (30) 39 (22) 
Missing 590 (12) 31 (18) 
Comorbid SMI disorder     
No 4500 (93) 162 (92) 
Yes 337 (7) 14 (8) 
Comorbid personality disorder     
No 4564 (94) 159 (90) 
Yes 273 (6) 17 (10) 
Comorbid alcohol use disorder     
No 3860 (80) 109 (62) 
Yes 977 (20) 67 (38) 
SOCIO-DEMOGRAPHIC VARIABLES     
Age group at first F11 diagnosis     
14-24 415 (9) 8 (5) 
25-29 693 (14) 12 (7) 
30-34 872 (18) 26 (15) 
35-39 949 (20) 37 (21) 
40-44 938 (19) 31 (18) 
45+ 970 (20) 62 (35) 
Missing 0 0 
Gender     
Female 1404 (29) 46 (26) 
Male 3433 (71) 130 (74) 
Ethnicity     
White British 3266 (68) 140 (74) 
Other White 595 (12) 22 (13) 
Black 516 (11) 10 (6) 
Mixed, unknown & other 460 (10) 4 (2) 
Level of deprivation (0-100, in tertiles)     
Low (2.6 - 28.5) 1362 (28) 41 (230 
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Moderate (28.6 - 38.2) 1376 (28) 54 (31) 
High (38.3 +) 1393 (29) 56 (32) 
Missing 706 (15) 25 (14) 
Relationship status     
Not in a relationship 4215 (87) 163 (93) 
In a relationship 390 (8) 9 (5) 
Missing 232 (5) 4 (2) 
SEVERITY OF DRUG USE     
Age group at first use     
0-14 378 (8) 17 (10) 
15-19 1391 (29) 69 (39) 
20-24 948 (20) 20 (11) 
25-29 578 (12) 14 (8) 
30+ 754 (16) 28 (16) 
Missing 788 (16) 28 (16) 
Days of opiate use in past 4 weeks     
None 1534 (32) 62 (35) 
1-27 1337 (28) 36 (20) 
Everyday 1398 (29) 48 (27) 
Missing 568 (12) 30 (17) 
Total number of different drugs used     
1 848 (18) 34 (19) 
2 1398 (29) 50 (28) 
3 1349 (28) 52 (29) 
4+ 1242 (26) 40 (23) 
RISK BEHAVIORS     
Injected     
Not injected 3227 (67) 92 (52) 
Injected 1382 (29) 72 (41) 
Missing 228 (5) 12 (7) 
PHYSICAL HEALTH     
Physical health status (0-20, in tertiles)     
Poor (0-9) 1283 (27) 79 (45) 
Moderate (10-13) 1451 (30) 42 (24) 
Good (14-20) 1514 (31) 24 (14) 




4.4.2 MORTALITY IN OPIOID USE DISORDER AND THE GENERAL POPULATION 
Mortality rates in this cohort were substantially higher than in the general population (Table 
4.2) (SMR 4.23; 95% 3.63-4.90), especially for women with OUD where rate was over five 
times the general population (SMR 5.69; 95% CI 4.16-7.59). To explore this elevated risk in 
more detail I proceeded to identify specific factors associated with mortality in this cohort. 
 
 
Table 4.2 Indirect age-standardised mortality ratios stratified by gender for opioid use 
disorder diagnosis in SLAM compared to population of England and Wales in 2008. 
 n Expected deaths Observed deaths SMR (95% CI) 
Total 4837 41.6 176 4.23 (3.63 – 4.90) 
Female 1404 8.1 46 5.69 (4.16 – 7.59) 
Male 3433 33.6 130 3.87 (3.24 – 4.60) 
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4.4.3 ALL-CAUSE MORTALITY IN OPIOID USE DISORDER 
The proportional hazard assumptions for Cox survival analysis were checked with no 
significant interactions between mortality, psychiatric comorbidity and time. Table 4.3 
summarizes findings from initial Cox regression models of factors potentially associated with 
all-cause mortality in patients with OUD. Associations between psychological health and all-
cause mortality remained the same after adjustment for age and gender. Better psychological 
health status was protective (HR 0.96, 95% CI 0.92 - 0.99, per unit increase in the 
psychological health status scale), while those with co-morbid PD and AUD were at 
increased risk of mortality after age and gender adjustment (adjusted HR 2.04, 95% CI 1.23-
3.36; HR 2.42, 95% CI 1.77-3.28).  
 
No associations were found between severe mental illness and mortality. Age at diagnosis, 
increased level of deprivation, and injecting drug administration were also all associated with 
an increased risk of mortality in the age and gender adjusted models.  Initiation of drug use 
between ages 20 to 24 was associated with decreased mortality risk when compared to 
younger age at first use. Similarly, being in a relationship, good/moderate physical health and 
ethnicity other than white were associated with a decreased mortality risk. 
 
Table 4.4 displays Cox regression associations between psychiatric co-morbidities and all-
cause mortality after controlling for blocks of variables. Better psychological health status, on 
a 20-point scale, was associated with lower risk of mortality when adjusted for socio-
demographic factors (HR 0.95 per unit increment, 95% CI 0.91–0.99), but not statistically 
significant after adjustment for other factors.  
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Comorbid diagnosis of SMI was not significantly associated with mortality in this cohort.  
However, the presence of comorbid PD or AUD were found to be associated with increased 
mortality in all models, including the fully adjusted model (adjusted HR 2.15, 95% CI 1.17-
3.95, p=0.014; HR 2.28, 95% CI 1.54-3.36, respectively).  
 
In addition, I tested for the presence of interactions between comorbid PD, age and gender 
(p=0.364; p=0.641 respectively), and comorbid AUD, age and gender (p = 0.052; p=0.399 






Table 4.3 Crude and age and gender adjusted Cox regression models for associations with 
all-cause mortality in individuals with Opiate Use Disorder (OUD). 
  
Crude Hazard Ratio 
(95% CI) 
Adjusted by Age & 
Gender 
Age & gender 
Adjusted P 
Value 
Psychiatric Well-Being       
Psychological Health Status* 0.96 (0.92 - 0.99) 0.96 (0.92 - 0.99) 0.013 
Comorbid Serious Mental Illness       
Not Present Referent Referent   
Present 1.21 (0.70 - 2.09) 1.18 (0.69 - 2.05) 0.544 
Comorbid Personality disorder       
Not Present Referent Referent   
Present 1.90 (1.15 - 3.13) 2.04 (1.23 - 3.36) 0.006 
Comorbid alcohol use disorder       
Not Present Referent Referent   
Present 2.48 (1.83 - 3.37) 2.42 (1.77 - 3.28) <0.001 
Socio-Demographic Factors       
Age at first F11 diagnosis** 1.04 (1.03 - 1.06) 1.04 (1.03 - 1.06) <0.001 
Gender       
Female Referent Referent   
Male 1.16 (0.83 - 1.62) 1.08 (0.77 - 1.52) 0.643 
Ethnicity       
White British Referent Referent   
Other White 0.94 (0.60 - 1.47) 0.95 (0.61 - 1.49) 0.820 
Black 0.46 (0.24 - 0.87) 0.45 (0.24 - 0.86 0.016 
Other and unknown 0.21 (0.08 - 0.56) 0.24 (0.89 - 0.65) 0.005 
Level of deprivation** 1.01 (1.00 - 1.03) 1.01 (1.00 - 1.24) 0.178 
Relationship Status       
Not in a relationship Referent Referent   
In a relationship 0.60 (0.31 - 1.18) 0.50 (0.25 - 0.99) 0.045 
Severity of Drug Use       
Age at first use       
0-14 Referent Referent   
15-19 1.07 (0.63 - 1.81) 1.09 (0.64 - 1.85) 0.754 
20-24 0.46 (0.24 - 0.88) 0.47 (0.25 - 0.90) 0.021 
25-29 0.52 (0.26 - 1.06) 0.50 (0.25 - 1.02) 0.106 
30+ 0.83 (0.46 - 1.52) 0.60 (0.33 - 1.12) 0.106 






Statistically significant (p<0.05) hazard ratios are in bold. 
*Continuous variable, calculated per unit increase in the psychological/physical health status scale. 
The higher the score for psychological/physical scale, the better the psychological/physical health 
status. 
** Continuous variable, calculated per unit increase in the deprivation score. The higher the score, 
the higher the level of deprivation/older age at first F11 diagnosis/higher number of total drugs used. 
None Referent Referent   
1 day - 27 days 0.62 (0.41 - 0.93) 0.67 (0.44 - 1.01) 0.056 
Everyday 0.77 (0.53 - 1.12) 0.89 (0.61 - 1.31) 0.558 
Total Number of Drugs Used** 0.98 (0.88 - 1.08) 0.99 (0.90 - 1.10) 0.862 
Risk Behaviours       
Injected       
Not injected Referent Referent   
Injected 1.77 (1.30 - 2.41) 1.78 (1.31 - 2.43) <0.001 
Physical Health       
Physical Health Status* 0.90 (0.87 - 0.93) 0.90 (0.87 - 0.93) <0.001 
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Table 4.4 Cox regression analyses of associations between psychological health and all-cause mortality in individuals with opiate use disorder (OUD). 
  
HR Adj. for Socio-
demographic factors (a) 
(95% CI) 
HR Adj. for Age, 
Gender & Severity of 
Drug Use (b) (95% CI) 
HR Adj. for Age, 
Gender & Risk 
Behaviours (c) (95% CI) 
HR Adj. for Age, 
Gender & Physical 
Health (d) (95% CI) 
Fully Adjusted 
Model (e) (95% CI) 
Psychological Well-Being           
Psychological Health Status 0.95 (0.91 - 0.99) 0.97 (0.93 - 1.00) 0.97 (0.93 - 1.01) 1.02 (0.98 - 1.06) 1.01 (0.97 - 1.06) 
Comorbid Serious Mental Illness 
 
        
Not Present Referent Referent Referent Referent Referent 
Present 1.23 (0.70 - 2.18) 0.99 (0.50 - 1.96) 1.14 (0.63 - 2.05) 0.90 (0.46 - 1.77) 0.72 (0.34 - 1.53) 
Comorbid Personality disorder           
Not Present Referent Referent Referent Referent Referent 
Present 2.04 (1.19 - 3.49) 2.01 (1.15 - 3.52) 2.10 (1.25 - 3.53) 2.33 (1.38 - 3.93) 2.15 (1.17 - 3.95) 
Comorbid Alcohol Use disorder           
Not Present Referent Referent Referent Referent Referent 
Present 2.38 (1.71 - 3.31) 2.47 (1.73 - 3.53) 2.42 (1.77 - 3.32) 2.24 (1.88 - 3.13) 2.28 (1.54 - 3.36) 
 
(a) Age at OUD diagnosis, Gender, Ethnicity, Level of Deprivation, Relationship status     
(b) Age at OUD diagnosis, Gender, Frequency of Opiate Use, Age at First Use, Total number of different drugs used     
(c) Age at OUD diagnosis, Gender, Intravenous drug administration  
(d) Age at OUD diagnosis, Gender, Physical Health Rating     
(e) Adjusted for all variables in Table 3        
Statistically significant (p<0.05) hazard ratios are in bold. 
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4.4.4 CAUSE-SPECIFIC MORTALITY IN OPIOID USE DISORDER 
I was able to obtain data on recorded underlying cause for 83% of deaths in this cohort 
(146/176) and these are presented in Table 4.5. Overdose was the most common cause of death 
(31%). When causes of death were grouped into natural/unnatural causes, the majority of 
deaths were due to natural causes (61%) with liver disease being the largest natural cause 
subgroup (23%).  
 
The mean age at death was 43 years, but the difference between mean age at death in patients 
dying from unnatural and natural causes was almost a decade. AUD and PD were 
independently associated with increased risk of mortality by liver disease (Table 4.6) (sub-
distribution hazard ratio [SHR] 7.28, 95% CI 2.65-19.97; SHR 3.82, 95% CI 1.40-10.46). AUD 
was also significantly associated with overdose death (SHR 2.53, 95% CI 1.14-5.61).  
 
No significant associations were found for deaths by causes other than the above. Of those who 
died of alcoholic and other hepatic causes, 65% had previously received an AUD diagnosis on 
the ePJS system (data not shown in tables). 
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Table 4.5 Underlying causes of death among opioid dependent individuals. 
Underlying cause of death N (%) Males (%) Females (%) 
Mean age at death 
(SD) 
Overdose 45 (31) 26 (18) 19 (13) 38 (7.93) 
Alcoholic and unspecified liver disease 34 (23) 27 (18) 7 (5) 45 (8.52) 
Infectious disease 14 (10) 11 (8) 3 (2) 44 (7.71) 
Pneumonia and other pulmonary 18 (12) 14 (10) 4 (3) 49 (8.82) 
Other natural causes 23 (16) 16 (11) 7 (5) 49 (11.51) 
Other external causes 12 (8) 11 (8) 1 (1) 38 (8.53) 










Table 4.6 Competing risk regression analyses of factors associated with cause-specific mortality in opioid-dependent individuals in fully adjusted 
models. 
  
Fully adj. SHR for overdose 
mortality (95% CI)*  
Fully adj. SHR for alcoholic and other 
liver disease mortality (95% CI)* 
Fully adj. SHR for all other causes 
of mortality (95% CI)* 
Psychological Well-Being       
Psychological Health Status 1.02 (0.92 - 1.13) 1.01 (0.93 - 1.10) 1.02 (0.95 - 1.10) 
Comorbid Serious Mental Illness 
 
    
Not Present Referent Referent Referent 
Present 0.75 (0.15 - 3.76) 0.30 (0.05 – 1.97) 0.46 (0.10 – 2.18) 
Comorbid Personality disorder       
Not Present Referent Referent Referent 
Present 1.34 (0.38 - 4.71) 3.82 (1.40 – 10.46) 2.11 (0.68 - 6.53) 
Comorbid Alcohol Use disorder       
Not Present Referent Referent Referent 
Present 2.53 (1.14 - 5.61) 7.28 (2.65 – 19.97) 0.89 (0.44 - 1.81) 
    
*Adjusted for socio-demographic factors, severity of drug use, risk behaviours and physical health (see Table 3 for full list of confounders) 




4.5.1 PRINCIPAL FINDINGS 
Analyses presented in this investigation have shown that individuals with OUD have more 
than four times the risk of mortality compared to the general population. A further two-fold 
increased risk of all-cause mortality was identified in OUD patients with comorbid PD and 
AUD, compared to those without these comorbidities. Those with AUD in addition to OUD 
had twice the risk of fatal overdose and more than seven-fold higher risk of death caused by 
liver disease. Also, those with comorbid PD were at almost four-fold risk of death of liver 
disease, compared to OUD patients without PD. However, no associations between mortality 
and serious mental illness, and psychological status were found. 
 
4.5.2 RESULTS IN RELATION TO PREVIOUS RESEARCH 
The association between alcohol and mortality (both overdose and liver disease) fits within 
the current body of knowledge. Alcohol, the most commonly detected concomitant substance 
in opioid-related deaths (along with benzodiazepines) (PHE, 2016), potentiates the 
respiratory depressant effect of heroin and other opioids. Thus, concomitant use of alcohol 
may well lead to fatality from overdose, due to this interaction (Darke et al., 2000). Alcohol 
abuse is also strongly associated with methadone-related deaths (NTA, 2007). Chronic HCV 
is a major cause of liver cirrhosis, as is alcohol misuse (McCartney & Beard, 2010; Menon et 
al., 2001).  
 
HCV occurs at rates between 40% to 90% in injecting drug users (Limburg, 2004) and the 
combined effect of HCV and alcohol consumption is deleterious for liver disease (Poynard et 
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al., 1997). The risk for developing cirrhosis in patients who are HCV-positive and abuse 
alcohol has been reported to be 147 times higher than HCV-positive patients who abstain 
(Poynard et al., 1997). Comorbid AUD in OUD patients, therefore, presents particular 
challenges for clinicians; for example, how best to respond to clients who are under the 
influence of alcohol when presenting for their medication? There is little research evidence to 
guide the clinician as to how best to respond to these circumstances (NTA, 2009), and given 
the heightened mortality rates in this group, more research and guidance is needed.  
 
Current research in PD and OUD reports that screening positively for a borderline personality 
disorder (BPD) was a risk factor for suicide attempts in heroin-using population (Maloney et 
al., 2007) and highlights the importance of assessing impulsivity and psychiatric comorbidity 
when determining risk factors for suicidal behaviour (Maloney et al., 2009).  
 
This study investigated mortality risk beyond suicide. The independent association of 
comorbid PD, with all-cause and liver-disease mortality might reflect the cumulative 
influences of a more chaotic lifestyle, such as engagement in risk behaviours, alcohol use, 
difficulties forming stable relationships, impulsivity, and less treatable addiction. It is 
possible that either the use of opioids is especially harmful for individuals with PD, or the use 
of heroin or other opioids might aggravate a pre-existing PD. Alternatively, OUDs and some 
PDs may be tautological (Rounsaville et al., 1998).  
 
There results presented here should, however, be interpreted with caution. Antisocial 
Personality Disorder, for example, is a particularly problematic diagnosis for drug users. An 
illicit opioid user, for instance, will have a high chance of qualifying for the diagnosis due to 
their illicit drug use, regardless of whether they actually have a PD, creating additional 
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challenges to the treatment providers. Nonetheless, only a small proportion of dual-diagnosis 
patients actually receive treatment for both PD and OUD disorders (SAMHSA, 2012). 
Patients with co-occurring disorders can face challenges accessing treatment, as they may be 
excluded from mental health services if they admit to a substance abuse problem, and vice 
versa (SAMHSA, 2012). 
 
I did not find a significant association between mortality and psychological health rating - a 
reliable measure of indication for problems with anxiety, depressive symptoms and other 
emotional problems (Marsden et al., 2008). Previous literature focusing on the impact of 
depression and anxiety in opioid users is also mixed; one study found that higher levels of 
anxiety have been associated with mortality (Gossop et al., 2002), whereas other found no 
such association (Arendt et al., 2011).  
 
Although studies have consistently shown that between a quarter and a third of heroin users 
meet the criteria for a life-time diagnosis of major depression (Darke & Ross, 1997; 
Dinwiddie et al., 1992), I did not see this in my sample - only 3.5% of the cohort received 
ICD-10 diagnosis of a depressive disorder. This low proportion of comorbid depressive 
disorders may result from (a) a tendency to under-diagnose depression in people with OUD 
perhaps because services focus more on the primary OUD diagnosis and/or diagnoses which 
are deemed to be more life threatening, (b) mood disorder may improve with effective 
management of the addiction, and (c) reluctance to make a diagnosis which might lead to 




4.5.3 STRENGTHS OF THIS INVESTIGATION 
This study has a number of strengths. SLaM is a large provider of secondary mental 
healthcare in Europe, with close to 100% monopoly provision to its geographic catchment. I 
was, thus, able to draw on electronic addictions service clinical records of almost five 
thousand OUD patients, thereby, potentially providing the statistical power (although not 
specifically calculated ) to simultaneously control for a range of potential confounders. SLaM 
patient death-tracing is regularly updated and is based on death certificates issued across the 
UK for both active and non-active SLaM patients. Furthermore, I was able to determine 83% 
of underlying causes of death for this cohort by linking our SLAM data with external ONS 
data, which include those derived from coroners’ reports.  
 
4.5.4 LIMITATIONS OF THIS INVESTIGATION 
The results of this study need to be considered with caution, in light of certain limitations. 
This is an observational study and residual confounding is possible. Potential confounders 
included use of a deprivation score rather than a direct measure of socio-economic status.  
The measure for physical health is a single and self-reported measure, which does not capture 
all possible physical diseases. It should be noted that mean age at ICD-10-F11 diagnosis was 
37.5 years, which does not reflect the “classic-profile” of heroin/opioid addicts who will first 
approach services in their early or mid-20s. This is because our data were limited to diagnosis 
given within the observation period, therefore may not reflect a true representative of age at 
first OUD diagnosis, which may have been given in treatment episodes prior to the start of 
my analytical period. I was able to establish causes of mortality based on ONS linked data; 
however, it was decided not to differentiate between deaths coded as intentional (i.e. suicide) 
and non-intentional (i.e. accidental) overdoses. Furthermore, SLaM is a secondary service 
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provider, and the sample would not have included heroin users within the community who 
are not known to addictions services or who seek help privately. The generalizability of 
findings is, therefore, to specialist secondary care services. Finally, my indicator for 
depression and anxiety was based on a subjective psychological health status rating and not a 
clinical diagnosis. I chose this measure because of the surprisingly low numbers of ICD-10 
depression diagnoses in the cohort.  
 
Despite the relatively large cohort, the number of deaths within those with SMI comorbidity 
was small and important effects might have been missed. Future research should explore 
these associations further using larger samples. Similarly, the relatively small OUD+PD 
sample put limits on power for further and more detailed analysis. To aid our understanding 
of mortality risk in this group, further research should focus on differences in specific 
personality types, and with a particular focus on directions of casualty (i.e. longitudinal 
analysis). Furthermore, the inclusion criteria included date of OUD and having seen a 
clinician at least once during the observation period. Therefore, I was not able to explore 
associations with mortality by frequency of clinician contact - to establish the possible 
differences in hazard ratios for people with the minimum criteria for inclusion compared to 
those with frequent clinician contact during the study timeframe. This, also, is a worthwhile 





These findings carry important implications for clinicians, researchers and service providers.  
The results suggest among people with OUD, a patient group with an already substantially 
elevated risk of premature mortality, the presence of co-morbid PD and/or AUD puts these 
individuals at even greater risk. This marked observation should prompt a change of practice 
for clinicians and also for those responsible for defining and purchasing health care services. 
Existing treatments for OUD are already known to reduce mortality (Cornish et al., 2010) and  
the treatment being delivered influences resulting long-term mortality (Faggiano et al., 2003). 
Correctly tailored treatment is, therefore, even more important when AUD or PD co-exist 
with the OUD diagnosis. This study highlights the importance of assessment for PD and 
AUD in OUD patients in order to identify individuals at substantially elevated mortality risk 
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Introduction: Risk assessments are widely used but their ability to predict outcomes in OUD 
treatment remains unclear. Therefore, the aim of this investigation was to explore whether 
addiction-specific brief risk screening is effective in identifying high mortality risk groups 
and if subsequent clinical actions following risk assessment impacts on mortality levels. 
 
Aim: To determine if routine brief risk assessments given to OUD patients actually predict 
all-cause or cause specific mortality. Also, to determine if these risks may be modified by 
admission to services. 
 
Methods: OUD patients were identified in the SLaM Case Register. Deaths were identified 
through database linkage to the national mortality dataset. Cox and competing-risk regression 
were used to model associations between brief risk assessment domains and all-cause and 
overdose mortality in 4,488 OUD patients, with up-to 6-year follow-up time where 227 
deaths were registered. Data were stratified by admission to general mental health services. 
 
Results: All-cause mortality was significantly associated with unsafe injecting (HR 1.53, 
95% CI 1.10 - 2.11) and clinically appraised likelihood of accidental overdose (HR 1.48, 
95% CI 1.00 - 2.19). Overdose mortality was significantly associated with unsafe injecting 
(SHR 2.52, 95% CI 1.11 - 5.70) and clinically appraised suicidality (SHR 2.89, 95% CI 1.38 
- 6.03). Suicidality was associated with a twofold increase in mortality risk among OUD 
patients who were not admitted to mental health services within two months of their risk 




Conclusions: Addiction-specific brief risk screening can identify OUD patient subgroups at 
increased risk of all-cause and overdose mortality, including risks related to suicidality, 
injecting practices and accidental overdose. OUD patients, where suicidality is evident, who 
are not admitted into services are particularly vulnerable, as suicidality was associated with 
an increased mortality risk among OUD patients who were not admitted to mental health 








5.2.1 EXISTING LITERATURE 
People dependent on heroin or other opioids are up to 14 times more likely to die than their 
peers (Darke & Ross, 2002). Worldwide, an estimated 69,000 people die from opioid 
overdose (accidental or deliberate) each year (WHO, 2014). In England and Wales, more 
than 1,200 deaths registered in 2015 involved an opiate drug (ONS, 2016). Assessing and 
managing risks is a paramount element of care planning and treatment provision to people 
with drug dependence, particularly in opioid dependence (DOH, 2007). Assessment of risks 
within the addictions services should be substance misuse specific, prioritizing directly 
related risks such as overdose, poly-drug use, suicide and/or unsafe injecting practices (NTA, 
2006a, 2006b). 
 
The effectiveness of risk assessment tools in predicting mortality in mental healthcare is 
unclear. Wand and colleagues (2012) reported the inability to conduct a systematic review 
due to a paucity of studies evaluating the effectiveness of risk assessments; and found little 
evidence to conclude whether risk assessments are effective in relation to self-harm or suicide 
reduction. Studies attempting to identify individuals who are more likely to die by suicide 
have been largely unsuccessful, primarily due to its low prevalence, even within high-risk 
groups (Harriss & Hawton, 2005; Kapur, 2005). A recent study of people receiving 
secondary mental healthcare reported that the level of clinically appraised risk of self-neglect 
(but not suicide or violence) predicted all-cause mortality, but the study did not stratify 




5.2.2 AIMS AND HYPOTHESES 
Given the differences in aetiology, symptoms, care provision and risk factors between mental 
health diagnostic groups, it is important to investigate these separately as advised by the NTA 
(NTA, 2006a, 2006b). Therefore, the aim of the investigation presented in this chapter was to 
determine if addiction-specific brief risk assessment, completed for OUD patients, is 
effective in highlighting risks of all-cause and overdose mortality; to investigate mortality 
levels in patients clinically appraised as displaying suicidality, increased likelihood of 
accidental overdose and unsafe injecting practices; and determine if associations between 
clinically appraised risks and mortality differs depending on subsequent clinical actions such 




5.3.1 STUDY SETTING 
Data for this investigation were derived from the SLaM-based CRIS system described in 
detail in Chapter 3. Study-specific variables and their completion rates were first explored 
using the front-end CRIS, and the data extraction plan was developed in accordance with the 
requirements and advice from the bioinformatics team who then extracted the full data set for 
these analyses. 
 
5.3.2 INCLUSION CRITERIA 
As described in Chapter 3, diagnoses in CRIS are coded in accordance with the 10th edition 
of the International Classification of Diseases (WHO, 1993). This study cohort comprised 
SLaM patients who were diagnosed with an ICD-10 F11 primary or secondary OUD between 
1st April 2008 to 31st March 2014 (inclusive), and who had at least one item completed on the 
Brief Risk Scale Assessment-Addictions (BRSA-A) during the observation period. Diagnoses 
were derived from their designated SLAM EHR structured fields and from free-text fields 
using NLP, for which performance is evaluated in Chapter 3.  
 
5.3.3 MAIN OUTCOME MEASURES 
All-cause mortality 
The main outcome in this study was all-cause mortality in individuals with primary or 
secondary diagnosis of OUD, within the period 1st April 2008 to 31st March 2014. Every 
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death in the UK is reported to the ONS-GRO, which is then conveyed to the NHS Care 
Records Service and available to all NHS organizations. The majority of deaths are registered 
with ONS within five days and SLaM mortality updates are performed on a monthly basis.  
This allowed me to establish deaths within the observation period, for both active and 
inactive SLaM patients. The full procedure for identifying and confirming SLaM patient 
deaths has been described in Chapter 3.  
 
Cause-specific mortality 
Additionally, 68.7% of all those who died had death certificate information. This information 
allowed me to establish cause-specific mortality, and more specifically coding for overdose 
mortality. Fatal overdoses included a combination of both intentional (i.e. suicide) and 
unintentional (i.e. drug poisoning) overdose deaths, with ICD-10 codes X409-X450, Y120, 
Y125 and F119 sub-classified as such. The relationship between heroin overdose and suicide 
is problematic due to ambiguous circumstantial information and unclear intent (Cantor et al, 
2001), therefore, for these analyses I grouped suicide by overdose and fatal drug poisonings 
into one group. The cause of death information is based on a static ONS-CRIS data linkage 
and is more likely to reflect a proportion of delayed as well as recent occurrences of deaths 
within the ONS (2011), resulting in the 31% missing causes of death in our cohort (see 







5.3.4 EXPLANATORY VARIABLES 
Exposures of interest 
The main exposures of interest in this study were patients’ risks of suicidality, likelihood of 
overdose and injecting practices. These three risk domains were recorded using the BRSA-A 
(described below) in patients with OUD.  
 
Potential confounders 
In addition to the main exposures of interest, a number of other covariates were considered as 
potential confounders. Patients’ risks associated with violence, health, social variables, and 
service use were also recorded on the BRSA-A. Ethnicity and gender are routinely recorded 
on SLaM electronic patient records in their designated fields. Age was calculated on the date 
on which individuals received their first BRSA-A assessment within the observation 
period.  As in the previous chapter, ethnic group classifications were condensed to “White 
British”, “Other White background”, “African, Caribbean and other black background”, and 
“Mixed, unknown and other”.  
 
Area-level deprivation was established by linking the patient’s residential postcode to the UK 
Census data projected for 2007 in lower super output area units. The full procedure for 
measuring level of deprivation is described in Chapter 3. Homelessness variable was 
established by merging information from area-level deprivation and homelessness/unstable 
housing item on the BRSA-A scale.  
 
Information on patient admissions to a SLaM secondary mental health service in the two-
month period after BRSA-A assessment was also extracted. This information included 
128 
 
general admissions to SLaM and information on prescription of opioid substitute treatment 
(OST) medication (i.e. buprenorphine, methadone, Suboxone [buprenorphine/naloxone]) in 
the 2-month period after BRSA-A completion. Information extracted included both inpatient 
and outpatient community service admissions/prescriptions in a 60-day (two months) 
observation period after the BRSA-A completion.  
 
5.3.5 RISK ASSESSMENT INSTRUMENT 
Completion of the BRSA-A is a required procedure for the addictions clinical team on all 
active cases. This risk measure was developed by SLaM clinicians to encourage identification 
and formal recording of risk areas specific to substance misuse patients; these are then used 
in their care planning. The BRSA-A should be completed for each service user at the point of 
referral, as part of the service user’s initial assessment when he or she first comes into contact 
with SLaM services. The completion of the BRSA-A assists in informing clinical staff 
whether a full risk screen is then required (SLaM, 2011). 
 
The BRSA-A includes twenty-seven binary items (0=no risk; 1=risk detected). These 
individual items have been sub-classified into seven risk domains: suicidality, accidental 
overdose, injecting practices, violence, health, social, and service use.  The full list of 
individual BRSA-A items and their classified risk domains is presented in Table 5.1. For 
analytical purposes, I collapsed relevant BRSA-A items into three domains according to 





The suicidality domain consisted of suicide attempt history, suicidal ideation, carer concern 
and major mental illness items. The likelihood of accidental overdose domain consisted of 
reduced tolerance, recent abstinence, alcohol abuse and poly-substance use. The unsafe 
injecting domain included previous/current injecting, high risk injecting, and sharing of 
injecting equipment items.  
 
A score of one was assigned if any item within a given risk domain was scored as present; 
and a score of zero if all items within that risk domain were scored as absent – this increased 
power for all-cause and cause-specific overdose investigations. I chose to focus on these 
three domains as exposures of interest because of their likely relationship with mortality in 
this patient group (WHO, 2013). Remaining BRSA-A items were included in analyses 
individually, as potential confounders.  
 
5.3.6 STATISTICAL ANALYSIS 
The proportional hazards assumptions were checked using likelihood ratio tests, with no 
statistically significant interaction between the BRSA-A domains, mortality and time. Cox 
regression (Cox, 1972) survival analyses were used to model the associations between the 
suicidality,  accidental overdose and unsafe injecting domains (obtained from the first BRSA-
A assessment in the observation period) and all-cause mortality.  
 
Competing risk regression was performed to model cause-specific overdose deaths for the 
same domains. The date of ‘at risk’ period for each individual patient commenced from the 
date of their first BRSA-A assessment within the observation period (between 1 April 2008 
130 
 
to 31 March 2014) and ended on the day of their death or the end of observation period, 
whichever came first.  
 
I also used likelihood ratio tests to examine potential interactions between risk domains and 
admissions to SLaM services in the two-month period after the assessment was conducted, 
and between risk domains and the OST prescriptions in the same observation period. Where a 
significant interaction was found I stratified the data accordingly and re-ran the Cox models 
with all-cause mortality as the outcome. Kaplan-Meier survival curves were used to visualize 
results for the stratified analyses. All analyses were conducted using STATA 12, with 




5.4.1 COHORT CHARACTERISTICS 
The total number of patients with primary or secondary ICD-10 F11 OUD diagnosis within 
the six-year period between 1st April 2008 and 31st March 2014 was 5,335 and BRSA-A was 
completed for 84.1% (n=4,488) of those. There were no significant differences between age 
(calculated at midpoint observation period for this comparison), gender, ethnicity and 
mortality in people with and without completed BRSA-A assessments.  
 
There were no individual missing items within the group who had the BRSA-A completed. 
Therefore, the total number of individuals who met the inclusion criteria and whose data were 
extracted for analysis was 4,488 (71.8% male; 66.9% “White British”), with 227 registered 
deaths (detailed in Table 5.1).  
 
Patients contributed a total of 17,805 at-risk person years. Age at risk assessment within our 
observation period ranged from 15 to 73 years with a mean age of 37.6 (SD=9.07), and with 
mean age at death of 43.7 (SD=9.15). More than a quarter (27.4%) of our OUD cohort were 
found to have a comorbid major mental illness. The majority of patients (64.2%) were 
admitted into SLaM services in the subsequent two months after their risk assessment was 










deaths (% per 
row) 
Total 4,488 227 (5.1) 
BRSA-A items and domains 
  
Suicide     
Suicide attempt history 1,279  91 (7.1) 
Suicide ideations 306  13 (4.2) 
Carer concern 205  17 (8.3) 
Major mental illness 1,225  75 (6.1) 
Accidental Overdose     
Reduced tolerance 738  47 (6.4) 
Recent abstinence 823  41 (5) 
Alcohol abuse 1,220 109 (8.9) 
Poly-substance 2,615  155 (5.9) 
Injecting     
Previously injecting 1,433 102 (7.1) 
Currently injecting 1,047  81 (7.7) 
High risk injector 515  49 (9.5) 
Share injecting equipment 367  32 (8.7) 
Violence     
Violent past 1,051 45 (4.3) 
Violent thoughts 84  5 (6) 
Violent behaviour 119  8 (6.7) 
Violence Concern 117  10 (8.6) 
Health BRSA Items     
BBV Infections 900  92 (10.2) 
Hist. of substance related seizures 588  59 (10) 
Unmet needs 717  92 (12.8) 
Cognitive impairment 220  24 (10.9) 
High risk sexual behaviour 258  14 (5.4) 
Social BRSA Items     
Homeless / unstable housing 1,341  76 (5.7) 
Childcare / social service problems 392  17 (4.3) 
Social isolation 1,246  88 (7.1) 
Self-neglect 816  74 (9.1) 
Criminal activity 1,037  47 (4.5) 
Service Use Items     
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Erratic engagement 880  56 (6.4) 
Socio-demographic variables     
Age at assessment     
15-24 358 9 (2.1) 
25-29 614 13 (2.1) 
30-34 833 36 (4.3) 
35-39 888  47 (5.3) 
40-44 869  45 (5.2) 
45-49 536  33 (6.2) 
50+ 390 44 (11.3) 
Gender     
Males 3,224  166 (5.2) 
Females 1,264  61 (4.8) 
Ethnicity     
White British 3,002  170 (5.7) 
Other White 622  32 (5.1) 
Black 466  15 (3.2) 
Mixed, unknown & other 398  10 (2.5) 
Level of deprivation (in tertiles)      
Low  (2.19 -27.42) 1,468  67 (4.6) 
Moderate (27.43 - 37.0) 1,470 77 (5.2) 
High (37.1+) 1,474  82 (5.6) 
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5.4.2 ALL-CAUSE MORTALITY FOR BRSA-A RISK CLUSTERS 
Crude mortality rates per 10,000 person years (PY) for all-cause and cause-specific mortality 
are presented in Table 5.2 below. Furthermore, associations between suicidality, accidental 
overdose and unsafe injecting BRSA-A risk domains and all-cause mortality are represented 
in Table 5.3. In the fully adjusted models with all-cause mortality as an outcome, BRSA-A 
assessed unsafe injecting and likelihood of accidental overdose was associated with increased 
risk of all-cause mortality (HR 1.53, 95% CI 1.10 - 2.11; HR 1.48, 95% CI 1.00-2.19, 
respectively). 
 
5.4.3 CAUSE-SPECIFIC MORTALITY FOR BRSA-A RISK CLUSTERS 
I was also able to obtain data on recorded underlying cause for 68.7% of deaths in this cohort 
(156 / 227), with overdose deaths (both accidental and intentional) being the largest group 
(n=44). Other predominant causes of deaths within this cohort were deaths from hepatic 
causes (n=39) and infectious diseases (n=35) (data not shown in tables). In the fully adjusted 
competing risk regression models I found that BRSA-A assessed suicidality and unsafe 
injecting risks were independently and significantly associated with increased overdose 
mortality (SHR 2.89, 95% CI 1.38 - 6.03; SHR 2.52, 95% CI 1.11 - 5.70, respectively). 













Table 5.3 Fully adjusted Cox and competing risk regression models examining associations between all-cause and cause-specific mortality and 
BRSA-A appraised suicidality, likelihood of accidental overdose and unsafe injecting. 
 
       
Risk Cluster 
Fully adj.a all-cause 
HR (95%CI) 
p value a  
Fully adj.a SHR                       
for overdoseb deaths 
(95% CI) 
p value a 
Fully adj.a SHR                       
for deaths other than 
overdose (95% CI) 
p value a 
Suicidality             
None detected   Reference   Reference   Reference   
Detected (n=1,929, 120 deaths) 1.23 (0.92 - 1.64) 0.154 2.89 (1.38 - 6.03) 0.005 0.83 (0.55 - 1.26) 0.378 
Likelihood of Accidental Overdose             
None detected   Reference   Reference   Reference   
Detected (n=3,416, 194 deaths) 1.48 (1.00 - 2.19) 0.049 2.82 (0.83 - 9.62) 0.097 1.23 (0.73 - 2.08) 0.43 
Unsafe Injecting             
None detected   Reference   Reference   Reference   
Detected (n=2,249, 161 deaths) 1.53 (1.10 - 2.11) 0.011 2.52 (1.11 - 5.70) 0.027 1.37 (0.83 - 2.29) 0.221 
 
 
HR, hazard ratio; CI, confidence interval; SHR, sub-distribution hazard ratio. 
a. Adjusted for all variables listed in Table 5.1  
    
b. Accidental and intentional overdoses 







Table 5.4 Cox regression analyses examining associations between suicide risk domain and all-cause mortality in individuals with opioid use 
















HR, hazard ratio; CI, confidence interval. 
a. Adjusted for all variables listed in Table 5.1.  










HR (95% CI) 
p valuea 
Not admitted (N = 1602, 90 Deaths)         
No suicidality  detected Reference   Reference   
Suicidality detected (n=631) 2.37 (1.56 - 3.62) <0.001 2.03 (1.67 - 3.24) 0.003 
Admitted (N = 2881, 137 Deaths)         
No  suicidality detected Reference   Reference   
Suicide risk detected (n=1,294) 1.27 (0.91 - 1.78) 0.162 0.91 (0.63 - 1.32) 0.636 
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5.4.4 ADMISSIONS TO SERVICES AND BRSA-A RISK ASSESSMENT.  
In view of the significant findings above (Table 5.3), I further tested for the presence of 
interactions between admission in the two-month period immediately after BRSA-A assessment 
and 1) suicidality, 2) accidental overdose and 3) unsafe injecting domains, in models where the 
outcome was all-cause mortality. An interaction between BRSA-A suicide risk and SLaM 
admission was found. Additionally, in all-cause mortality models, I tested for interactions between 
the types of opioid substitute treatment (i.e. buprenorphine, methadone, Suboxone 
[buprenorphine/naloxone]) and the three BRSA-A risk domains mentioned above, but none was 
found (data not in tables).  
After stratifying the analysis by admission to SLaM services (presented in Table 5.4) I found that 
an association between BRSA-A suicidality and all-cause mortality was present in the group who 
had not been admitted into SLaM services in the two months after their risk assessment (HR 2.03, 
95% CI 1.67 - 3.24), but not for the admitted group.  
The Kaplan-Meier survival curve in Figure 5.1 visualizes results for suicide risk domain stratified 
by admission to SLaM service showing the reduced survival in BRSA-A patients where 
suicidality was assessed as being present who were not admitted. Of all those admitted, 65.9% 
were admitted to addiction services, with other most common admissions being to psychological 








Figure 5.1 Kaplan-Meier survival curve for BRSA-A suicidality domain and admissions to SLaM 
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5.4.5 ESTABLISHING REASONS FOR NON-ADMISSION 
To establish the cause of non-admission, a manual search (where all free-text clinical notes and 
correspondence were reviewed) in the electronic patient records was conducted in a random 
sample of 200 patients who were not admitted to services in the 2-month period after their risk 
assessment (n=100 where suicidality was assessed as being present; n=100 where suicidality was 
not evident). Of those where suicidality was classified as being present, a manual electronic 
patient data search revealed that the leading causes for non-admission were loss of contact with 
the patient (51%) and transfer out of services (26%). Similarly, in the sample where suicidality 
was not evident, the leading causes for non-admissions were loss of contact with the patient 
(48%), transfer out of services (22%) and incarceration (11%). No interactions between BRSA-A 




5.5.1 PRINCIPAL FINDINGS 
Three important findings arising from this study need to be noted. First, addiction-specific 
brief risk screening assessment may provide useful information to identify subgroups at 
elevated risk of mortality. Second, specific domains within the BRSA-A were particularly 
informative -  suicidality was found to be associated with increased risk of overdose 
mortality; unsafe injecting practices were associated with both all-cause and overdose 
mortality; and increased likelihood of accidental overdose was associated with all-cause 
mortality but not fatal overdoses. Finally, suicidality was associated with a twofold increased 
all-cause mortality risk among OUD patients who were not admitted to mental health services 
within two months of their risk assessment. However, I found no evidence that suicidality 
presented a similar risk in the subgroup who were admitted into mental health services during 
this time frame. These finding suggest that OUD patients with clinically evident suicidality 
who are not admitted to mental health services promptly may be particularly vulnerable. 
 
5.5.2 RESULTS IN RELATION TO PREVIOUS RESEARCH 
 
Whilst the relationship between drug injecting practices and increased all-cause and overdose 
mortality in OUD is consistent with current literature (Degenhardt et al., 2011; WHO, 2013), 
the relationship between overdose, suicide and intent is not as clear. Several studies have 
questioned to what extent heroin overdoses are de facto suicide attempts. An association 
between heroin overdose and suicide was noted, for example, in a study of 77 overdose 
survivors admitted to accident and emergency, with 49% reporting suicidal thoughts or 
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feelings immediately prior to overdose (Neale, 2000). In another study, among a London 
treatment sample, 50% of those with a history of overdose had two attempted suicides 
compared to 18% of those with no history of overdose (Vingoe et al., 2009). However, Darke 
and Ross (2000) reported that while 40% of methadone maintenance participants had 
attempted suicide, only 10% had done so by means of a deliberate heroin overdose. Drug 
overdose was the most common method of attempted suicide, but by means of non-opioid 
pharmaceutical preparations. Conversely, heroin overdose among their participants 
overwhelmingly appeared to be accidental (92%). 
 
My data suggest that screening positively on at least one item within the suicidality domain 
(including suicide attempt and/or ideation, carer concern or major mental illness) is, 
independently of accidental overdose risk factors, associated with an almost three-fold 
increase in fatal overdose. Although I do not know whether fatal overdoses in this cohort 
were indeed caused by heroin, other drugs, or a mixture of the two, it is noteworthy that in 
2014 in England and Wales, more than a half of all deaths from drug poisoning involved an 
opiate drug (ONS, 2015).  
 
Second, because the intent was unknown, I do not know which overdose deaths in our cohort 
were accidental and which were suicides. However, I did find an association between 
suicidality and overdose fatalities and did not find associations between increased likelihood 
of accidental overdose and overdose fatalities. This could be interpreted either that most 
overdose fatalities were deliberate (suicides), or that identification of patients as ‘likely to 
accidentally overdose’ resulted in higher visibility to services which then resulted in 
improved healthcare. Increased likelihood of accidental overdose may be addressed within 
addiction services, for example, by overdose training or supply of naloxone antidote. 
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However, suicidality may be much more complex and problematic to address and with the 
need for dual-diagnostic/multidisciplinary care plan approaches addressing high levels of 
underlying depression and other psychiatric comorbidities (Bogdanowicz et al., 2015; Cantor 
et al., 2001; Darke et al., 2007). 
 
The elevated mortality risk in patients where suicidality was evident, and who were not 
admitted to mental health services in the subsequent two months, highlights the importance 
of admission, access to services and treatment provision. McCowen and colleagues describe 
history of admission as being a risk factor for mortality in this patient group (McCowan, 
Kidd, & Fahey, 2009). However, my study suggests that timing of admission itself is a 
protective factor for those at risk. Furthermore, non-admission into services was largely due 
to loss of contact and transfers out of service/catchment area. Drop-out from treatment (and 
relapse) and erratic engagement in services appears to be highly prominent in this patient 
group, and both are known to increase mortality considerably (Degenhardt et al., 2011; Zanis 
& Woody, 1998). Similarly, times of transition between services involved in the care of 
people with opioid dependence are particularly ‘risky’, for example after release from prison 
(Merrall et al., 2010). OUD patients who are assessed as being at risk of suicide and, 
subsequently, disengage with current services may require more determined strategies for 
patient follow-up and service transition due to their high risk of mortality. Without better 
outreach for these poorly engaged groups, current policy will maintain inequalities for more 





5.5.3 STRENGTHS AND WEAKNESSES OF THIS INVESTIGATION 
The results of this study need to be considered in light of certain limitations, alongside 
acknowledgement of strengths. SLaM is a large provider of secondary mental healthcare in 
Europe, with close to 100% monopoly provision to its geographic catchment. As a result, I 
was able to draw on electronic addictions service clinical records of almost five thousand 
OUD patients allowing to simultaneously control for a range of potential confounders. The 
inclusion criteria specified primary or secondary OUD diagnosis. Whilst the use of NLP 
applications allowed me to supplement the existing structured fields, it did not allow to me 
establish whether these diagnoses were primary or secondary, and measure their impact on 
outcomes.  
 
SLaM patient death-tracing is regularly updated and is based on death certificates issued 
across the UK for both active and non-active SLaM patients. This is not the case for 
underlying cause of death, which derives from additional static ONS linked data. Information 
on underlying cause of death was only present in 69% of cases. Additionally, as discussed, I 
could not differentiate between intentional (i.e. suicide-related) and non-intentional (i.e. 
accidental) overdose deaths. Similarly, toxicology reports were not available, and it was 
therefore unclear which drugs were involved in the overdose deaths.  
 
The clinical risk assessment information used for analysis was the first within the observation 
period but may not have been the first risk assessment conducted in an individual’s lifetime. 
Given the mean age of our cohort as 37 years, there will be individuals who have had 
previous treatment episodes and subsequently previous risk assessment conducted, occurring 
prior to our observation period. Similarly, I do not know if any (and which) 
circumstantial/treatment changes occurred in the period beyond the subsequent two months 
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after their risk screen and until their death/end of observation period, which might have 
influenced mortality risk in addition to clinically appraised suicide risk. However, given that 
a high proportion of people did not enter treatment due to loss of contact, it seems that the 
combination of suicidality and erratic engagement in services increases mortality risk in the 
longer term.  
 
It is important to note that my analysis investigated admissions to mental health services 
across SLaM, and not to addictions services only. I chose to broaden my focus because 
suicide risk in OUD may not necessarily be attended to within the addiction setting in the 
first instance, especially in cases of psychiatric comorbidity. The identification of reasons for 
non-admission was extracted from a random sample and not the entire non-admitted sub-
cohort. Although the administration of BRSA-A assessments is mandated in practice, only 
84% of OUD patients had the BRSA-A scale completed.   
 
Finally, more consideration has to be given to the brief risk assessment screen as a measure 
of exposure status, which has advantages and disadvantages. The BRSA-A was not formally 
evaluated as a measurement tool in terms of constructs such as inter-rater or test–retest 
reliability, or its discriminant validity. However, this is a real-world measure, developed by 






Prompt identification of those at risk is key. The current chapter provides evidence that 
addiction-specific risk assessment may be useful in identifying those whose risk may be 
elevated in a timely manner. The findings also point out associations between suicidality and 
overdose mortality in people with opioid dependence, and highlights the importance of 
admission to mental health services for those where suicidality is evident. Prompt 
identification and management of those at risk using brief risk assessment may be useful to 























CHAPTER 6  TREATMENT AND TIMING: ANALYSIS OF CLUSTERING OF 
OVERDOSE DEATHS IMMEDIATELY AFTER CESSATION OF OPIOID 
SUBTITUTION TREATMENT AND FOLLOWING TRANSFERS OF PATIENTS 




The contents of this chapter have contributed to the following: 
 
Publication in a peer-reviewed journal: 
Bogdanowicz, K.M., Stewart, R., Chang, C.K., Shetty, H., Khondoker, M., Day. E., Hayes, 
R.D., Strang, J. Excess overdose mortality immediately after cessation of opioid substitute 
therapy and following transfer of patients and their care: findings from analysis of integration 
of deaths data with catchment area healthcare data on a sample of opioid use disorder 







Aims: The aim of the analysis reported in this chapter was to investigate clustering of deaths 
in the period immediately after transfer of patients and their care and after end of OST, in a 
cohort of opioid dependent individuals in specialist addiction treatment.  
 
Methods: Mortality data were identified within a sample of 5,445 patients with OUD who 
had received OST treatment between 1st April 2008 and 31st December 2013. Circumstances 
and distribution of the 332 deaths identified within the observation window were explored. 
 
Measurements: Mortality incidence rates after the end of treatment/transfer for overdose 
mortality. 
 
Findings: The study identified higher concentrations of overdose deaths in the first 28 days 
after a planned end of OST treatment and within 28 days after a transfer of patient between 
services, even when continuation of OST treatment had been arranged. Of 32 (56%) patients 
who died of overdose after a planned OST cessation, 18 patients died within 180 days, of 
whom 5 died in the first 2 weeks and a further 4 died in the reminder of the first month post-
termination of OST. Of the 47 individuals who died from overdose after having been 
transferred between services, 20 (43%) died within 180 days of this transfer, of whom 9 died 
in the first 2 weeks and a further 5 died in the reminder of the first month post-transfer.  
 
These results translate into an overdose mortality rate of 77.2 per 1000 person-days within 28 
days post-OST cessation/transfer, compared with a rate of 1.9 per 1000 person-days for 
overdoses after the first month of treatment cessation/transfer (rate ratio [RR] = 41.4; 25.1 -
66.1, 95% CI; p <0.0001). 
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Conclusions: High clustering of fatal overdoses in the early post-OST period was observed. I 
also found a substantially higher concentration of deaths in the period immediately following 
transfer of patients to a different treatment care-provider. This excess mortality is pronounced 
in the first month post-transfer, and especially so in the first fortnight. Further research is 
urgently required.   
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6.2 INTRODUCTION 
6.2.1 PREVIOUS RESEARCH 
 
Heroin and other opioids contribute disproportionately to drug-related deaths. The use of 
heroin and other opioids is rare – only 0.1% of responders in the most recent household-
based CSEW, compared with cocaine (2.3%) or cannabis (6.7%) (CSEW, 2015). 
Nevertheless, heroin and other opioids were involved in 53% of all DRDs, and with fatalities 
reported as involving heroin and/or morphine (heroin breaks down into morphine and hence 
morphine-positive often means heroin use) having increased by almost two-thirds between 
2012 and 2014 (ONS, 2015). 
 
Research has shown consistently that OST is protective against death (Caplehorn, et al., 
1996; Faggiano et al., 2003). More recently, it has also been identified that there is a short-
lived substantial excess mortality after termination of OST where, in a national primary care 
cohort, the risk of death has been found to increase eight-fold in the month immediately after 
the end of OST (Cornish et al., 2010). Several other studies have reported similar findings 
(Cousins et al., 2016; Davoli et al., 2007; Strang et al., 2003), but none has examined 
interruptions to continuity of care, such as transfers of patients to alternative service or care-
provider.  
 
The present chapter reports findings from preliminary, exploratory analysis 1of mortality 
patterns amongst patients with opioid use disorder who have received OST treatment within a 
large secondary mental health service provider (Perera et al., 2015; Stewart et al., 2009). 
Within this work, I have examined factors associated with clustering of deaths.  
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6.3 METHODS 
6.3.1 STUDY SETTING 
SLaM is one of the largest secondary mental healthcare services in Europe, providing 
addiction services to a catchment population of approximately 1.36 million residents across 
seven ethnically and socially diverse, high population density boroughs of south-east London 
(Perera et al., 2015). In 2008, the CRIS system was developed, which accesses patients’ 
electronic health records in a de-identified format, allowing researchers to search and retrieve 
complete case records for analysis. There are currently more than 280,000 patients 
represented on the system. CRIS is approved as a dataset for secondary analysis by 
Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5), and its protocol is 
described in detail elsewhere (Perera et al., 2016; Stewart et al., 2009). 
 
6.3.2 INCLUSION CRITERIA 
The study sample comprised SLaM patients diagnosed with primary or secondary OUD 
between 1st April 2008 and 31st December 2013 who died within the same observation 
period. Diagnoses were derived from their designated SLAM EHR structured fields and from 
free-text fields using NLP application for ‘diagnosis’, which extracts any text strings 
associated with a diagnosis statement in order to supplement the structured fields. The 
performance has been explained and evaluated in Chapter 3 and reported elsewhere (Perera et 
al., 2015). 
 
Every death in the UK is reported to the ONS-GRO, which is then conveyed to the NHS Care 
Records Service and is available to all NHS organisation; and consequently in CRIS. This 
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identifies deaths within the observation period, for both current and previous SLaM patients. 
The full procedure for identifying and confirming SLaM patient deaths has been described by 
Chang et al (2010) and is detailed in Chapter 3. In addition, a linkage to data specifically 
derived from death certificates made it possible to establish the recorded underlying cause of 
each death in those where this information was available.  
 
6.3.3 MEASURES AND CALCULATIONS 
 
In the present chapter, I investigated potential clustering of deaths after a clinically planned 
termination of OST and after a transfer of patient and their care to another service or care 
provider, with arrangement for continuation of OST. The main characteristic of interest in 
this study was the timing of death, specifically overdose deaths, in OUD patients who were 
prescribed OST treatment. Incidence rates and relative risk were calculated and Kaplan-





Using CRIS, I extracted de-identified individual records on all patients with an OUD who 
died between 1st April 2008 to 31st December 2013. Searching backwards from each death 
date, I looked for the start and end dates of the most recent OST treatment episode. This 
information was primarily derived from treatment care plan notes, with each OST treatment 
episode starting with the date of the first prescription for substitute opioids relating to most 
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recent treatment episode and ended with the expiry of their last prescription. The name of the 
last prescribed OST medication was also noted.  
 
In all cases, a search through discharge notes and free-text fields, including event notes and 
correspondence, was also conducted manually for validation purposes and to supplement data 
not available in the structured fields. In order to perform a systematic and consistent manual 
data extraction and its coding, a set of ‘gold-standard’ guidelines were developed first which 
were then rigidly followed and adhered to during the entire manual extraction process. These 
guidelines included a set of locations Particular attention was given to treatment episodes 
with a gap of less than 28 days between the end of one episode and the start date of the next. 
In such cases, examination of event and discharge notes was particularly useful, as it allowed 
me to establish whether a patient genuinely stopped and restarted their treatment in a four-
week period. The 28-day rule was adopted from Cornish and colleagues (2010). 
 
 
Categorising reasons for end of treatment 
 
Reasons for cessation of OST treatment were extracted from patients’ treatment care plans, in 
discharge notes and other free-text fields. By cross-examining these sources, I categorised 
reasons for end of treatment into the following: 1). ‘Planned end of OST treatment’ (patients 
with a clinically planned discharge following cessation of OST); 2). ‘Transfer’ (patients who 
were transferred to another service or care provider who would then take over patients’ care, 
including OST prescribing); 3). ‘Dropout’ (patients with a clinically unplanned OST 
cessation, such as non-compliance, failure to attend key-working sessions and/or failure to 
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collect prescribed OST medications); and 4). ‘Died in treatment’ (if death occurred during an 
OST treatment episode). Types of transfer were also noted. 
 
6.4 RESULTS 
6.4.1 SAMPLE CHARACTERISTICS 
 
The total number of patients with primary or secondary ICD-10 F11 OUD diagnosis within 
the observation window was 5,335, with 385 deaths identified in this sample. Of the 385 
individuals who died, 53 (14%) were never prescribed OST within SLaM and/or their records 
contained no information with regard to their treatment history, and were therefore excluded 
from further analysis. A further 116 (35%) of the remaining 332 patients died whilst still in 
OST treatment in SLaM and hence were not considered further in this analysis of deaths post-
OST treatment and post-transfer.  
 
The remaining sample of 216 deaths are the focus of the analysis reported in this chapter. 
They comprised 66 patients with a planned termination of OST treatment, 109 who were 
transferred to another service or care-provider, and 41 who dropped out of OST treatment.  
 
As presented in Table 6.1, most patients were male, with mean age of 45 years at the time of 
their death. The median duration of patients’ last OST treatment episode was just below 8 
months (235.5 days, inter-quartile range 52-560 days) and the median interval between end of 
treatment/transfer and death was almost 1 year (349 days, inter-quartile range 62-800 days). 
Most destinations for transfers between services were primary care, followed by 
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independent/third-sector drug treatment providers, transfer to alternative (usually out of area) 
CDAT services, and to general hospitals.  
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Table 6.1 Cohort characteristics (n=216). 
 N (%) 
Total Study Sample 216 
Males 151 (69.9) 
Age  
>= 29 17 (7.9) 
30-39 55 (25.5) 
40-49 73 (33.8) 
50-59 49 (22.7) 
60+ 22 (10.1) 
Planned OST end 66  (30.6) 
Drop-Outs 41  (19) 
Transfer between services 109 (50.5) 
Transfer to primary care 42  (38.5) 
Transfer to independent/third-party sector 21  (19.3) 
Transfer to alternative community drug treatment service  16  (14.7) 
Transfer to general hospital  14  (12.8) 
Transfer to prison 5  (4.6) 
Other transfers 11  (10.9) 
Last prescribed medication  
Methadone 179 (82.9) 
Buprenorphine 31 (14.3) 
Other (diamorphine, Suboxone, morphine) 6 (2.8) 
Last treatment episode duration  
One month or less 37 (17.1) 
Between one month and six months 59 (27.3) 
Between six months and one year 43 (19.9) 





6.4.2 MORTALITY RATES 
Under the assumption that the number of patients under treatment remain constant throughout 
the observation period, there appears to be a higher concentration of all-cause deaths within a 
month after a planned end of OST treatment and also high concentrations of deaths in the 
first month after a transfer between services, even when continuation of OST treatment was 
arranged.  
 
There were 66 individuals who died after a planned termination of OST treatment and 109 
who died after a transfer between services. Of the 66 individuals who died after a planned 
termination of OST treatment, 27 (41%) died within 180 days of treatment cessation, with 12 
of those being within the first 28 days and 7 within the first fortnight post-termination. Of the 
109 who died after transfer between services, 43 (39%) died within 180 days of this transfer, 
with 26 dying in the first 28 days and 17 within the first fortnight post-transfer. Similarly, of 
the 41 who died after having dropped out of treatment, 12 (29%) died within 180 days of this 
transfer, with 4 of these being within the first fortnight post-drop-out (details not shown in 
tables).  
 
The primary interest was in deaths caused by a fatal overdose. I was able to ascertain the 
cause of death in 96% of patients (208 out of 216), summarised in Table 6.2. Overdose 
fatalities were the most common (49%) followed by liver-related deaths (14%).  
 
To establish whether transfer of care and termination of OST treatment were associated with 
increased risk of overdose, I restricted further analysis to fatal overdoses only. Of the 103 
individuals who died of overdose, 47 were in the post-transfer subgroup and 32 occurred after 
a planned end of OST, and with high clustering of overdoses occurring in both subgroups.  
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More specifically, 20 out of 47 (43%) of the post-transfer overdose deaths occurred within 
180 days, of which 9 died in the first 2 weeks and a further 5 died in the remainder of the first 
month. Similarly, 18 out of 32 (56%) of overdose deaths occurred within 180 days of planned 
OST cessation, of which 5 died in the first 2 weeks and a further 4 died in remainder of the 
first month. Twenty-four overdoses occurred in the drop-out group, and with five occurring 
within 180 days but none were recorded within the first fortnight. Figures 6.1 and 6.2 show 
distribution of overdose deaths within 180 days post-transfer with continuation of OST 
treatment and post-treatment with planned cessation of OST, respectively. 
 
Combining the three reasons for OST treatment end (transfer, planned discharge and drop-
out), the total follow-up -time was 42,716 person-days, with 311 person-days in the group 
who fatally overdosed in the first 28 days after post-OST cessation/transfer; and with a rate of 
77.2 deaths per 1000 person-days compared with a rate of 1.9 deaths per 1000 person-days in 
the group who died of overdose at a point after the first month of treatment cessation/transfer. 
The rate ratio comparing the two groups was 41.4 (25.1-66.1 95% CI; p <0.0001). Figures 
6.1 shows the survival probabilities for time since the end of treatment/transfer and overdose 
mortality for total follow-up time. Figure 6.2 displays the survival probabilities for time since 
end of treatment/transfer and overdose mortality within 180 days after end of treatment, 








Table 6.2 Underlying causes of death (n=208/216). 
Underlying cause of death Total (%) Males Females 
Overdose 103 (49.5) 71 (68.9) 32 (31.1) 
Liver disease 30 (14.4) 22 (73.3) 8 (26.7) 
Infectious disease 12 (5.8) 9 (75) 3 (25) 
Pneumonia and other pulmonary 15 (7.2) 11 (73.3) 4 (26.7) 
Other natural cause 30 (14.4) 17 (56.7) 13 (43.3) 
Other unnatural cause 15 (7.2) 14 (93.3) 1 (6.7) 






Figure 6.1 Kaplan Meier survival curves for time since SLaM 








Figure 6.2 Kaplan Meier survival curves for time since SLaM 
treatment cessation/transfer (in days) for overdose deaths, stratified 
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This study examined circumstances surrounding the deaths of patients with a diagnosis of 
opioid use disorder who had received OST treatment in SLaM within a near five-year 
observation period. In addition to substantial clustering of deaths in the early post-OST 
period as reported by others (Cornish et al., 2010; Cousins et al., 2016; Davoli et al., 2007; 
Strang et al., 2003), there was also a substantial excess mortality, and especially overdose 
mortality, in the period immediately following transfer of the patient and their care to a 
different treatment care-provider, with this excess mortality particularly pronounced in the 
first month post-transfer.  
 
Increased risk of death immediately after dropout from treatment may not be surprising 
(Darke et al., 2005) and overdose risk post-termination of OST treatment is already 
recognised (albeit, limited) (Cornish et al., 2010; Cousins et al., 2016; Davoli et al., 2007; 
Strang et al., 2003). However, the finding of a marked excess of overdose deaths in the 
period immediately after transfers of patients and their care despite continuation of OST 
treatment is new and unexpected. Large ‘transferred’ subgroups included patients 
experiencing transitions from secondary to primary care or to large independent (i.e. non-
NHS) care-provider organisations who had secured new NHS contracts after the introduction 
of competitive tendering procedures (DoH, 2013). If the purpose of such re-organisation is to 
achieve greater effectiveness and more cost-effective use of resources, then it might have 
been expected that transfer of patients and their treatments would result in better patient 
stability, and stable or lowered risk of mortality (Darke et al., 2005); however, these analyses 




These results need deeper and wider exploration, as little is known about the de-stabilisation 
that may accompany changes to service delivery. The present data did not allow me to 
ascertain what happened to patients after a transfer. Consequently, I was not able to establish 
whether any failures had occurred during the period of transition itself, or whether any de-
stabilisation occurred after a successful initial transfer to the new care provider.   
 
This study urgently needs fuller exploration and replication. Before any potential 
explanations are discussed with regard to the mechanisms behind excess deaths post-transfer 
with continuation of OST, further investigations should focus on exploring these findings 
using extended data and adjustments for potential confounders, as well as service-user 
consultations. Although the current analyses were limited to crude associations, these 
findings provide important insights into practice, the impact of service organisation 
(including service re-organisational changes) and the associated risks of overdose deaths.  
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CHAPTER 7  MULTIVARIABLE ANALYSIS OF RISK OF MORTALITY AFTER 
CESSATION OF OPIOID SUBSTITUTION TREATMENT AND TRANSFERS OF 







Introduction: There is evidence that opioid misusers have elevated mortality risk after 
cessation of OST treatment but little is known about de-stabilisation that may occur with 
changes to service delivery, such as a transfer to alternative service provider, even when 
OST medication is arranged to continue. 
 
Aim: The aim of the analysis presented in this chapter was to extend the preliminary 
analysis outlined in Chapter 6, to investigate the associations between all-cause / cause-
specific mortality and the three treatment exit types: planned OST cessation, unplanned 
OST cessation and transfer of patient and their care with arranged continuation of OST, in 
relation to in opioid dependency; adjusting for potential confounders. 
 
Methods: OUD patients who were enrolled in OST treatment were identified in the SLaM 
Case Register, within the observation period between 1st April 2008 and 31st January 2016. 
Deaths were identified through database linkage to the UK Office of National Statistics 
national mortality dataset. Cox and competing risk regression models were used to 
investigate the effect of treatment exit type on all-cause and cause-specific mortality 
(respectively) in patients diagnosed with OUD.  
 
Results: Of 4,316 OUD patients who met the inclusion criteria 380 had died. Overall, being 
out of treatment (including time after transfer out of SLaM) was associated with a 7-fold 
increase of overdose mortality (adjusted SHR 7.51, 95% CI 4.73 – 11.90) in the fully 
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adjusted models, compared to remaining in treatment. The overdose mortality risk in 
patients who were being transferred out of SLaM with the view to continue OST treatment 
with alternative care provider was associated with an eightfold (adjusted SHR 8.82, 95% CI 
5.35 – 14.56) increased risk of overdose mortality compared to remaining in treatment. 
Compared to being in treatment, dropping out of treatment and having a planned OST 
cessation were also associated with an increased overdose mortality (adjusted SHR 5.43, 
95% CI 3.15 – 9.39; adjusted SHR 3.18, 95% CI 1.84 – 5.48, respectively). 
 
Conclusions: In addition to elevated mortality risk post drop-out and post planned cessation 
of OST treatment, elevated overdose mortality risk is associated with transfer to an 
alternative service provider with the view to continuing OST treatment. These associations 
persist after adjusting for a broad range of potential confounders. These findings provide 
important insights into practice, the impact of service organisation (including service re-
organisational changes) and the associated risks of overdose death. The results provide 






Preliminary analysis examining mortality patterns outlined in Chapter 6 showed high 
clustering of overdose deaths in the period immediately post-discharge with a planned 
termination of OST, and post-transfer of patient and their care to an alternative service 
provider where continuation of OST was arranged.  
 
These findings are novel, unexpected, and provide potentially important insights into 
practice, the impact of service organisation and the associated risks of overdose deaths. 
They also provided groundwork for urgently needed further research requiring deeper 
exploration of findings.  
 
Analysis and, subsequently, findings in the previous chapter were limited - inclusive of only 
those patients who died, therefore without the possibility for multivariable analysis and 
adjustment for potential confounders. The present chapter extends the investigations of 
mortality risk after the end of OST or after a transfer out of SLaM, adjusting for a broad 
range of potential confounders in a cohort of all OUD patients who received OST within 
SLaM within specified observation period.  
 
7.2.1 EXISTING LITERATURE 
 
Increased mortality after cessation of OST treatment is thought to be influenced by the loss 
of tolerance during a subsequent relapse to opioid use (Strang et al., 2003). Studies report 
elevated risk of mortality after discharge from OST treatment, whether planned or 
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unplanned (Cornish et al., 2010) and in both inpatient and community drug and alcohol 
services (Davoli et al., 2007; Strang et al., 2003). However, as discussed in Chapter 2, these 
studies are limited to cohorts which have:  small sample sizes (Strang et al., 2003); 
restrictive inclusion criteria cohorts (Cornish et al., 2010; Strang et al., 2003); limited 
adjustment of potential confounding (Davoli et al., 2007); or with no information on the 
underlying causes of death (Cornish et al., 2010). What is more, none of these studies take 
into consideration the possible impact of disruptions in patient care (as explored in detail in 
Chapter 2).  
 
Little is known with regards to de-stabilisation that may occur with changes to service 
delivery even when OST medication is arranged to continue. Periods of transitions from 
prison back to the community are known to be associated with high overdose risk 
immediately after release (Singleton et al., 2003) but, as explained in Chapter 2, research on 
provision of OST medication pre- and post-release through transitional care programmes is 
inconclusive (Farrell & Marsden, 2008; Merrall et al., 2010). Cornish and colleagues 
(2010), discussed in the preceding chapter, have investigated mortality risks post planned 
OST cessation, but patients who were transferred out of treatment to an alternative service 
provider (approximately 10% per year) were considered lost to follow-up and not 
investigated further.  
 
Transfers of patients are a common practice; which might occur as part of a successful 
patient treatment journey where a transfer from secondary to primary care is deemed 
appropriate by both the patient and the clinician. Alternatively, a transfer of patients might 
occur irrespectively of the individuals’ treatment stage, for example, in instances of 
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transfers to independent care-provider organisations who had secured new NHS contracts 
after introduction of competitive tendering procedures (DoH, 2013).   
 
The 2015 State of the Sector report (DrugScope, 2015) found that 44% of drug and alcohol 
services had been through tendering or contract re-negotiation in the previous year and 49% 
of all drug and alcohol services are expected to go through one of these processes again 
during the year ahead. Concerns were expressed that frequent retendering can be 
destabilizing for both service users and staff, and constitute a diversion of scarce resources 
away from the delivery of frontline services (ACMD, 2015). The impact, if any, of these re-




There appears to be a transient elevated risk of death in the very early stages of treatment 
(first 28 days) (Degenhardt et al., 2009), and briefly, following the end of treatment 
(Chapter 6). These risks require careful assessment and investigations with a particular 
attention to circumstances surrounding a treatment end and death, which includes any 
disruptions in treatment, which were not explored in previous studies.  
 
This chapter extends the preliminary findings presented in Chapter 6 by: 1) investigating 
risks associated with all-cause and cause-specific mortality after a planned and unplanned 
OST treatment exit, as well as after a transfer of patient and their care to alternative service 





7.3 METHODS  
7.3.1 STUDY SETTING 
 
Data for this investigation was derived from the SLaM based CRIS system, which uses 
EHRs in a de-identified format, allowing researchers to search and retrieve complete case 
records for analytical purposes. The CRIS tool is described in detail in Chapter 3. The 
study-specific variables and their completion rates were first located and explored using the 
front-end CRIS – which allows researchers to explore, search and retrieve data located in 
structured fields or undertake key word searches within free text using basic Boolean 
operators only. Second, a full data extraction plan was created and retrieved using CRIS 
SQL, where the cohort, unlike in Chapter 6, was not restricted to those who died so that a 
multivariable analysis could be undertaken. Study-specific variables, their location and 
extraction format are described below.  
 
7.3.2 INCLUSION CRITERIA 
 
The study sample comprised SLaM patients diagnosed with primary or secondary opioid 
use disorder (discussed in detail in Chapter 3) between 1st April 2008 and 31st January 2016 
and who were prescribed one or more of the following opioid substitute therapy drugs: (i) 
methadone, (ii) buprenorphine; (iii) Suboxone (naloxone/buprenorphine) within the same 
observation period. Diagnoses were derived from their designated SLAM EHR structured 
fields and from free-text fields using NLP, the performance and evaluation of which is 




7.3.3 MAIN OUTCOME MEASURES 
 
The main outcome measure was all-cause mortality derived from the NHS Care Records 
Service, and cause-specific mortality derived from the ONS based on coroner reports, with 
a specific interest in overdose mortality. The full procedure for identifying and confirming 
SLaM patient deaths has been described in Chapter 3. The patient’s follow-up ceased either 
on the date of their death or at the end of the observation period (31st January 2016), 
whichever occurred first.  
 
7.3.4 EXPLANATORY VARIABLES 
 
Exposures of interest 
 
The main exposure of interest in this investigation was the type of OST treatment exit from 
SLaM, including planned treatment cessation, unplanned treatment cessation (i.e. drop out) 
or the transfer of the patient and their care to another service provider with continuation of 
OST. 
 
I defined patients as being “on treatment” from the date of their first prescribed OST 
medication within the observation period until the date of their treatment end date, 
corresponding with the expiry of their last OST medication. The exception to this rule was 
in instances where patients had a gap of less than 28 days between the end of one treatment 
episode and the start of the next. In such cases, I defined the patient as being “on treatment” 
during this gap. I adapted the “28-day rule” from Cornish and colleagues (2010) where it 
was considered unlikely that a patient would genuinely stop and restart treatment within a 
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four-week period. Each patient could contribute to more than one treatment episode in 
analysis, in instances where a patient entered and completed/dropped out/was transferred 
more than once within the observation period.  
 
Data for all those who died was validated by a manual search through discharge notes and 
free-text fields, including event notes and correspondence as explained in detail in Chapter 
6. The observation period for the current investigation was extended until 31st January 2016 
and additional deaths which occurred between the period of 1st January 2014 and 31st 
January 2016 were manually validated as in the preceding chapter. That is, by examining 
electronic medical records individually for all additional deaths by searching backwards 
from the date of death to establish the start and end dates of patients’ last OST treatment 
episode, as well as the reason for treatment cessation or transfer. 
 
The remaining treatment episode start and end dates (i.e. all treatment episodes for those 
who did not die and for all preceding treatment episodes for those who died) were extracted 
from treatment plan structured fields using CRIS SQL. Data was also validated on 100 
randomly selected treatment episodes. Data validation involved reading through case notes 
to establish whether treatment start/end dates which were systematically extracted from 
structured fields through CRIS SQL (and applied to the entire cohort) accurately 










In addition to the main exposure of interest, a number of other covariates were included in 
these analyses, as potential confounders. Age, calculated at the start of each on-treatment 
episode (based on date of birth), and gender are routinely recorded in patient records. Area-
level deprivation was established by linking the patient’s residential postcode to the UK 
Census data projected for 2007 in lower super output area units (detailed in Chapter 3). 
Deprivation score was calculated based on postcodes reported closest to the start of each 
episode, and with coding for homelessness where appropriate. Ethnic group classifications 
were condensed to “White British”, “Other White background”, “African, Caribbean and 
other black background”, and “Mixed, unknown and other”. Additionally, I also extracted 
the name of OST medication prescribed at the start of each on-treatment episode and the 
last prescribed OST medication before off-treatment or transfer episode commenced.   
 
Based on mortality risks identified in Chapter 4, comorbid diagnosis of PD) and AUD, 
reported ever before or one month after each episode start, were also extracted for inclusion 
in these analysis. As with OUD diagnosis, psychiatric comorbidity was extracted from 
structured fields and using NLP for diagnosis reported in free-text fields. The NLP 
application for diagnosis sought to extract any text strings associated with the statement of 
diagnosis in question in order to supplement the existing text fields. Its performance has 
been evaluated in Chapter 3 and elsewhere (Perera et al., 2015; Sultana et al., 2014). The 
cohort was classified as having a comorbid diagnosis of PD if they had received either a 
specific personality disorder (ICD-10-F60) or mixed and other PD diagnosis (ICD-10-F61), 
and comorbid AUD if they had received an ICD-10-F10 diagnosis. Additionally, an 




Clinically appraised risk of suicidality, accidental overdose and unsafe injecting practices 
were identified using the BRSA-A scale, as detailed and fully explored in Chapter 5. The 
suicidality risk domain consisted of suicide attempt history, suicidal ideation, carer concern 
and major mental illness items on the BRSA-A. Similarly, the likelihood of accidental 
overdose risk domain consisted of reduced tolerance, recent abstinence, alcohol abuse and 
poly-substance use. The unsafe injecting risk domain included previous/current injecting, 
high risk injecting, and sharing of injecting equipment items. A score of one was assigned if 
any item within a given risk domain was scored as present; or zero if all items within that 
risk domain were scored as absent. 
 
Problem substances 1, 2, and 3, derived from NDTMS, were used to generate indicators of 
poly-drug use. Physical and psychological health status - reliable, self-reported measures of 
physical and psychological health, were also extracted and used as a proxy indicator of 
physical and psychological health. This measure is part of the TOP scale, which was 
formally evaluated by Marsden and colleagues (2008) (as discussed in detail in Chapter 4). 
 
 
7.3.5 STATISTICAL ANALYSIS 
 
Each individual patient’s ‘at risk’ period commenced from the start date of their first on-
treatment episode within SLaM within the observation period and ended on the date of exit 
from SLaM, the date of their death or was censored at the end of the observation period. 
Each patient could contribute to more than one treatment episode in the analysis in instances 
174 
 
where a patient re-entered treatment again within the observation period, this clustering was 
taken into account in all the analyses. 
 
I calculated Cox proportional hazards models (1972) to obtain crude, age and gender 
adjusted and fully adjusted estimates of the relationship between all-cause mortality and 
exposures of interest including being off treatment, and the off treatment subgroups 
(planned, unplanned and transfers where continuation of OST was arranged elsewhere). 
Cox proportional hazards models were further used to produce crude and age/gender 
adjusted estimates of the relationship between a range of potential confounders and all-
cause mortality. Competing risk regression was performed to investigate a fully adjusted 
association between being off treatment/ off treatment subgroups and overdose mortality; 
and to determine fully adjusted associations between being off treatment/ off treatment 
subgroups and non-overdose mortality.   
 
The fully adjusted models controlled for the following variables: age and gender, socio-
demographic factors (ethnicity, deprivation level), OST type (methadone, 
buprenorphine/Suboxone), risk assessment factors (overdose risk, suicidality, injecting 
practices), physical and mental health factors (psychological health status, physical health 
status, comorbid diagnosis of PD), and poly-substance use (the reported number of 
additional illicit substances used, alcohol misuse or dependence). Interaction between 
mortality, treatment exit and the type of OST medication prescribed were also tested. 
Proportional hazard assumptions were checked and met using likelihood ratio tests, with no 
significant interactions between the treatment exit types, all-cause mortality and time.  All 




7.4.1 COHORT CHARACTERISTICS  
 
The characteristics of the cohort are presented in Table 7.1. The total number of individuals 
extracted from CRIS who met the inclusion criteria was 4,316 (72% male; 67% “White 
British”), with 380 deaths registered within this cohort. Patients contributed a total of 
22,159 person years at risk: 13,123 person years on treatment and 9,036 person years off 
treatment (including time after a transfer). Age at patient’s first entry (within the 
observation period) to SLaM treatment ranged from 14 to 74 with a mean age 38.8 (SD 
8.80) – although this may not have been the patient’s first approach to addiction services 
over their lifetime. The mean age at death was 44 years (SD 9.60). 117 patients died while 
on-treatment and the median length of OST treatment episode was 270 days (range 91-764). 
There were 989 planned treatment exits, 670 unplanned exits and 1430 transfers during the 











Total patients 4316 380 (9) 
Treatment     
On treatment 4316 117 (3) 
Planned exits 989 92 (9) 
Unplanned exits  670 60 (9) 
Transfers 1430  111 (8) 
Gender     
Males 3110  282 (9) 
Females 1206  98 (8) 
Age*     
15 - 24 303  11 (4) 
25 - 29 572  23 (4) 
30 - 34 764 47 (6) 
35 - 39 849 67 (8) 
40 - 44 886 80 (9) 
45 - 49 518  63 (12) 
50+ 424  89 (21) 
Ethnicity     
White British 2903 309 (11) 
Other white  627  40 (6) 
Black 396  15 (4) 
Mixed and other 390  16 (4) 
Deprivation score* (0-100, in tertiles)     
Low 1270  89 (4) 
Moderate 1280  143 (11) 
High 1585  127 (8) 
Homeless 170  19  (11) 
Missing 11  2 (18) 
Risk assessment     
Overdose risk     
Not detected 910  61 (7) 
Detected 3406  319 (9) 
Injecting practices     
Not detected 1881  99 (5) 
Detected 2435  281 (12) 
Suicadality     
Not detected 2121  160 (8) 
Detected 2195  220 (10) 
Mental and Physical Health     
Physical health status     
Poor 555  97 (17) 
Moderate 1196  132 (11) 
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Good 2410  141 (6) 
Missing 155  10 (6) 
Psychological status     
Poor 605  83 (14) 
Moderate 1289  125 (10) 
Good 2269  162 (7) 
Missing 155  10 (6) 
Comorbid personality disorder     
No 4044  350 (9) 
Yes 272  30 (11) 
Poly-substance use     
Number of additional drugs used     
1 1695  177 (10) 
2 1904  156 (8) 
3+ 717  47 (7) 
Alcohol misuse or dependence     
No 2859  201 (7) 
Yes 1457  179 (12) 
OST Drug     
Buprenorphine / Suboxone 962 63 (7) 
Methadone 3354  317 (9) 
 
7.4.2 ALL-CAUSE MORTALITY 
 
Table 7.2 summarizes findings from crude and age and gender adjusted Cox regression 
models of factors potentially associated with all-cause mortality in patients with OUD. 
There were no significant differences between males and females before or after adjustment 
for age (adjusted HR 0.98, 95% CI 0.78 – 1.23, p=0.862). Those with comorbid PD and 
alcohol misuse or dependence had elevated mortality after adjustment for age and gender 
(adjusted HR 1.77, 95% CI 1.21 – 2.59; adjusted HR 2.42, 95% CI 1.96-2.98, respectively). 
Patients who were prescribed methadone as part of their OST treatment had increased 
mortality risk (adjusted HR 1.33, 95% CI 1.04 – 1.70) compared to those who were 




Overall, being out of treatment elevated risk of mortality by almost fourfold before and after 
adjustment for age and gender (adjusted HR 3.79, 95% CI 2.99 – 4.79) (Table 7.2). This 
mortality ratio persisted even after full adjustment (adjusted HR 3.78, 95% CI 2.92 – 4.89) 
(Table 7.3).   
 
Of the three exit types, being transferred out of SLaM to alternative service provider with 
the view to continue their OST treatment elsewhere was most strongly associated with all-
cause mortality in crude (HR 6.16, 95% CI 4.67 – 8.13) and age and gender adjusted models 
(adjusted HR 5.77, 95% CI 4.37 - 7.61) (Table 7.2). This strong association persisted in the 
fully adjusted models (HR 5.51, 95% CI 4.03 – 7.54) (Table 7.3).  
 
Both planned and unplanned OST cessations (i.e. drop outs) also had elevated mortality in 
both crude (HR 2.78, 95% CI 2.08 – 3.73; HR 3.40, 95% CI 2.47 – 4.70 respectively) 
(Table 7.2), and in fully adjusted models (adjusted HR 2.85, 95% CI 2.10– 3.89; adjusted 
HR 3.62, 95% CI 2.54 – 5.16, respectively) (Table 7.3).  
 
When compared to a planned OST treatment cessation (instead of comparing to being on 
treatment), being transferred was associated with an almost twofold greater risk of mortality 
(adjusted HR 1.91, 95% CI .37 – 2.66, p>0.001) but there was no evidence that dropping 
out of treatment was a greater risk for mortality than a planned OST cessation (data not 
show in tables). In addition, I also tested for the presence of an interaction between the 
treatment exit types and the type of OST medication prescribed, but none was detected (data 




Table 7.2 Crude and age and gender adjusted Cox regression models for associations between 
potential risk factors and all-cause mortality (n=4316). 
 
Variable 
Crude HR (95% 
CI) 
Crude p value 
Age & gender adj. 
HR (95% CI) 
Age & gender 
adj. p value 
Treatment Factors         
Overall on treatment 1.00   1.00   
Overall off treatment 3.84 (3.04 - 4.86) <0.001 3.79 (2.99 - 4.79) <0.001 
Treatment exit Type   
On treatment 1.00   1.00   
Planned 2.78 (2.08 - 3.73) <0.001 2.69 (2.00 - 3.60) <0.001 
Unplanned 3.40 (2.47 - 4.70) <0.001 3.69 (2.67 - 5.10) <0.001 
Transfer 6.16 (4.67 - 8.13) <0.001 5.77 (4.37 - 7.61) <0.001 
OST Type:   
Buprenorphine/ 
Suboxone 
1.00   1.00   
Methadone 1.41 (1.10 - 1.79) 0.006 1.33 (1.04 - 1.70) 0.024 
Socio-demographic 
factors 
        
Gender:   
Female 1.00   1.00   
Male 1.10 (0.87 - 1.38) 0.430 0.98 (0.78 - 1.23) 0.862 
Age* 1.06 (1.04 - 1.07) <0.001 1.06 (1.04 - 1.69) <0.001 
Ethnicity:   
White British 1.00   1.00   
Other White 0.66 (0.48 - 0.92) 0.014 0.71 9 0.51 - 0.98) 0.039 
Black 0.34 (0.20 - 0.57) <0.001 0.31 (0.18 - 0.52) <0.001 
Mixed and other 0.41 (0.25 - 0.68) <0.001 0.47 (0.29 - 0.79) 0.004 
Deprivation score   
Low 1.00   1.00   
Moderate 1.49 (1.15 - 1.92) 0.003 1.46 (1.13 - 1.90) 0.004 
High 1.23 (0.94 - 1.62) 0.123 1.18 (0.90 - 1.54) 0.233 
Risk Assessment         
Overdose risk   
Not detected 1.00   1.00   
Detected 1.56 (1.18 - 2.10) 0.002 1.70 (1.29 - 2.24) <0.001 
Injecting practices   
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Not detected 1.00   1.00   
Detected 2.28 (1.82 - 2.87) <0.001 2.16 (1.72 - 2.71) <0.001 
Suicidality   
Not detected 1.00   1.00   
Detected 1.67 (1.36 - 2.05) <0.001 1.71 (1.39 - 2.10) <0.001 
Mental and Physical 
Health 
        
Physical health status   
Poor 1.00   1.00   
Moderate 0.63 (0.49 - 0.80) <0.001 0.68 (0.53 - 0.86) <0.001 
Good 0.38 (0.29 - 0.49) <0.001 0.43 (0.33 - 0.56) <0.001 
Psychological status   
Poor 1.00   1.00   
Moderate 0.73 (0.57 - 0.93) 0.011 0.73 (0.57 - 0.93) 0.011 
Good 0.64 (0.50 - 0.83) 0.001 0.64 (0.50 - 0.83) 0.001 
Comordid PD   
No 1.00   1.00   
Yes 1.77 (1.21 - 2.59) 0.003 1.77 (1.21 - 2.59) 0.003 
Poly-substance use         
Number of additional 
drugs used* 
1.19 (1.03 - 1.38) 0.017 1.20 (1.04 - 1.39) 0.015 
Alcohol misuse or AUD   
No 1.00   1.00   
Yes 2.58 (2.09 - 3.16) <0.001 2.42 (1.96 - 2.98) <0.001 
 













7.4.3 OVERDOSE MORTALITY 
 
I was able to obtain data on recorded underlying cause for 73% of deaths in the cohort (277 
/ 380). Overall, there were 149 fatal overdoses and these include both accidental and 
intentional poisonings. Liver disease was the cause of death for 44 patients. Other 
predominant causes were those due to infectious diseases (n=22), pulmonary disease (n=19) 
and other natural causes (n=27).  
 
In the fully adjusted competing risk models, being out of treatment was associated with a 
more than sevenfold increased overdose mortality risk compared to being in treatment 
(adjusted SHR 7.51, 95% CI 4.73 – 11.90). Moreover, compared to being in treatment, 
overdose mortality was almost nine-fold higher post-transfer (adjusted SHR 8.82, 95% CI 
5.35 – 14.56) and more than fivefold higher after dropping out of treatment (adjusted SHR 
5.43, 95% CI 3.15 – 9.39).  
 
Additionally, by changing the reference point, I tested whether the 
planned/unplanned/transferred sub-groups differed from each other. Groups were different 
in both all-cause mortality (HR 1.52, 95% CI 1.07 – 2.16 transferred vs planned; HR 1.93, 
95% CI 1.41 – 2.64 transferred vs unplanned) and overdose mortality (HR 2.78, 95% CI 
1.65 – 4.68 transferred vs unplanned; HR 1.42, 95% CI 1.04 – 2.68 transferred vs planned) 
(data not shown in tables). 
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Table 7.3 Fully adjusted Cox and competing risk regression examining associations between all-cause and cause-specific mortality and 









cause p value  
Fully adj.* SHR1                       
for overdose2 
deaths (95% CI) 
Fully adj.* for 
OD± deaths p 
value 
Fully adj.* SHR1                       
for deaths other 
than  OD (95% 
CI) 
Fully adj.* other 
deaths p value 






Overall off treatment 115 (42) 3.78 (2.92 - 4.89) <0.001 7.51 (4.73 -11.90) <0.001 2.01 (1.30 - 3.11) 0.002 
Treatment Exit Type 
       






Planned 31 (11) 2.85 (2.10 - 3.89) <0.001 3.18 (1.84 - 5.48) <0.001 2.85 (1.71 - 4.75) <0.001 
Unplanned 29 (10) 3.62 (2.54 - 5.16) <0.001 5.43 (3.15 - 9.39) <0.001 2.82 (1.42 - 5.62) 0.003 
Transfers 55 (20) 5.51 (4.03 - 7.54) <0.001 8.82 (5.35 -14.56) <0.001 2.87 (1.53 - 5.38) 0.001 
 
* Adjusted for all variables listed in Table 1.  
1 Subdistribution hazard ratio 
2 Accidental and intentional overdoses. 




7.5.1 PRINCIPAL FINDINGS 
 
Important findings arise from these analyses. First, compared to being enrolled in OST 
treatment in SLaM, being out of OST treatment (including being transferred out of treatment 
with the view to continue OST) was associated with a substantially higher risk of mortality. 
This is especially evident for overdose mortality, which was sevenfold higher out of treatment 
and eightfold greater when care was transferred to an alternative service provider. Both a 
planned OST cessation and dropping out of treatment were also associated with elevated risk of 
all-cause and overdose mortality. 
 
7.5.2 RESULTS IN RELATION TO PREVIOUS RESEARCH 
The overall higher risk of death out of treatment for patients with OUD is consistent with 
existing literature (Brugal et al., 2005; Darke et al., 2005). In particular, dropout from drug and 
alcohol treatment is known to have markedly increased mortality risk, especially for fatal 
overdose (Bargagli et al., 2007). The increased risk of death post-planned OST treatment 
cessation has also been recognised, especially in the first month after cessation of treatment 
(Cornish et al., 2010; Davoli et al., 2007; Strang et al., 2003). However, this study found more 
than eightfold excess overdose mortality following the transfer of patient and their care to an 
alternative treatment care-provider, where the patients’ OST was arranged to continue. The 





Changes within treatment, such as a transfer from methadone to buprenorphine are common 
and are known to be destabilizing for the patient (Breen et al., 2003; Walsh et al., 1994, 1995). 
Thus, extra care is taken during such periods; and decisions between such transfers are made 
collaboratively by patients and service providers.  Little is known, however, about the de-
stabilisation that may accompany changes to service delivery. Transfers of patients are a 
common practice; Cornish and colleagues (2010) report that around 10% of patients per year 
are transferred between the services, but this subgroup was excluded from their analysis.  
 
Another large-scale study investigating mortality risk post-treatment cessation does not report 
on patients who might have been transferred out of treatment (Davoli et al., 2007). A 
Norwegian study (Ravndal & Amundsen, 2010) of mortality among drug users after discharge 
from inpatient treatment reports an elevated risk of dying from overdose within the first 4 
weeks of leaving medication-free inpatient programmes. The definition of leaving treatment in 
this study however, involved a completion of inpatient treatment and a transfer to psychosocial 
rehabilitation. The study reports unadjusted excess overdose mortality rare ratio of 15.7 but all 
deaths occurred in patients who have dropped out of treatment. Similarly, periods of transitions 
from prison back to the community are known to have high transient overdose risk after 
release, but research on provision of OST medication pre- and post-release through transitional 
care programmes is inconclusive (Merrall et al., 2010; Farrell & Marsden, 2008; Bird et al., 
2015). 
 
As described in the previous chapter, transfers might occur as part of a successful patient 
treatment journey where a transfer from secondary to primary care is deemed appropriate by 
both the patient and the clinician. Alternatively, a transfer of patients might occur irrespectively 
of the individuals’ treatment stage, for example, in instances of transfers to independent care-
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provider organisations who had secured new NHS contracts after introduction of competitive 
tendering procedures (DoH, 2013) or from prison back to the community.    
 
In the previous investigation (Chapter 6) I found that large ‘transferred’ subgroups included 
patients experiencing transitions from secondary to primary care or to large independent care-
provider organisations who had secured new NHS contracts after the introduction of 
competitive tendering procedures (DoH, 2013). Re-organisational changes are thought to be 
conducted for greater effectiveness and cost-effectiveness. Therefore, one might expect to find 
successful transfer of patients and their treatments, patient stability, and stable or lowered risk 
of mortality (Darke et al., 2005), however these analyses instead indicated a high number of 
fatal overdoses in such groups. 
 
7.5.3 STUDY STRENGTHS  
 
The study has a number of strengths. As discussed in the previous chapters, SLaM is a large 
provider of secondary mental healthcare in Europe, with close to 100% monopoly provision to 
its multicultural and ethically diverse geographic catchment. I was thus able to draw on 
electronic addiction service clinical records of almost five thousand OUD patients allowing 
adjustment (although not formally calculated) for a broad range of confounders. SLaM patient 
death tracing is regularly updated and is based on death certificates issued across the UK for 
both active and non-active SLaM patients. Furthermore, I was able to determine 73% of 






7.5.4 STUDY LIMITATIONS 
 
The results of the study need to be considered in light of certain limitations. This is an 
observational study and residual confounding is possible. Potential confounders included 
deprivation score rather than a direct measure to socio-economic status.  Certain variables, such 
as HCV status and education level were excluded from analysis due to large number of missing 
values. SLaM is limited to secondary mental health care patients, therefore does not include 
patients in primary care or those seeking help privately Opioid addiction is, however, primarily 
treated within secondary mental health community setting (NDTMS, 2013), and this population 
would not be captured by other studies restricted to primary care data (e.g. Cornish et al., 
2010).  
 
The present data did not allow me to ascertain what happened to patients after a transfer. 
Consequently, I was not able to establish whether any failures had occurred during the period 
of transition itself (drop outs), or whether any de-stabilisation occurred after a successful 
transition to the new care provider.  Although I was able to detect high mortality rates 
associated with being transferred out of treatment and cessation OST treatment, comparisons of 
immediate risk periods in and out of treatment (i.e. within the first month post-
treatment/transfer) was beyond the current scope of this analysis. However, the preceding 
chapter, which examined circumstances surrounding the deaths of these patients, indicates that 
this risk may be most prominent in the first month after cessation of treatment and transfer of 
patient and their care. Additionally, I was unable to measure the potential ‘epoch’ effect of 
heroin drought in 2010/11 (SOCA, 2011, 2012, 2013, 2014), whereby background overdose 
risk may have been lower during earlier in-treatment period of observation and higher during 




No formal power calculation was performed in this thesis and it is possible that possible that 
some analyses were somewhat under-powered, as indicated by large confidence intervals. 
Finally, the current data could not differentiate between intentional and unintentional overdose 
deaths. Similarly, toxicology reports were not available, and it was therefore unclear which 





The results presented here, together with those presented in the preceding chapter need fuller 
exploration and replication. In addition to elevated mortality risk post dropout and post planned 
cessation of OST treatment, being transferred to an alternative service provider with the view to 
continue OST treatment was associated with an eightfold increased mortality risk compared to 
continuing treatment in SLaM. Further investigations should focus on exploring these findings 
to determine whether deaths following a transfer occur during the period of transition itself (i.e. 
resulting in drop out), or whether any de-stabilisation occurred after a successful transition and 
successful continuation of OST. Studies should also focus on determining the exact high-risk 
periods and establish whether similar transient risk period exists as that identified post OST 
cessation or post-prison release. These findings provide important insights into practice, the 
impact of service organisation (including service re-organisational changes) and the associated 
risks of overdose death and further research is urgently required.  
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8.1 SUMMARY OF FINDINGS 
 
Enrollment in treatment is the single most effective road to recovery and to minimize harms 
associated with opiate drug-use during this journey (Darke et al., 2000; Davidson et al., 2003; 
McGregor et al., 1998; Pierce et al., 2016). However, certain mortality risks within OUD 
treatment exist and these need careful exploration and interpretation.  
 
This thesis utilized anonymized patient health records from one of the largest mental health 
service providers in Europe and explored mortality risk factors, at both patient-level and 
service-level, in individuals with OUD enrolled in secondary drug and alcohol treatment. The 
aims of the thesis were: 
 
5. To explore associations between psychological wellbeing, comorbid diagnosis of PD, 
SMI and AUD, in relation to all-cause and cause-specific mortality in opioid 
dependence. 
6. To determine if addiction-specific, routine brief risk assessments given to OUD patients 
can predict all-cause or cause specific mortality. Also, to determine if these risks may be 
modified by admission to services. 
7. To investigate clustering of deaths, especially fatal overdoses, in the period immediately 
after transfer of patients and their care, and after end of OST in a cohort of opioid 
dependent individuals in specialist addiction treatment. 
8. To investigate the associations between planned OST cessation, unplanned OST 
cessation and transfer of patient and their care with arranged continuation of OST, in 
relation to all-cause and cause-specific mortality in opioid dependence with adjustment 




In summary, the findings of this thesis provide evidence of the burden of opioid use disorder 
in secondary mental health services and the general population.  
 
First, this thesis identified that addiction-specific brief risk screening can identify OUD 
patient subgroups at increased risk of all-cause and overdose mortality. These subgroups 
include those at risk of accidental overdose, at risk due to injecting practices and at risk of 
suicidality. Second, the results highlight the need for admission to services, where suicidality 
is evident, as results in Chapter 4 show reduced survival in patients where suicidality was 
assessed as being present, but who were not admitted into services following the assessment. 
 
Third, the study found that the presence of co-morbid PD and AUD puts OUD individuals at 
greater risk of mortality, compared with OUD patients without such co-morbidities. This is 
true for all-cause mortality, fatal overdose and liver-related fatalities (as seen in Chapter 4). 
 
Finally, investigations of time and context were also conducted. The risk of overdose 
mortality increased to eightfold in patients whose care was transferred to an alternative 
service provider where their OST was arranged to continue (Chapter 7) compared to those 
who remained with their original treatment provider. Mortality was also significantly 
elevated for patients with a planned OST cessation and in those who have dropped out of 
treatment, but not to the same extent as those who were transferred (Chapter 7). This is a 
novel and potentially important finding. 
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Upon examination of circumstances surrounding the deaths of patients who had received 
OST treatment it was found that, in addition to substantial clustering of deaths in the early 
post-OST period, there was also a substantial excess overdose mortality in the period 
immediately following transfer of the patient and their care to a different treatment care-
provider, with this excess mortality pronounced in the first month post-transfer (Chapter 6).  
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8.2 OPIOID USE DISORDER AND MORTALITY 
In England and Wales, deaths involving opioids doubled in the last three years and are now 
the highest since records began (ONS, 2016). New estimations are therefore required, and 
evidence from Chapters 4 provides support for the argument that there is a need to focus on 
deaths by natural causes as well as drug-related deaths.  
 
Cohort studies provide a valuable means of estimating drug related mortality rates. In this 
thesis, mortality rates amongst the OUD cohort, known to secondary addictions services, was 
substantially higher than the general population. This is especially elevated for women where 
the rate was over five times the general population (see Chapter 4). These findings are 
consistent with existing literature (Degenhardt et al., 2009; Hayes et al., 2011).  
 
While overdose is a major cause of premature mortality amongst heroin using populations, 
equal consideration should be given to other prominent causes of deaths, especially by 
natural causes, as seen in Chapter 4. Looking beyond unnatural causes of mortality may help 
improve our understanding of the pathways to premature mortality among opioid users, 
identify subgroups at substantially elevated mortality risk and inform commissioning bodies 
of the extent of services needed for a successful recovery. 
 
Throughout this thesis, overdose deaths constituted the largest proportion of underlying 
causes of death. Both fatal and non-fatal overdose investigations are certainly a matter of 
importance. However, the second most prominent cause was attributed to natural deaths, such 
as liver disease (see Chapters 4-7). This is especially evident in those who misuse alcohol 
and/or those with PD. These findings are consistent with previous reports, although there 
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seems to be a limited interest in studying specific risks associated mortality in heroin using 
populations beyond overdose (Johnson et al., 2015). 
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8.3 INDIVIDUAL FACTORS AND MORTALITY 
The needs of a typical opioid dependent patient are complex and extensive, not only through 
their level of physical and psychological dependence to the opioid drug but also through poor 
psychosocial functioning (Arendt et al., 2011; Bargagli et al., 2006; Darke, 2011; Darke & 
Ross 2002; Ghodse et al., 1985; Gossop et al., 2002; Davoli et al., 1993; Shah et al., 2008). 
For many people, addiction to opioids is a persistent and relapsing disorder, with only a 
minority successfully achieving lasting recovery following a single episode of treatment 
(Dennis et al., 2005; Strang et al., 2014).  
 
Deaths among opioid users predominantly occur among white, long-term, dependent, socially 
isolated males, especially those who inject drug; with prison histories, who are typically 
unemployed (see Tables 2.1.-2.2. in Chapter 2). Findings in this thesis are consistent with this 
view in terms of age, ethnicity, lower socioeconomic status (measured by deprivation score) 
and injecting practices (Chapter 4, 5 and 7).  
 
Upon review of the literature in Chapter 2, it was found that the impact of psychiatric 
comorbidity on mortality risk in substance use disorders has received only moderate 
attention, with existing investigations reporting mixed results (Arendt et al., 2011; Davoli et 
al., 1993; Gossop et al., 2002; Mattisson et al., 2011) and that in-depth investigations of risks 
in relation to natural causes of mortality are limited. Both limitations are addressed in this 
thesis, particularly in Chapter 4.  
 
First, co-morbid physical health problems are often overlooked, despite known elevated rates 
of cardiovascular and renal disease and diabetes among these populations (Strang et al., 2014; 
Wadland & Ferenchick, 2004). In this thesis, fatalities due to liver disease (other than those 
 195 
related to HCV) were extremely common in this patient group (as demonstrated in Chapters 4 
- 7). Chapter 4 presented a sevenfold increase in liver-related deaths in OUD patients who 
misuse alcohol; and, perhaps more surprisingly, a near fourfold risk of liver-related death in 
OUD patients with a PD, compared to patients without these comorbid problems (in addition 
to elevated overdose risk in OUD+AUD subgroup). This increase in deaths is thought to be 
influenced by higher levels of impulsivity and risk-taking behavior – a core feature of a 
personality disorder (WHO, 1993), which might result in more chaotic lifestyle in addition to 
that associated with drug use.  
 
Co-morbid psychiatric problems and alcohol misuse in OUD patients are troublesome; and 
only a small proportion of dual-diagnosis patients actually receive treatment for both PD and 
OUD disorders (SAMHSA, 2012). Patients with co-occurring disorders can face challenges 
accessing treatment, as they may be excluded from mental health services if they admit to a 
substance abuse problem, and vice versa (SAMHSA, 2012). Similarly, opioid patients with a 
co-occurring alcohol problem, who present themselves to CDAT services might be turned 
away from receiving their OST medication due to existing risks of concurrent use of opioids 






8.4 SERVICE PROVISION AND MORTALITY 
The results presented in this thesis add to the current body of knowledge with regards to risks 
associated with service provision in opioid dependency. They also provide evidence for the 
need to restructure and/or improve certain aspects of drug and alcohol treatment in the UK. 
These include the need for effective dual-diagnosis services (Chapters 3-4), better outreach 
for people with history of erratic service engagement (Chapters 4-6), continuation of care and 
overdose prevention for those newly discharged and those transferred between services 
(Chapters 5-6).  
 
This is the first study evaluating the effectiveness of the BRSA-A scale – a “real-world” 
measure of associated risks, used presently in a large addictions service. We now know that 
the assessment of drug-related risks, especially accidental overdose, suicidality and those 
associated with injection of opioids, can be done effectively (Chapter 5) by using a simple, 
and relatively quick to conduct, assessment. Consisting of only binary items, such a simple 
scale might be straightforward (but useful) to implement in other services, for better 
identification of drug-related risks. This would be especially relevant in general medicine or 
dual-diagnosis OUD patients who present for treatment at services other than addiction 
services.  
 
Second, Hickman and colleagues (2016) recently highlighted the need to accumulate 
evidence on risk of mortality on and off OST. They advised that more studies of this kind are 
needed so that ‘stratified medicine’ for treatment of OUD can be provided; and that pooled 
experience and evidence from different health-care systems is necessary in order to tailor 
specific treatments and ensure that ‘the right patient gets the right treatment at the right time’. 
This thesis addresses this request by investigating mortality after planned and unplanned OST 
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cessations with the inclusion of transfers between services. Results presented here extend the 
studies of others (Cornish et al., 2010; Cousins et al., 2016; Davoli et al., 2007; Strang et al., 
2003) to identify specific times and locations of increased risk of fatal outcomes. 
 
There is a localization of deaths in time and context. In the “transit zone” between time in 
prison and post-release return to the community, a large concentration of deaths, occurring 
particularly during the first fortnight post-release was found (Singleton et al., 2003). Similar 
clustering at the end of in-patient and post- detoxification from OST has been reported by 
others (Cornish et al., 2010; Ravndal & Amundsen, 2010; Strang et al., 2003) and in this 
thesis (Chapters 6-7). The present thesis extends existing literature not only to include data 
from secondary care and specific causes of death, but also with regards to the transfer of 
patients during an active enrollment in OST.  
 
No previous study has investigated the impact of transfers of OUD patients and their care (as 
explained in Chapter 2). These transfers include those from secondary to primary care, which 
may be deemed as a positive transfer, agreed by both the patient and the clinician. They also 
include transfers irrespectively of the individuals’ treatment stage - for example, in instances 
of transfers to independent care-provider organisations who had secured new NHS contracts 
after introduction of competitive tendering procedures (DoH, 2013).  Approximately 50% of 
addiction services are expected to go through such tendering procedures in the new year 
(DrugScope, 2015). Therefore, more transfers of patients might be expected, potentially 
resulting in a high number of fatal overdoses.  
 
Greater awareness of times and situations of overdose risk in relation to treatment and 
subsequent exits from treatment were identified in this thesis. However, strategies to prevent 
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opiate overdose deaths have been only minimally explored in literature (Strang, 
2015). Unless progress is made, the large excess mortality will continue unchecked (Strang, 
2015). With this improved understanding of the risk factors in time and context, further 
research (as will be discussed later) should focus on utilizing these findings to implement 
effective strategies to prevent fatalities. 
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8.5 STRENGTHS AND LIMITATIONS 
8.5.1 ORIGINALITY 
This thesis adds to the existing body of research on risks associated with mortality in heroin 
using population. This thesis not only addresses patient-level factors but also investigates 
mortality in relation to service provision and organisational changes – an area with very 
limited existing literature. No previous studies have evaluated the effectiveness of the BRSA-
A in highlighting those OUD patients at highest risk. This thesis also provides evidence for 
the need for prompt admission to services where suicidality is evident; the need for effective 
assessment and management of dual-diagnostic patients with PD and alcohol misuse; and 
highlighted the elevated mortality, especially overdose, associated with discharge from 
treatment and disruptions in patient care. This thesis also utilises recent technological 
advantages by using a large anonymised electronic patient records data and externally linked 
data, and with innovative data extraction approaches. The combination of these provided 
near-complete patient health records data for robust analysis and adjustment for a broad range 
of potential confounding factors, which is often limited in existing literature.  
 
8.5.2 DATA SOURCE, STUDY DESIGN AND SAMPLE 
This thesis incorporates a series of cohort studies, which has important advantages. 
Participant-derived recall bias is less likely to occur, as symptoms and treatment progress are 
recorded by the clinician at or close to the time of their occurrence. The majority of variables 
used in this thesis did not rely on information recalled from the past (with the exception of 
age at first drug use, which was used as a potential confounder). However, all measurements 
are potentially subject to error. Misclassification might occur, as records may be missing or 
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incomplete. For example, completion of tobacco use information was poor and the variable 
was removed from analysis (thereby potentially introducing residual confounding, discussed 
further below). 
 
SLaM is a secondary mental health service therefore generalizability of findings are to those 
known to secondary mental health services, thereby under-represent users not in touch with 
services, from whom adverse outcomes might be subsequently more prevalent. Nonetheless, 
SLaM holds close to 100% monopoly provision to its ethnically diverse and multicultural 
geographical catchment, hence representative of those seeking secondary care in this 
catchment.  
 
In January 2017, the CRIS database (which strengths and limitations are described in detail in 
Chapter 3) held complete ePJS records for more than 280,000 individuals. This figure 
represents a near 100% representation of the SLaM service-user population, with just 3 
patients opting-out of CRIS (which means that their EHRs were not present in CRIS for 
research purposes) since it was developed. Thus, any potential bias that comes with low 
response rates was not an issue in this thesis. I was able to draw on electronic addictions 
service clinical records of approximately 5,000 OUD patients, and with a generous follow-up 
period of up to 7 years, which increased the likelihood to detect rarer events and longer-term 
outcomes. 
 
Death tracing is regularly updated (monthly) in SLaM and is based on death certificates 
issued across the UK for both active and non-active SLaM patients (as described in detail in 
Chapter 3). Thus, misclassification of mortality was unlikely (unless patient died abroad).  
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Additionally, I was able to determine the underlying causes of deaths for the majority of 
deaths in each analysis (83% in Chapter 4; 69% in Chapter 5; 96% in Chapter 6; 73% in 
Chapter 7). High completion rates for underlying causes of death were important, as lack of 
this information would result in large number of deaths dropped from analysis, thus 
potentially introducing selection bias for those with and without specified causes.  
 
It was possible to determine underlying causes of death through data linkage with the ONS 
data. The completion rates for cause-specific mortality figures differ as the observation 
periods and the inclusion criteria changed with specific research aims.  Furthermore, unlike 
death-tracing, the cause of death data is a static data linkage, with irregular updates. Each 
update request requires a number of administrative tasks from both the SLaM linkage team 
and the ONS team, resulting in severe delays. ONS also reports approximate 6-month to 1 
year delay in establishing causes of death (ONS, 2011), which requires analytical period 
adjustments at extraction-level to avoid having excessive missing data from the most recent 
deaths in the dataset used for analysis. Furthermore, there is likely to have been differential 
ascertainment of cause of death by type due to registration delay following referral for 
coronial investigation of suicide /fatal overdose but probably not for disease causes. Thus, 
more of the overdoses and suicides than disease deaths are likely to have been missing, with 
implications for the proportion of deaths assigned to these. I was also unable to determine 
whether overdoses were deliberate or unintentional as these were grouped together.  
 
Data linkages, while increasing the richness of available data can also present their own set of 
challenges. Performing new data linkages is a long and complex process. While the current 
thesis primarily focussed on fatal overdoses, non-fatal overdoses are of clinical significance 
because a history of overdose strongly predicts future overdoses, thus those who overdosed 
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are likely to do so again (Darke et al., 1996; McGregor et al., 1998; Powis et al., 1999; Kerr 
et al., 2007). For this reason, I have tried to perform data linkage between CRIS and LAS so 
that data on fatal as well as non-fatal opioid overdose call-outs could be captured for analysis, 
thus providing important information of one’s drug use behaviour and severity of risk. 
However, after discussions with the LAS and the data linkage team, this has proven 
unsuccessful due to the quality of electronic data (with some data remaining only in paper 
records) held by LAS, the volume of approvals, administrative tasks required and PhD time 
constraints.  
 
Similarly, one of the major limitations in Chapters 6 and 7 is the inability to establish what 
happened to patients after their transfer of care. Consequently, I was not able to establish 
whether any failures had occurred during the period of transition itself, or whether any de-
stabilisation occurred after a successful transition to the new care provider. This is an 
important question, which might have been successfully answered if data linkage with the 
third-party sector (e.g. non-NHS) was in place/possible.  
 
Treatment provision in drug and alcohol services is extensive and complex. Patients, 
especially opioid dependent patients, enter, dropout, re-enter and transfer between services or 
prison frequently (Palmer et al., 2009), and capturing one’s complete journey through 
services is problematic. Therefore, the need for novel integrated data linkages is great, as is 
the need for novel data extraction approaches.  
 
The completeness of data relied on information entered by the NHS staff. Often, designated 
structured fields are not utilized by clinicians rather information is typed in free-text fields, 
resulting in difficulties in capturing this information using the CRIS front-end.  
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A range of NLP applications are in place to extract information from free-text, but these are 
specific and limited to those features in the text considered high priority for the research 
undertaken to date and development of new applications is extremely complex and labour 
intensive, for example, as that described by Kadra et al. (2015). Throughout this thesis, a 
significant amount of time was spent on manual data searches and manual data extractions. 
NLP, however, was extremely useful in extracting diagnosis information to supplement data 
from structured fields (performance of which is described and evaluated in Chapter 3). In 
Chapter 5 for example, for an additional 280 (6%) patients the earliest OUD diagnosis within 
the observation period was obtained from the free-text fields using NLP – patients who, 
otherwise, might not have been captured in this cohort. If I had relied solely on structured 
fields, these diagnosis dates would have either appeared later or potentially these patients not 
have been captured at all om this cohort. 
 
8.5.3 CONFOUNDING 
Confounding is a fundamental consideration in epidemiology and a central issue in any 
observational study design. Not all confounding can be controlled for and, ultimately, the 
best method for removing confounding effects is through randomization (Prince et al., 
2003). However, randomization is limited ethically to interventions which might be 
beneficial but where no strong evidence exists one way or another (Prince et al., 2003). 
Randomizing “real-world” scenarios, especially the impact of provision of services is also 
problematic. In this thesis, as in other observational studies, potential confounding was 
addressed by adjustment.  
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Although no specific power calculation were performed in this thesis, complete patient EHRs 
available for analytical purposes for almost 5000 OUD patients potentially provided the 
statistical power to simultaneously control for a large number of potential confounders. 
Throughout the analysis, I was able to include a broad range of factors in multivariable 
analyses, including socio-demographic variables, clinically appraised risks, poly-substance 
use information, severity of drug use, physical health and psychiatric comorbidity. Although 
the sample size is considered a strength throughout the thesis, some analyses were possibly 
underpowered, as indicated by large confidence intervals (e.g. Table 4.6 or 7.3) and as 
mentioned in Chapter 4 where low number of comorbid SMI patients are present.  
 
Diagnosis and socio-demographic information are routinely recorded in SLaM. NDTMS and 
TOP were excellent sources of information about the severity and patterns of drug use, and 
with high completion rates (95% and 89% respectively, see Chapter 3 for more details on 
TOP and NDTMS). The BRSA-A provided valuable source of risk information which was 
used in Chapters 5 and 7 as potential confounders (in addition to exposures of interest in 
Chapter 5).   
 
Nonetheless, as with all observational studies, residual confounding is possible (e.g. 
smoking). Furthermore, my potential confounders included deprivation score rather than a 
direct measure of socio-economic status (calculations of which are explained in Chapter 3). 
Measures of physical and psychological health (included in models in Chapters 4 and 7) is a 
single and self-reported measure used as proxy indicators of physical health and problems 
with anxiety, depression and other emotional problems. The mean age at diagnosis (for 
example as seen in Chapter 4) was around 37 years, which does not reflect the “classic 
profile” of a heroin user who would normally approach services in their early 20s. This is 
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because data is limited to observation periods and may not reflect the true representative of 
age at first OUD diagnosis.   
 
The NLP application searching free text annotations to establish patient’s ‘smoking status’ 
(current, past or never) only returned data for 4.32% of patients (n=209 / 4,837) suggesting 
that an overwhelming majority of patients never smoked. This is unlikely to be an accurate 
reflection of smoking status in this patient group. Previous research indicates smoking 
reaches high levels in drug users, especially heroin using population (Cookson et al., 2014). 
However, this poor recording of patients smoking status within addiction was not surprising, 
as previous research identified that staff rated smoking treatment significantly less important 
than treatment of other substances and only 29% of staff thought it should be addressed early 
in a client’s primary addiction treatment (Cookson et al., 2014). Consequently, smoking 
status derived from this NLP application, (although valid and reliable when used in other 
patient groups [Wu et al., 2013]) was excluded from this cohort.  
 
HoNOS, a standard measure and widely used measure of patient wellbeing (Wing et al., 
1998), reaches high completion rates across a number of diagnostic groups (e.g. 83% of all 
SLaM patients with schizoaffective disorder). In the OUD cohort, however, HoNOS 
completion rate was only 14%. Therefore, alternative sources of information were searched 
to supplement this information for inclusion as potential confounders. 
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8.6 CLINICAL AND POLICY IMPLICATIONS 
Clinical staff, the policy makers and patients should be aware of risks associated with OST 
treatment, which have been noted in this thesis.  
 
Psychiatric comorbidity is not only common amongst heroin users, but higher mortality rates 
are found in those with comorbid PD and AUD (Chapter 4). This is especially true for OUD 
patients with AUD whose rate of death by hepatic disease increases by more than sevenfold. 
However, the treatment of such patients can be problematic. For example, how best to 
respond to clients who are under the influence of alcohol when presenting for their 
medication? There is little guidance as to how best to respond to these circumstances (NTA, 
2009) and, given the heightened mortality rates in this group, more guidance is needed.  
 
Similarly, OUD patients with comorbid personality disorder have been shown to have  
increased rates of mortality, especially by liver-related disease (Chapter 4), but only a small 
proportion of dual-diagnosis patients actually receive treatment for both PD and OUD 
disorders (SAMHSA, 2012). Patients with co-occurring disorders can face challenges 
accessing treatment, as they may be excluded from mental health services if they admit to a 
substance abuse problem, and vice versa (SAMHSA, 2012). Care for this population needs to 
be properly coordinated within an integrated care pathway (Strang et al., 2014) 
 
The need for integrated care is also partially reiterated in Chapter 5, which has shown 
elevated mortality in OUD patients where suicidality was present. Suicidality may be much 
more complex and problematic to address within the addictions services, and with the need 
for dual-diagnostic/multidisciplinary care plan approaches, addressing high levels of 
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underlying depression and other psychiatric comorbidities (Cantor et al., 2001; Darke, et al., 
2007). 
 
Rather than seeing people with dual diagnosis as having two main problems, it may be more 
effective to acknowledge that they have complex needs (Hughes, 2006). Consequently, 
mental health staff would require drug and alcohol awareness and training and vice versa, to 
ensure a shared philosophy and knowledge base. Identification of OUD-related risks alone, 
can be achieved using a simple and brief screening (i.e. BRSA-A), which could be made 
aware of across services.   
 
Clinical staff and the commissioning bodies, also need to be aware of the increased (twofold) 
mortality risk associated with non-admission of OUD patients where suicidality was 
clinically assessed as present. This risk was no longer present in suicidal OUD patients who 
were admitted to services (Chapter 5). With this in mind, Chapter 6 reports that non-
admission into services was largely due to loss of contact and transfers out of 
service/catchment area (and not because of clinician’s decision).  
 
Drop out from treatment (and relapse) and erratic engagement in services appears to be 
highly prominent in this patient group (Degenhardt et al., 2011; Zanis & Woody, 1998). 
OUD patients who are assessed as being at risk of suicide and subsequently disengage with 
current services may require more determined strategies for patient follow-ups and service 
transition due to their high risk of mortality.  
 
Attention to hard-to-reach populations is an essential component of the healthcare provision 
in a locality. Addiction problems are often more prevalent among these populations and may 
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be complicating their condition (Strang et al., 2014). Without better outreach for these poorly 
engagaged groups, current policy will maintain inequalities for more vulnerable groups. 
 
Finally, commissioning bodies and clinicians need to be aware of the marked excess of 
overdose deaths after transfers of patients and their care despite continuation of OST (see 
Chapters 6 and 7). In Chapter 6 it was found that of those patients who died following a 
transfer, large subgroups included patients transitioned from secondary to primary care or to 
large independent care-provider organisations who had secured new NHS contracts after the 
introduction of competitive tendering procedures (DoH, 2013). If the purpose of such re-
organisation is to achieve greater effectiveness and more cost-effective use of resources, then 
it might have been expected that we would find successful transfer of patients and their 
treatments, patient stability, and stable or lowered risk of mortality (Darke et al., 2005); 
however, these analysis instead indicated a high number of fatal overdoses particularity in the 
first month post-transfer. Therefore, more consideration should be taken when re-
commissioning is proposed; and, if carried out, effective overdose prevention strategies 
should be in place during periods of patient transfer.  
 
In fact, any transfer of patients whether due to escalation of treatment (e.g. to an inpatient 
unit) or as part of successful recovery (e.g. from secondary to primary care) needs to be 
undertaken with caution, similar to that which occurs at the time of discharge from services 
following successful detoxification from any opioids. One way of potentially minimising 
overdose risk in such situations is the pre-provision of naloxone. This, however, comes with 
its own legislative and organizational challenges requiring revision (Strang, 2015).  
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8.7 FURTHER RESEARCH RECOMMENDATIONS 
8.7.1 IMMEDIATE RESEARCH QUESTIONS 
Several questions remain unanswered due to the limitations of data or are beyond the scope 
of this thesis. First, what happened to patients who were transferred out of services to 
continue their treatment elsewhere? Did they successfully transition to the alternative service 
or drop out in the process? Significantly higher levels of mortality were found in patients who 
were transferred from SLaM but establishing answers to the above questions was not possible 
at present.  
 
Moreover, crude analyses indicate high clustering of deaths in the first month post-transfer. Is 
this still the case after adjustment using multivariable methods of analysis? Are transient risks 
post-transfer similar to that on post-discharge or post-prison release (Cornish et al., 2010; 
Davoli et al., 2007; Farrell & Marsden, 2008; Singleton, 2003)? If so, what are the 
mechanisms behind these excess deaths? Are these also attributed to the loss of tolerance 
after a subsequent relapse (Strang et al., 2003)? These results need deeper and wider 
exploration. Answers to these questions are urgently needed and further research should 
focus on replicating these results and expand analysis to fully capture the transition 
processes.  
 
Despite the relatively large cohort, the number of deaths within those with SMI comorbidity 
was small and important effects might have been missed. Future research should explore 
these associations further using larger samples. Similarly, ICD-10 diagnosis of depression 
were not included in the analysis in Chapter 4 and a proxy measure was used instead. Low 
numbers of OUD+depression patients were surprising and suggest either under-reporting of 
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symptoms by patients or lack of initiative to evaluate symptoms and diagnose patients from 
the clinical staff. Further research should be carried out in this area to further strengthen the 
argument for improved availability and provision of dual-diagnostic services.  
 
The relatively small OUD+PD sample put limits on power for further and more detailed 
analysis. Although higher mortality risks have been identified, it is still unclear exactly which 
personality disorders are problematic. To aid in the understanding of mortality risk in this 
group, further research should focus on differences between the types of personality 
disorders, and with a particular focus on directions of casualty (i.e. longitudinal analysis) to 
establish whether PD is particularly harmful to opioid users or the use of opioids aggravates a 
pre-existing PD. 
 
Finally, the BRSA-A was not formally evaluated as a measurement in terms of constructs 
such as inter-rater or test–retest reliability, or its discriminant validity. However, this is a 
“real-world” measure, developed by clinicians and is actively used in daily practice, and 
results (Chapter 5) suggest its effectiveness in highlighting those at highest risk. Further 
evaluations of the scale is a worthwhile research target, if the scale was to be introduced 
across mental health services.  
 
8.7.2 THE LONG TERM VIEW 
Integration and extraction of data 
 
First, the continuity of integration of datasets is important. National records data linkages are 
needed as these enable statistically powerful studies to ascertain which specific causes of 
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death are elevated and to identify the key behavioral and demographic risk factors. For 
example, the Drug Data Warehouse (Millar et al., 2012; Pierce et al., 2015) - an anonymous, 
case-linked collection of secondary datasets about substance users in England and Wales. 
This is the largest opioid user cohort with cause specific mortality, with almost 200,000 
opioid users represented on the system; incorporating data from drug treatment services, 
prison and probation services, criminal justice referral, and drug testing on arrest schemes. 
Capturing one’s journey through dependence and recovery is a long and complex process, 
and integration of data would allow for highly informative continuity of research in opioid 
dependence. 
 
Similarly, at the time of its development, the CRIS database contained 123 000 cases and the 
CRIS application was primarily restricted to that imposed by the format of the source EHR 
fields. Since then, the SLaM BRC Case Register has expanded substantially, not only in case 
numbers (now over 280 000) but also, most importantly, in the scale and depth of derived and 
externally linked information available. A priority for development has been to continue the 
integration of external data and to develop more efficient ways of using open-text data using 
NLP (Perera et al., 2015). If the obstacles described earlier could be overcome then a linkage 
of LAS data with CRIS would not only provide much needed information surrounding non-
fatal overdoses but might also be beneficial in research within other mental health disorders.  
 
Furthermore, much time was spent on manual retrieval of data surrounding the circumstances 
of deaths. It is near impossible to manually code free text fields on a large scale due to time 
and labour constrains. Without the continuous development of NLP applications, much 
information “buried” in free text fields would not be accessible in a systematic way. NLP 
applications specific to addictions services should be developed to enable researchers to 
 212 
retrieve crucial information placed within the free-text fields. While the process of linking 
data and development of individual NLP applications is long and complex, it almost certainly 
is worth the effort.  
 
 
Personalized treatment approach 
 
People with OUD often present to treatment services with varying levels of addiction severity 
and many have coexisting health and social problems which follow addiction onset, or are 
independent of the primary disorder (Kleber et al., 2007). Data from numerous studies 
indicate that there are large individual differences in patients, for example, in their response 
to most effective treatments that have been standardized and with therapists who adhere 
closely to treatment manuals (McKay, 2009).  
 
Despite these considerable variations in patient dependence severity and individual 
differences, most treatments in the addictions strive to deliver essentially the same ‘blanket 
approach’ intervention to all patients, regardless of circumstances surrounding their 
treatment, history and personal factors; and without effective evaluations of risk, especially 
the risk of overdose and mortality (Marsden et al., 2014). 
 
The variability in patients highlights the need for adaptive models of care—that is, tailored 
interventions that specify treatment modifications triggered by the patient's individual 




With existing literature and results from this thesis, a relatively good knowledge base on 
mortality risk factors in opioid dependency exists and the availability of electronic health data 
in mental health has opened doors to treatment innovations, through the availability and 
integration of relevant information at the point of care (Costa et al., 2009; Kawamoto, et al., 
2005; Schreiber & Giustini, 2009). 
 
Information management systems which facilitate the making of decisions by clinicians have 
been well-established in the clinical arena for more than forty years (de Dombal et al., 1972). 
However, prognostic modelling of possible outcomes using multivariate models, and drawing 
on recent technical developments such as natural language processing and electronic health 
records, whilst feeding information to a clinician in real-time has not been developed for 
addictions services. 
 
Prognostic models are often too complex for daily use in clinical settings without computer 
support. However, the introduction of computerised patient records, such as ePJS can enable 
not only the development and validation of such risk-profile modelling but also facilitate their 
application in routine care (James, 2001; Kawamoto et al., 2005). 
 
Firstly, however, a consultation and a technical appraisal of such novel clinical decision-
making tool should be carried out with the NHS clinical staff, for example semi-structured 
interviews might be undertaken. This exercise would assess the utility and acceptability of 
electronic patient risk profiles; and establish satisfactory standards and clinical requirements 
to maximize its usefulness by determining the type and form of risk information that the 
clinicians would find most useful. I obtained necessary approvals (including KCL ethics and 
R&D approvals; borough lead and gatekeeper approvals) and supporting documents 
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(including participant information leaflet, consent form, indicative interview process) are 
already obtained as part of this PhD (see appendix vii. for KCL ethics approval). The work 
however was beyond the current scope of thesis as other research questions (as presented in 




In conclusion, the findings of this thesis provide evidence of the burden of opioid use 
disorder in secondary mental health services and the general population. Individual as well as 
service-related risks have been identified.  
 
The elevated risks of all-cause and/or overdose and liver-related mortality were associated 
with OUD patients with comorbid PD and who misuse alcohol. This highlights the need for 
assessment of psychiatric comorbidity and poly-substance use, and improvement of 
integrated care.  
 
Further mortality risks were found in suicidal OUD patients who were not admitted to 
services; in patients who were discharged from OST services or dropped out; and in those 
who were transferred between services to continue their OST elsewhere.  
 
The risks associated with discharge and transfer were particularly prominent in the first 
month after leaving SLaM. These results highlight risks associated with re-commissioning of 
addictions services and the need to implement effective overdose prevention strategies in 
such situations.  
 
Finally, the study found an effective addictions-related measure which may be helpful to 
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